National Institute for Health and Care Excellence

Version 1.0

Depression in adults: treatment and management

Chapter 17: Network meta-analysis - detailed methods and results

NICE Guideline <…>

Methods, evidence and recommendations

18 July 2017

Draft for Consultation

Developed by the National Guideline Alliance, hosted by the Royal College of Obstetricians and Gynaecologists

Disclaimer
Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

Copyright
National Institute for Health and Care Excellence [2017]. All rights reserved.

Contents

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17 Network meta-analysis - detailed methods and results

TSU, Bristol, Edna Keeney and Sofia Dias

17.1 Introduction

The purpose of this analysis was to estimate the comparative effectiveness of various interventions for treating depression in populations with less severe and more severe populations. In total 351 studies were included in these analyses comparing 81 interventions and combinations of interventions.

The outcomes analysed were discontinuation for any reason, discontinuation due to side effects, remission, response and standardised mean difference (SMD). The SMD measure of effect was used to combine evidence from studies reporting efficacy in terms of a continuous measurement on various depression scales.

The studies and data used for every outcome analysed in the NMA are provided in Appendix T of the full guideline.

17.2 Methods

17.2.1 Network meta-analysis

In order to take all trial information into consideration network meta-analyses (NMA) were conducted. NMA is a generalisation of standard pairwise meta-analysis for A versus B trials, to data structures that include, for example, A versus B, B versus C, and A versus C trials (Dias et al. 2004, Lu and Ades 2004, Caldwell et al. 2005). A basic assumption of NMA methods is that direct and indirect evidence estimate the same parameter, that is, the relative effect between A and B measured directly from an A versus B trial, is the same as the relative effect between A and B estimated indirectly from A versus C and B versus C trials. NMA techniques strengthen inference concerning the relative effect of two treatments by including both direct and indirect comparisons between treatments, and, at the same time, allow simultaneous inference on all treatments inference on all treatments while respecting randomisation (Lu and Ades 2004, Caldwell et al. 2004).

Simultaneous inference on the relative effects of all treatments is possible whenever treatments are part of a single ‘network of evidence’, that is, every treatment is linked to at least one of the other treatments under assessment. The correlation between the random effects of multi-arm trials (i.e. those with more than 2 arms) in the network is taken into account in the analysis (Dias et al. 2004). In a NMA we assume that intervention A is similar (in dose, administration etc.) when it appears in the A *v* B and A *v* C studies and also that every patient included the network has an equal probability of being assigned to any of the interventions (Caldwell et al. 2005) - a concept called ‘joint randomisability’ (Santi 2012).

A Bayesian framework is used to estimate all parameters, using Markov chain Monte Carlo simulation methods implemented in WinBUGS 1.4.3 (. Convergence was assessed using the Brooks-Gelman-Rubin diagnostic (Brooks and Gelman 1998) and was satisfactory by 60,000 simulations for all outcomes (Gelman and Rubin 1992). A further simulation sample of at least 40,000 iterations post-convergence was obtained on which all reported results were based. Sample WinBUGS code is provided in Appendix 1.

For binary data, studies with zero or 100% events in all arms were excluded from the analysis because these studies provide no evidence on relative effects (Dias et al. 2011). For studies with zero or 100% events in one arm only, we planned to analyse the data without

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

continuity corrections where computationally possible. Where this was not possible, we used a continuity correction where we added 0.5 to both the number of events and the number of non-events, which has shown to perform well when there is an approximate 1:1 randomisation ratio across intervention arms (Sweeting et al. 2004).

17.2.25 Reporting of Results

Network diagrams are presented within each relevant section and by outcome. The edges (lines) connecting each pair of interventions represent a direct comparison.

Relative intervention effects are reported as posterior median odds ratios (OR) and 95% credible intervals (CrI) compared to Pill placebo. The full list of log ORs for each class compared to every other is reported in Appendix 4.

We also report posterior mean rank of each class (and 95% CrIs), with the convention that the lower the rank the better the class. The posterior mean rank of each intervention can be found in Appendix 5. Only interventions and classes of interest were included in the calculations of the rankings. The interventions that were deemed not of interest by the guideline committee and therefore excluded from the rankings were imipramine, desipramine, any TCA, any SSRI, any AD, any SSRI + enhanced TAU, IPT + Pill placebo, CBT group (under 15 sessions) + imipramine, CBT individual (under 15 sessions) + any TCA, CBT individual (under 15 sessions) + any SSRI, and problem solving + any SSRI.

17.2.39 Class models

Classes of treatments are groups of interventions which are thought to have similar effects. Class models were used so that strength could be borrowed across treatments in the same class and to reconnect disconnected networks. For all but one outcome (remission in the less severe population) random class effect models were used which assume that the effects of treatments in a class are distributed around a common class mean with a within-class variance. In this way treatment effects are shrunk towards a class mean but estimates are more precise.

Update 2017

Intervention effects are reported for both individual treatments and classes of treatments. For treatments belonging to classes consisting of more than two treatments the pooled relative treatment effects were assumed to be exchangeable within class:

$$d_{1,k} \sim N(\cdot, \tau^2_{D_k})$$

where D_k indicates the class to which treatment *k* belongs.

For treatments belonging to a class formed only of themselves or one other treatment in the analysis, the relative treatment effects were assumed to come from a normal distribution with a class mean with variance being borrowed from another similar class in the model, where possible. The following rules applied where these classes had only one or two treatments and the corresponding class had more than two treatments:

- Exercise borrowed variance from Counselling
- Any AD borrowed from the sum of the variance of SSRIs and TCAs, where

$$\tau^2_{D_{AnyAD}} = (1/\tau^2_{D_{SSRIs}}) + (1/\tau^2_{D_{TCAs}})$$

- Combined (AD + TAU) also borrowed variance from the sum of the variance of SSRIs and TCAs
- Short-term psychodynamic psychotherapies borrowed variance from CBT
- Psychoeducational interventions borrowed variance from CBT
- Interpersonal Psychotherapy borrowed variance from CBT

National Institute for Health and Care Excellence [2017]. All rights reserved.

- Self-help borrowed variance from CBT
- Self-help with support borrowed variance from CBT
- Behavioural therapies borrowed variance from CBT
- Combined (IPT +AD) borrowed variance from Combined (CBT + AD)
- Combined (Short-term psychodynamic psychotherapies + AD) borrowed variance from Combined (CBT + AD)
- Combined (psych + placebo) borrowed variance from CBT
- Combined (Exercise + AD/CBT) borrowed variance from Combined (CBT + AD).

These assumptions were based on expert opinion from the guideline committee.

For treatments not believed to belong to a class in clinical practice, the relative treatment effects were given non-informative priors $d_{1,k} \sim N(0,100^2)$.

The within-class mean treatment effects were given vague priors $m_j \sim N(0,100^2)$ and the within-class variability had priors $\tau^2 \sim$ Half-normal$(0,0.19^2)$ chosen to express the prior belief that 95% of trials will give odds ratios within a factor of 1.5 from the estimated median odds ratio. This prior distribution was necessary due to the small number of interventions in each class, although it still covers a wide range of possible odds ratios within a class.

For treatments not believed to belong to a class, the within-class mean treatment effect was equal to the individual treatment effect, with no added variability.

We compared the fit of the random class effect models to that of fixed class effect models which assume that all treatments in a class have the same relative effect. In most cases the models had a very similar fit suggesting that the interventions had been grouped well into classes with small within-class variability.

Update 2017

17.2.4 Inconsistency checks

Consistency between the different sources of indirect and direct evidence was explored statistically by comparing the fit of a model assuming consistency with a model which allowed for inconsistency (also known as an unrelated treatment effect model). Goodness of fit was measured using the posterior mean of the residual deviance, which is a measure of the magnitude of the difference between the observed data and the model predictions for those data (Spiegelhalter et al. 2002). Smaller values are preferred, and in a well-fitting model the posterior mean residual deviance should be close to the number of data points (Spiegelhalter et al. 2002). We also report the deviance information criterion (DIC) which penalises model fit with model complexity (Spiegelhalter et al. 2002). Finally, we report the between studies standard deviation (heterogeneity parameter) to assess the degree of statistical heterogeneity. If the inconsistency model had the smallest posterior mean residual deviance or heterogeneity then this indicated potential inconsistency in the data. In comparing models, differences of ≥5 points for posterior mean residual deviance and DIC were considered meaningful (Spiegelhalter et al. 2002), with lower values being favoured. It should be noted that the inconsistency model did not assume any class relation between interventions. Comparisons between the relative effects of all pairs of interventions obtained from the consistency (NMA) model and those obtained from the inconsistency (pairwise) model (which does not take into account the indirect evidence in the estimation of effects) are provided in Appendix W.

17.2.5 SMD analysis: methods

We wished to include as many trials and information as possible in each analysis even when data were reported in different ways. This meant transforming the data in some cases. For the SMD analysis we wanted to conduct a NMA on the mean difference in change from baseline (CFB) (for which standard methods are available) (Dias et al. 2011). The data

National Institute for Health and Care Excellence [2017]. All rights reserved.

required for each arm of each study are the mean CFB, the standard deviation in CFB and the total number of individuals in that arm (or the standard error of the mean change from baseline).

However, some studies did not report these data, and instead reported:

1) the baseline and follow-up means, standard deviations and number of individuals, for each arm of the study;
2) the number of individuals responding to treatment in each arm of each study, out of the total number of individuals, defined as those improving by more than a certain percentage from baseline.

Studies reporting outcomes a) and b) above also provide information on the mean change from baseline, through the relationship between the underlying continuous scale and the measurements that can be derived from it.

For our analysis, if CFB data were available in a study we used that data. If that study did not report CFB but reported baseline and follow-up data we used the baseline and follow up data and transformed it to CFB. If a study reported neither CFB nor baseline and follow up data but did report response, we used the response data and transformed it to CFB.

17.2.5.17 Notation

To transform the data we assumed that n_{ik} individuals are randomised to each arm k (k>1) of study i=1,…,M, on which the following outcomes are recorded for individual j=1,…,n_{ik}:

x_{jik} - the score at baseline for individual j in arm k of trial i, on a given continuous scale;

y_{jik} - the score at follow-up for individual j in arm k of trial i, on a given continuous scale;

c_{jik} - the change from baseline for individual j in arm k of trial i, on a given continuous scale, where $c_{jik} = y_{jik} - x_{jik}$;

R_{jik} - response status at follow-up for individual j in arm k of trial i, defined as **at least a q_i% reduction** of the follow-up measurement on a given continuous scale, compared to baseline, i.e.

$$R_{jik} = \begin{cases} 1 & \text{if } y_{jik} - x_{jik} \le -q_i x_{jik} \\ 0 & \text{otherwise} \end{cases} \quad (1)$$

Note that different studies may have used a different cut-off q (although they would be expected to be the same for all arms of a study), and these are therefore indexed by study only.

17.2.5.21 Reported outcomes

Studies may report all or some of the following observed outcomes

$m_{X,ik}$ - the observed mean at baseline in arm k of trial i, on a given continuous scale;

$sd_{X,ik}$ - the observed standard deviation at baseline in arm k of trial i, on a given continuous scale;

$m_{Y,ik}$ - the observed mean at follow-up in arm k of trial i, on a given continuous scale;

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

$sd_{Y,ik}$ - the observed standard deviation at follow-up in arm *k* of trial *i*, on a given continuous scale;

$m_{C,ik}$ - the observed mean change from baseline in arm *k* of trial *i*, on a given continuous scale;

$sd_{C,ik}$ - the observed standard deviation in change from baseline in arm *k* of trial *i*, on a given continuous scale;

ρ_{ik} - the observed correlation between baseline and follow-up scores measured on the same individual in arm *k* of trial *i*. (Although this is rarely reported directly, it can be calculated when the means and standard deviations at baseline, follow-up and from the change scores are provided);

$r_{resp,ik}$ - the number of individuals achieving response in arm *k* of trial *i*, with response defined in equation (1).

17.2.5.3 Relationship between different outcomes

We assume that for each patient the baseline and follow-up measurements are sampled from a bivariate Normal distribution. Thus for all patients in arm *k* of trial *i*, we assume that their baseline, X_{ik}, and follow-up measurements Y_{ik}, are independent and identically distributed as

$$\begin{pmatrix} X_{ik} \\ Y_{ik} \end{pmatrix} \sim \mathrm{N}_2\left(\begin{pmatrix} \mu_{X,ik} \\ \mu_{Y,ik} \end{pmatrix}, \begin{bmatrix} \sigma^2_{X,ik} & \rho_{ik}\sigma_{X,ik}\sigma_{Y,ik} \\ \rho_{ik}\sigma_{X,ik}\sigma_{Y,ik} & \sigma^2_{Y,ik} \end{bmatrix}\right) \quad (2)$$

with $\mu_{X,ik}$ and $\mu_{Y,ik}$ representing the means and $\sigma^2_{X,ik}$ and $\sigma^2_{Y,ik}$ the variances at baseline and follow-up for individuals in arm *k* of trial *i*, respectively, and ρ_{ik} being the within arm and study correlation between baseline and follow-up measurements on the same individuals.

We define the mean change from baseline in arm *k* of trial *i* as $\theta_{ik} = \mu_{Y,ik} - \mu_{X,ik}$ as the parameter of interest.

17.2.5.4 NMA model for continuous outcomes

With continuous outcome data, meta-analysis is usually based on the sample means with standard errors, assumed known. Here we are interested in modelling the mean changes from baseline, which are assumed to be approximately normally distributed, with likelihood

$$m_{C,ik} \sim N\left(\theta_{ik}, se^2_{C,ik}\right)$$

The parameter of interest is the mean, θ_{ik}, of this distribution. For a random effects model we write

$$\theta_{ik} = \gamma_i + \delta_{ik} \quad (3)$$

where γ_i are the trial-specific effects of the treatment in arm 1 of trial *i*, treated as unrelated nuisance parameters, and the δ_{ik} are the trial-specific treatment effects of the treatment in

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

arm *k* relative to the treatment in arm 1 in that trial, where $\delta_{i1} = 0$. The trial-specific random effects δ_{ik}, represent the mean differences between the change from baseline for the treatment in arm *k* and the treatment in arm 1 of trial *i* and, in a random effects model,

$$\delta_{ik} \sim \text{Normal}(d_{t_{i1},t_{ik}}, \sigma^2) \quad (4)$$

where σ^2 denotes the between-study heterogeneity, assumed common to all treatment comparisons and $d_{t_{i1}t_{ik}} = d_{1,t_{ik}} - d_{1,t_{i1}}$ are the pooled mean differences, defined by the consistency equations ($d_{11} = 0$). The fixed effect model is obtained by replacing equation (3) with $\theta_{ik} = \gamma_i + d_{1,t_{ik}} - d_{1,t_{i1}}$. Where studies with more than 2 arms are present, a correlation is induced in the trial specific effects δ_{ik} so equation (4) is replaced by a multivariate normal distribution with correlation equal to 0.5 (Higgins and Whitehead 1996, Dias et al. 2011).

17.2.5.5 Likelihood and link functions for studies reporting other outcomes

17.2.5.5.1 Studies reporting mean and variance at follow-up

From the joint bivariate normal distribution in equation (2) we know that

$$(Y_{ik} - X_{ik}) \sim N\left(\theta_{ik}, \sigma^2_{X,ik} + \sigma^2_{Y,ik} - 2\rho_{ik}\sigma_{X,ik}\sigma_{Y,ik}\right) \quad (5)$$

Therefore, studies not reporting change from baseline but reporting the mean and variance at baseline and follow-up also provide information on the parameter of interest θ_{ik}, the mean change from baseline.

For these studies we can calculate the mean change from baseline as $m_{C,ik} = m_{Y,ik} - m_{X,ik}$. Using equation (5), the likelihood can be written as

$$m_{C,ik} \sim N\left(\theta_{ik}, se^2_{X,ik} + se^2_{Y,ik} - 2\rho_{ik}se_{X,ik}se_{Y,ik}\right)$$

Provided the standard errors at baseline and follow up can be obtained and that we have information on the within-study correlation, the remaining model is given in equations (3) and (4) can be used to pool the mean differences in change from baseline.

17.2.5.5.2 Studies reporting number of responders

Using equation (1), the probability of response for individuals in arm *k* of trial *i* is defined as

$$R_{ik} = \Pr(Y_{ik} - X_{ik} \le -qX_{ik}) \quad (6)$$

Conditioning on the baseline value X_{ik} we have

$$Y_{ik} \mid X_{ik} \sim N\left(\mu_{X,ik}(1-\rho_{ik}) + \theta_{ik} + \rho_{ik}X_{jik}, (1-\rho^2_{ik})\sigma^2_{X,ik}\right) \quad (7)$$

thus,

$$\begin{aligned} R_{ik} \mid X_{ik} &= \Pr_{Y|X}\left(Y_{ik} < (1-q)X_{ik}\right) \\ &= \Phi\left(aX_{ik} + b\right) \end{aligned} \quad (8)$$

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

with

$$a = \frac{1-q-\rho_{ik}}{\sigma_{X,ik}\sqrt{1-\rho_{ik}^2}}\ ,\ b = -\frac{\mu_{X,ik}(1-\rho_{ik})+\theta_{ik}}{\sigma_{X,ik}\sqrt{1-\rho_{ik}^2}}$$

Therefore the unconditional probability of response in arm *k* of trial *i* is

$$R_{ik} = E_{X_{ik}}\left[\Phi\left(aX_{ik}+b\right)\right] \quad (9)$$

It can be shown that

$$E_X\left[\Phi\left(aX+b\right)\right] = \Phi\left(\frac{aE(X)+b}{\sqrt{1+a^2Var(X)}}\right) \quad (10)$$

thus the probability of response for individuals in arm *k* of trial *i* can be written as

$$R_{ik} = \Phi\left(\frac{-q(\mu_{X,ik}+\theta_{ik})}{\sigma_{X,ik}\sqrt{(1-q)(1-q-2\rho_{ik})}}\right) \quad (11)$$

Therefore, studies not reporting the change from baseline or follow-up measures, but providing information on the probability of response, also provide information on the parameter of interest, the mean change from baseline θ_{ik}.

These studies have a binomial likelihood

$$r_{resp,ik} \sim \text{Binomial}(R_{ik}, n_{ik})$$

Provided the baseline mean and standard deviation for each study are reported and that we also have information on the correlation between baseline and follow-up scores in each arm of each study, we can replace these as if they are known into equation (11) and then use equations (3) and (4), as before.

Update 2017

17.2.5.6 Prior distributions and computation

In this case non-informative prior distributions are chosen for the pooled treatment effects, relative to treatment 1, d_{1k}, k=2,…,nt , where nt is the number of treatments in the network

$$d_{1k} \sim \text{Normal}(0, 100^2) \quad (12)$$

and a Uniform prior between 0 and 5 is chosen for the between-study heterogeneity, which is thought to be sufficiently wide to capture the variability in difference in mean change from baseline across trials making the same comparisons.

An informative prior distribution for the within class standard deviation is given as detailed in section 17.2.3.

17.2.5.7 Analysis on the SMD scale

In this case, studies also used different underlying continuous scales on which they report the means or the number of responders. As the methods noted above are study and arm specific, they apply regardless of which scale was used in that trial, although care needs to be taken to ensure that the pre-specified cut-offs *q* and *h* are appropriate for the scale used in a particular study.

National Institute for Health and Care Excellence [2017]. All rights reserved.

Pooling of the difference in means across different scales is not appropriate. A common approach is to use the SMD, where the mean difference is divided by a standardising constant, which can be the population standard deviation for each scale (if known), or its estimate, s_i, often obtained by pooling the estimated standard deviations across all arms of the study (Cooper et al. 2009). The standardising constant can be adjusted in different ways (Cooper et al. 2009). We will illustrate the model using Cohen's d[16], but the analysis using another standardising constant can be done following the same principles.

The SMD for arm *k* of study *i* compared to arm 1 of study i, λ_{ik}, is given as

$$\lambda_{ik} = \frac{m_{ik} - m_{i1}}{s_i} \quad (13)$$

where s_i in a two arm study is given as

$$s_i = \sqrt{\frac{(n_{i1}-1)sd^2_{i1} + (n_{i2}-1)sd^2_{i2}}{n_{i1}+n_{i2}-2}} \quad (14)$$

and in a three arm study is given as

$$s_i = \sqrt{\frac{(n_{i1}-1)sd^2_{i1} + (n_{i2}-1)sd^2_{i2} + (n_{i3}-1)sd^2_{i3}}{n_{i1}+n_{i2}+n_{i3}-3}} \quad (15)$$

The likelihood for each study reporting the various outcomes are as before, but the parameter of interest is now the SMD λ_{ik}. Thus the model is defined as

$$\lambda_{ik} = \gamma_i + \delta_{ik} \quad (16)$$

This model is linked to the mean change from baseline through the following relationship

$$\theta_{ik} = \lambda_{ik} s_i \quad (17)$$

Prior distributions can be defined as before.

Update 2017

17.2.6 Response analysis: methods

The economic model is driven by the probabilities of response on each treatment which are informed both by studies reporting response and studies reporting continuous measures. Again we wanted to include as much data as possible in the analysis. For studies not reporting response we transformed the continuous data first to the SMD scale and then to response. The data required for each arm of each study are the number of individuals responding to treatment in each arm of each study, out of the total number of individuals, defined as those improving by more than a certain percentage from baseline;

However, some studies did not report these data, and instead reported:

a) the mean CFB, the standard deviation in CFB and the total number of individuals in that arm (or the standard error of the mean change from baseline).
b) the baseline and follow-up means, standard deviations and number of individuals, for each arm of the study.

Studies reporting outcomes a) and b) above also provide information on probability of response through the relationship between the underlying continuous scale and the measurements that can be derived from it.

National Institute for Health and Care Excellence [2017]. All rights reserved.

For this analysis, if response data were available in a study we used that data. If that study did not report response but reported CFB we used the CFB data and transformed it to response. If a study reported neither response nor CFB but did report baseline and follow up data, we used the baseline and follow up data and transformed it to response.

We first hoped to transform the continuous data to response using the same method as that for transforming the response to continuous data given in equation (11). Due to limitations with the WinBUGS software however we were unable to do so and instead used a different method of converting SMD to log-odds ratio (LOR) of response recommended by the Cochrane collaboration (Higgins and Green 2011).

17.2.6.10 Notation

For trials reporting response the following model was used:

$$R_{ik} \sim \text{Binomial}(p_{ik}, n_{ik})$$

where r_{jk} is the number of individuals achieving response in arm k of trial j, n_{jk} is the total number of individuals in arm k of trial j, and p_{jk} is the probability of response in arm k of trial j. These probabilities are modelled on the log-odds scale as:

$$\text{logit}(p_{ik}) = \alpha_i + \eta_{ik}$$

where η_{ik} represents the relative treatment effect of the treatment in arm k compared with the treatment in arm 1 in trial i, on the log-odds ratio (LOR) scale and $\eta_{i1} = 0$. Thus $\eta_{ik} > 0$ favours the treatment in arm k and $\eta_{ik} < 0$ favours the treatment in arm 1.

The LOR of response can be related to a notional SMD for response using the formula (Chinn 2000):

$$LOR_{\text{Response}} = -\frac{\pi}{\sqrt{3}} SMD_{\text{Response}} \qquad (18)$$

noting the change in sign to retain the interpretation of a positive LOR favouring treatment k.

The LOR was obtained from transforming the treatment effect from the SMD scale using Equation (18). So, the treatment effect on response is informed by the treatment effect in studies on the pooled scale of symptoms as:

$$\eta_{ik} = \left(-\frac{\pi}{\sqrt{3}} \delta_{ik} \right)$$

Standard NMA random and fixed effects model can used to pool η, as described in section 17.2.5.4. Prior distributions can also be defined as before.

Sample WinBUGS code for both the SMD and response analyses is provided in Appendix 1.

17.2.7 Information on within-study correlation and standard deviation at follow-up

To apply the methods described in sections 17.2.5.5.1 and 17.2.5.5.2 we needed information on a) the correlation between baseline and follow-up scores and b) the relationship between standard deviations (SDs) at baseline and follow up.

For a) we identified 7 studies in our dataset that provided information on mean and SD at baseline, mean and SD at follow-up and the mean and SD of change from baseline (Appendix 2). The correlations calculated from these studies ranged from 0 to 0.88, which meant that no meaningful summary of this correlation could be used.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

We also identified various data sources (included in Appendix 2) for correlations relating to psychological and pharmacological treatments but the evidence was inconclusive and often based on limited numbers of patients. We decided to assume a correlation of 0.5 and vary this in sensitivity analysis as described in section 17.4.

For b) we plotted the SDs at baseline and follow-up from every study that reported both by type of intervention and population (Figure 1 and Figure 2). The black line on these plots is the regression line and the red line is the line of equality where y=x. The regression equation is also shown. We assumed equality of the SD at baseline and follow-up as this was reasonably supported by the data in Figure 1 and Figure 2. In a sensitivity analysis, the regression equations in Figure 1 and Figure 2 were used to obtain the SD at follow-up from the reported SD at baseline.

Figure 1: Plot of SDs at baseline and follow-up – Population with more severe depression



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 2: Plot of SDs at baseline and follow up – population with less severe depression



17.2.84 Empirical checks

Some studies reported change from baseline as well as response, remission or both. We therefore checked agreement between the observed change from baseline and that obtained through the inverse of the transformations in equation (11), using the observed probabilities of response, calculated as the number of events out of the total number of individuals. The results for each population are plotted in Figure 3 and Figure 4 below. The black line is the line of equality. From these we were satisfied that the calculated figures provided a good estimation of the observed data.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 3: CFB estimated from Responders v Reported CFB – Less severe depression



Figure 4: CFB estimated from Responders v Reported CFB – More severe depression



We also considered transforming the remission data to CFB using the following equation where;

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

L_{jik} - remission status at follow-up for individual *j* in arm *k* of trial *i*, defined as having **follow-up measurement below pre-defined threshold h_i** on a given continuous scale, i.e.

$$L_{jik} = \begin{cases} 1 & \text{if } y_{jik} \le h_i \\ 0 & \text{otherwise} \end{cases} \quad (19)$$

Using equation (19), the probability of remission for individuals in arm *k* of trial *i* is defined as

$$L_{ik} = \Pr(Y_{ik} \le h) = \Phi\left(\frac{h - \theta_{ik} - \mu_{X,ik}}{\sigma_{Y,ik}}\right) \quad (20)$$

Therefore, studies providing information on the probability of remission, also provide information on the parameter of interest, the mean change from baseline θ_{ik}.

We again checked agreement between the observed change from baseline and that obtained through the inverse of the transformations in equation (20), using the observed probabilities of remission. In this instance however we noticed substantial disagreement between the two (Figure 5 and Figure 6) and decided not to include this transformation in the analysis.

Figure 5: CFB estimated from Remitters v Reported CFB – Less severe depression



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 6: CFB estimated from Remitters v Reported CFB – More severe depression



17.3 Results

17.3.1 Population: less severe depression

17.3.1.1 Outcome: discontinuation

This analysis was conducted using the NMA code given by Dias et al for binomial data (Dias et al. 2013, Dias et al. 2011) with the denominator being the total number of patients randomised. After excluding trials with zero events in all arms, 173 trials of 62 interventions and 23 classes were included for this outcome (Table 1, Figure 7, Figure 8).

Lower posterior mean residual deviance and DIC values in the NMA random effects consistency model suggested that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Moderate between trials heterogeneity was observed relative to the size of the intervention effect estimates,($\tau = 0.56$ (95% CrI 0.45 to 0.68)).

Table 1. Table of interventions, classes and number of patients randomised (N). Discontinuation

	Intervention	N	Class		N
1	Pill placebo	2789	**Pill placebo**	1	2789
2	Waitlist	1590	**Waitlist**	2	1590
3	Attention placebo	433	**Attention placebo**	3	433
4	TAU	2702	**TAU**	4	2861
5	Enhanced TAU	159		4	
6	Yoga	15	**Exercise***	5	1189
7	Exercise	1174		5	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
8	Mirtazapine	45	**Mirtazapine**	6	45
9	Amitriptyline	696	**TCA**	7	1795
10	Imipramine	727		7	
11	Lofepramine	149		7	
12	Desipramine	46		7	
13	Any TCA	177		7	
14	Citalopram	755	**SSRI**	8	4033
15	Escitalopram	633		8	
16	Fluoxetine	962		8	
17	Sertraline	1368		8	
18	Any SSRI	315		8	
19	Any AD	496	**Any AD***	9	496
20	Psychodynamic counselling	73	**Short-term psychodynamic psychotherapies**	10	418
21	Short-term psychodynamic psychotherapy group	22		10	
22	Short-term psychodynamic psychotherapy individual	323		10	
23	Cognitive bibliotherapy with support	396	**Self-help with support**	11	1734
24	Computerised psychodynamic therapy with support	47		11	
25	Computerised-CBT (CCBT) with support	1221		11	
26	Tailored computerised-CBT (CCBT) with support	70		11	
27	Cognitive bibliotherapy	684	**Self-help without support**	12	2135
28	Computerised-CBT (CCBT)	1297		12	
29	Online positive psychological intervention	143		12	
30	Self-examination therapy	11		12	
31	Psychoeducational group programme	431	**Psychoeducational interventions ***	13	431
32	Interpersonal psychotherapy (IPT)	767	**Interpersonal psychotherapy (IPT)***	14	767
33	Directive counselling	44	**Counselling**	15	419
34	Emotion-focused therapy (EFT)	17		15	
35	Non-directive counselling	341		15	
36	Relational client-centred therapy	17		15	
37	CBT individual (under 15 sessions)	366	**Cognitive and cognitive behavioural therapies**	16	2492
38	CBT individual (over 15 sessions)	1349		16	
39	CBT group (under 15 sessions)	263		16	
40	CBT group (over 15 sessions)	21		16	
41	Problem solving	200		16	
42	Rational emotive behaviour therapy (REBT)	57		16	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
43	Third-wave cognitive therapy individual	169		16	
44	Third-wave cognitive therapy group	67		16	
45	Behavioural activation	452	**Behavioural therapies**	17	798
46	Behavioural therapy (Lewinsohn 1976)	15		17	
47	Coping with Depression course (group)	316		17	
48	Coping with Depression course (individual)	15		17	
49	Any SSRI + Enhanced TAU	112	**Combined (AD + TAU)***	18	112
50	CBT group (under 15 sessions) + imipramine	34	**Combined (Cognitive and cognitive behavioural therapies + AD)**	19	160
51	CBT individual (over 15 sessions) + amitriptyline	15		19	
52	CBT individual (over 15 sessions) + any TCA	36		19	
53	CBT individual (under 15 sessions) + any TCA	22		19	
54	CBT individual (under 15 sessions) + any SSRI	18		19	
55	Problem solving + any SSRI	35		19	
56	Interpersonal psychotherapy (IPT) + imipramine	13	**Combined (IPT + AD)***	20	76
57	Interpersonal psychotherapy (IPT) + any AD	63		20	
58	Short-term psychodynamic psychotherapy individual + Any AD	260	**Combined (Short-term psychodynamic psychotherapies + AD)***	21	357
59	Short-term psychodynamic psychotherapy individual + any SSRI	97		21	
60	Interpersonal psychotherapy (IPT) + Pill placebo	43	**Combined (psych + placebo)***	22	43
61	Aerobic exercise (supervised) + sertraline	189	**Combined (Exercise + AD/CBT)***	23	210
62	Exercise + CBT individual (under 15 sessions)	21		23	

1 **Variance borrowed from another class as described in section 17.2.3*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 7: Network diagram of interventions. Discontinuation



Note: Without the use of a class model treatments 34 and 36 would be disconnected from the rest of the network.

Figure 8: Network diagram of classes. Discontinuation



There was no strong evidence to suggest that any intervention decreased or increased the odds of discontinuation compared to Pill placebo. The only interventions for which the

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

analysis suggested a decreased odds of discontinuation compared to Pill placebo were Waitlist, Exercise, CBT individual (over 15 sessions) and Third wave cognitive therapy (individual) (Figure 9). No class of interventions had an increased odds of discontinuation (Figure 10).

Figure 9: Log-odds ratio and 95% credible intervals of discontinuation for every intervention compared to placebo



Figure 10: Log-odds ratios and 95% credible intervals of discontinuation for every class compared to placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

The highest ranked class is Counselling with a posterior median rank of 3rd (95% CrI 1st to 18th). The three highest ranked interventions (Directive counselling, EFT and Relational client-centred therapy) also belong to this class. The lowest ranked class is Self-help with support at 18th (7th to 20th) and the lowest ranked treatment, Computerised psychodynamic therapy with support, belongs to this class (Table 2 and Appendix 5). We note however the wide credible intervals in the ranks, reflecting the uncertainty as to which class or treatment is best.

Table 2. Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Counselling	3	(1, 18)
Mirtazapine	4	(1, 20)
Exercise	5	(1, 18)
Waitlist	6	(2, 12)
Combined (Short-term psychodynamic psychotherapies + AD)	6	(1, 20)
Combined (Exercise + AD/CBT)	6	(1, 19)
Psychoeducational interventions	8	(1, 20)
Cognitive and cognitive behavioural therapies	8	(3, 15)
TAU	9	(5, 14)
Interpersonal psychotherapy (IPT)	10	(1, 20)
Attention placebo	11	(3, 18)
SSRIs	11	(4, 18)
Combined (IPT + AD)	11	(1, 20)
Pill placebo	14	(8, 18)
Combined (Cognitive and cognitive behavioural therapies + AD)	14	(3, 20)
TCAs	15	(6, 20)
Short-term psychodynamic psychotherapies	15	(3, 20)
Self-help without support	15	(4, 20)
Behavioural therapies	17	(6, 20)
Self-help with support	18	(7, 20)

Update 2017

17.3.1.29 Outcome: discontinuation due to side effects (SE)

This analysis was also conducted using the NMA code given by Dias et al for binomial data (Dias et al. 2013, Dias et al. 2011). As the economic model required an estimate of the relative effects (odds ratios) for discontinuation due to SE conditional on discontinuing, this analysis involved using the number of patients who discontinued for any reason as the denominator and the number who discontinued due to SE as the numerator. This was required as discontinuation and discontinuation due to SE are inter-related in the model with probabilities which must sum to 1.

After excluding trials which did not report both discontinuation and discontinuation due to SE and trials with zero events in all arms, 28 trials of 19 interventions and 10 classes were included for this outcome (Table 3, Figure 11, Figure 12).

Lower posterior mean residual deviance and between trials heterogeneity values in the random effects model suggested that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. High between trials heterogeneity was found relative to the size of the

National Institute for Health and Care Excellence [2017]. All rights reserved.

intervention effect estimates,($\tau = 0.62$ (95% CrI 0.05 to 1.31)) meaning that the results should be interpreted with caution.

Table 3. Table of interventions, classes and number of patients randomised (N). Discontinuation due to SE

	Intervention	N	Class		N
1	Pill placebo	394	**Pill placebo**	1	394
2	Exercise	15	**Exercise**	2	15
3	Amitriptyline	141	**TCA**	3	322
4	Imipramine	177		3	
5	Lofepramine	4		3	
6	Citalopram	6	**SSRI**	4	468
7	Escitalopram	101		4	
8	Fluoxetine	160		4	
9	Sertraline	191		4	
10	Any SSRI	10		4	
11	Short-term psychodynamic psychotherapy individual	5	**Short-term psychodynamic psychotherapies***	5	5
12	CBT individual (over 15 sessions)	5	**Cognitive and cognitive behavioural therapies**	6	58
13	CBT group (under 15 sessions)	28		6	
14	Problem solving	25		6	
15	CBT individual (over 15 sessions) + amitriptyline	5	**Combined (Cognitive and cognitive behavioural therapies + AD)**	7	12
16	Problem solving + any SSRI	7		7	
17	Short-term psychodynamic psychotherapy individual + any SSRI	4	**Combined (Short-term psychodynamic psychotherapies + AD)**	8	4
18	Aerobic exercise (supervised) + sertraline	12	**Combined (Exercise + AD/CBT)**	9	12
19	Mirtazapine	18	**Mirtazapine**	10	18

**Variance borrowed from CBT*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 11: Network diagram of interventions. Discontinuation due to SE



Note: Without the use of a class network interventions 10, 12, 14, 15, 16 and 17 would be disconnected from the rest of the network and would have to be excluded from the analysis.

Figure 12: Network diagram of classes. Discontinuation due to SE



The analysis suggested a decreased odds of discontinuation due to SE compared to Pill placebo with Exercise and an increased odds of discontinuation due to SE for Amitriptyline, Imipramine, Lofepramine, Fluoxetine, and Sertraline (Figure 13). The only class with a decreased odds of discontinuation was Exercise. Both TCAs and SSRIs increased the odds of discontinuation due to SE (Figure 14).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 13: Log-odds ratios and 95% credible intervals of discontinuation due to SE for every intervention compared to Pill placebo



Figure 14: Log-odds ratios and 95% credible intervals of discontinuation due to SE for every class compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

The highest ranked class is Exercise with a posterior median rank of 1st (95% CrI 1st to 3rd). This was also the highest ranked intervention at 2nd (95% CrI 1st to 5th). The lowest ranked intervention was Amitriptyline at 15th (95% CrI 12th to 16th). The lowest ranked class was short-term psychodynamic psychotherapies at 9th (3rd to 10th) (Table 4 and Appendix 5). We note that this estimate is very uncertain, most likely due to the low number of people randomised to this intervention (N = 5) (Table 3).

Table 4: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Exercise	1	(1 - 3)
Cognitive and cognitive behavioural therapies	2	(1 - 5)
Pill placebo	4	(2 - 6)
Combined (Short-term psychodynamic psychotherapies + AD)	5	(1 - 10)
Combined (Exercise + AD/CBT)	5	(2 - 10)
SSRI	6	(4 - 8)
Mirtazapine	6	(4 - 9)
TCA	8	(5 - 10)
Combined (Cognitive and cognitive behavioural therapies + AD)	8	(4 - 10)
Short-term psychodynamic psychotherapies	9	(3 - 10)

17.3.1.38 Outcome: remission in responders

Update 2017

Similar to the discontinuation due to SE analysis, this analysis was a conditional analysis with remission being conditional on response, to meet the requirements of the economic model. This analysis therefore used the number of patients who responded to treatment as the denominator and the number who went into remission as the numerator.

After excluding trials which did not report both response and remission and trials with zero events in all arms, 16 trials of 17 interventions and 10 classes were included for this outcome (Table 5, Figure 15, Figure 16).

In this case a fixed effect analysis was thought to be more appropriate due to the small number of trials making each comparison and the lack of any loops of evidence (interventions being compared both directly and indirectly) (Figure 16). From looking at the model fit statistics it was also decided to use a fixed class effect model as this had the lowest DIC (Appendix 3). The assumption in a fixed class effect model is that all treatments in a class have the same relative effect compared to placebo.

No meaningful differences were observed in posterior mean residual deviance or DIC values suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the fixed-effects NMA model with fixed class effects, assuming consistency.

Table 5: Table of interventions, classes and number of patients (N) included in remission analysis

	Intervention	N	Class		N
1	Pill placebo	160	**Pill placebo**	1	160
2	TAU	28	**TAU**	2	54
3	Enhanced TAU	26		2	
4	Imipramine	19	**TCA**	3	19
5	Citalopram	87	**SSRI**	4	505

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
6	Escitalopram	229		4	
7	Fluoxetine	149		4	
8	Sertraline	33		4	
9	Any SSRI	7		4	
10	Any AD	9	**Any AD**	5	9
11	Interpersonal psychotherapy (IPT)	20	**Interpersonal psychotherapy (IPT)**	6	20
12	CBT individual (over 15 sessions)	138	**Cognitive and cognitive behavioural therapies**	7	188
13	CBT group (under 15 sessions)	50		7	
14	Behavioural activation	196	**Behavioural therapies**	8	196
15	Any SSRI + Enhanced TAU	42	**Combined (AD + TAU)**	9	42
16	Short-term psychodynamic psychotherapy individual + any SSRI	26	**Combined (Short-term psychodynamic psychotherapies + AD)**	10	64
17	Short-term psychodynamic psychotherapy individual + Any AD	38		10	

1

Figure 15: Remission. Network diagram of all studies included in analysis by intervention



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Note: Interventions 1, 4, 5, 6, and 7 would have been disconnected from interventions 2, 8, 10, 11, 12, 13 and 14 without the use of a class network. Interventions 9 and 16 and 3 and 15 would also only have been compared to each other and intervention 17 would only have been compared to itself.

Figure 16: Remission. Network diagram of all studies included in analysis by class



The analysis suggested that the only intervention with an increased odds of remission compared to Pill placebo was Behavioural activation. Behavioural therapies were the only class with an increased odds of remission (Figure 17 and Figure 18).

Figure 17: Log-odds ratios and 95% credible intervals of remission for every intervention compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 18: Log-odds ratios and 95% credible intervals of remission for every class compared to Pill placebo.



Short-term psychodynamic psychotherapies + AD is the highest ranked class at 2nd (95% CrI 1st to 7th). Behavioural Therapies are also ranked 2nd however with tighter credible intervals of 1st to 4th. The lowest ranked class is Pill placebo (Table 6).

The highest ranked interventions are short-term psychodynamic psychotherapy individual + any SSRI and short-term psychodynamic psychotherapy individual + Any AD with a shared posterior median rank of 2nd (95% CrI 1st to 10th). The lowest ranked intervention is Pill placebo at 10th (95% CrI 6th to 12th) (Appendix 5).

Table 6: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Behavioural therapies	2	(1 - 4)
Combined (Short-term psychodynamic psychotherapies + AD)	2	(1 - 7)
Cognitive and cognitive behavioural therapies	4	(2 - 8)
TCA	5	(2 - 8)
SSRI	5	(3 - 7)
Interpersonal psychotherapy (IPT)	6	(1 - 8)
TAU	6	(2 - 8)
Pill placebo	6	(4 - 8)

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.3.1.41 Outcome: remission in those randomised

As very few trials reported both remission and response an additional analysis was carried out on all trials reporting remission with the number randomised to treatment as the denominator.

After excluding trials with zero events in all arms, 64 trials of 44 interventions and 21 classes were included for this outcome (Table 7, Figure 19 and Figure 20).

There was a substantial reduction in between study heterogeneity in the inconsistency model suggesting evidence of inconsistency (Appendix 3).

Reported results are based on the random-effects NMA model, assuming consistency. Moderate between trials heterogeneity was found relative to the size of the intervention effect estimates,$(\tau = 0.49\ (95\%\ \mathrm{CrI}\ 0.33\ \mathrm{to}\ 0.69))$.

Table 7: Table of interventions, classes and number of patients (N) included in remission in those randomised analysis

	Intervention	N	Class		N
1	Pill placebo	719	**Pill placebo**	1	719
2	Waitlist	149	**Waitlist**	2	149
3	Attention placebo	204	**Attention placebo**	3	204
4	TAU	1150	**TAU**	4	1258
5	Enhanced TAU	108		4	
6	Exercise	330	**Exercise***	5	330
7	Amitriptyline	62	**TCA**	6	372
8	Imipramine	140		6	
9	Desipramine	13		6	
10	Any TCA	157		6	
11	Citalopram	120	**SSRI**	7	1683
12	Escitalopram	617		7	
13	Fluoxetine	453		7	
14	Sertraline	195		7	
15	Any SSRI	298		7	
16	Any AD	323	**Any AD***	8	323
17	Psychodynamic counselling	73	**Short-term psychodynamic psychotherapies***	9	248
18	Short-term psychodynamic psychotherapy individual	175		9	
19	Computerised psychodynamic therapy with support	46	**Self-help with support***	10	832
20	Computerised-CBT (CCBT) with support	747		10	
21	Tailored computerised-CBT (CCBT) with support	39		10	
22	Cognitive bibliotherapy	290	**Self-help without support***	11	926
23	Computerised-CBT (CCBT)	636		11	
24	Psychoeducational group programme	119	**Psychoeducational interventions ***	12	119
25	Interpersonal psychotherapy (IPT)	519	**Interpersonal psychotherapy (IPT)***	13	519
26	Directive counselling	30	**Counselling**	14	64

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
27	Emotion-focused therapy (EFT)	17		14	
28	Relational client-centred therapy	17		14	
29	CBT individual (under 15 sessions)	174	**Cognitive and cognitive behavioural therapies**	15	1196
30	CBT individual (over 15 sessions)	534		15	
31	CBT group (under 15 sessions)	203		15	
32	Problem solving	110		15	
33	Rational emotive behaviour therapy (REBT)	57		15	
34	Third-wave cognitive therapy individual	118		15	
35	Behavioural activation	396	**Behavioural therapies***	16	545
36	Coping with Depression course (group)	149		16	
37	Any SSRI + Enhanced TAU	112	**Combined (AD + TAU)***	17	112
38	CBT group (under 15 sessions) + imipramine	34	**Combined (Cognitive and cognitive behavioural therapies + AD)**	18	84
39	Problem solving + any SSRI	35		18	
40	CBT individual (over 15 sessions) + amitriptyline	15		18	
41	Interpersonal psychotherapy (IPT) + any AD	63	**Combined (IPT + AD)***	19	63
42	Short-term psychodynamic psychotherapy individual + Any AD	260	**Combined (Short-term psychodynamic psychotherapies + AD)***	20	323
43	Short-term psychodynamic psychotherapy individual + any SSRI	63		20	
44	Aerobic exercise (supervised) + sertraline	110	**Combined (Exercise + AD/CBT)***	21	110

1 **Variance borrowed from another class as described in section 17.2.3*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 19: Remission in those randomised. Network diagram of all studies included in analysis by intervention



Note: Disconnected interventions are 5, 37, 27, and 28

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 20: Remission in those randomised. Network diagram of all studies included in analysis by class



The interventions with an increased odds of remission compared to Pill placebo were Escitalopram, Fluoxetine, IPT, Directive counselling, CBT individual (over 15 sessions), CBT group (under 15 sessions), Third-wave cognitive therapy individual, Behavioural activation, and Coping with Depression course (group). Waitlist was the only intervention with a decreased odds of remission. The classes with an increased odds of remission were CBT, Behavioural therapies and Counselling (Figure 21 and Figure 22).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 21: Log-odds ratios and 95% credible intervals of remission in those randomised for every intervention compared to Pill placebo



Figure 22: Log-odds ratios and 95% credible intervals of remission in those randomised for every class compared to Pill placebo



Counselling is the highest ranked class at 3rd (95% CrI 1st to 16th). The lowest ranked class is Waitlist (Table 8).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

The highest ranked interventions are Directive counselling (5th, CrI 1st to 25th) and Emotion focused therapy (3rd, CrI 1st to 31st). The lowest ranked intervention is Waitlist at 35th (95% CrI 33rd to 35th) (Appendix 5).

These results should be interpreted with caution due to the finding of potential inconsistency in the data.

Table 8: Posterior median rank and 95% credible intervals by class

Class	Posterior mean rank	95% CrIs
Counselling	3	(1,16)
Behavioural therapies	3	(1,9)
Combined (IPT + AD)	3	(1,17)
Combined (Short-term psychodynamic psychotherapies + AD)	4	(1,16)
Psychoeducational interventions	6	(1,17)
Interpersonal psychotherapy (IPT)	6	(1,16)
Cognitive and cognitive behavioural therapies	7	(3,12)
SSRIs	9	(3,14)
Short-term psychodynamic psychotherapies	9	(2,17)
Self-help with support	9	(2,17)
Combined (Cognitive and cognitive behavioural therapies + AD)	9	(2,17)
TCAs	11	(4,17)
Combined (Exercise + AD/CBT)	13	(2,19)
Pill placebo	14	(9,17)
TAU	14	(10,17)
Exercise	14	(3,19)
Self-help without support	15	(6,18)
Attention placebo	18	(15,19)
Waitlist	19	(17,19)

Update 2017

17.3.1.57 Outcome: response (completers)

As mentioned in the methods section, this analysis included trials reporting three types of data:

1. Number of individuals responding to treatment in each arm of each study, out of the total number of individuals, defined as those improving by more than a certain percentage from baseline
2. Mean change from baseline (CFB), the standard deviation in CFB and the total number of individuals in that arm
3. Baseline and follow-up means, standard deviations, and number of individuals, for each arm of the study.

The response analysis was first carried out only in those who completed treatment. After excluding trials with zero events in all arms, 52 trials reported response. Out of the remaining studies, 4 reported change from baseline in completers (but not response) and 35 reported baseline and final scores in completers (but not response or change from baseline). This meant that 91 trials of 50 interventions and 23 classes were included in the analysis for this outcome (Table 9, Figure 23, Figure 24).

National Institute for Health and Care Excellence [2017]. All rights reserved.

No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Moderate between trials heterogeneity was found relative to the size of the intervention effect estimates,($\tau = 0.45$ (95% CrI 0.29 to 0.64)).

Table 9: Table of interventions, classes and number of patients (N) included in response (completers) analysis

	Intervention	N	Class		N
1	Pill placebo	1694	**Pill placebo**	1	1694
2	Waitlist	353	**Waitlist**	2	353
3	Attention placebo	67	**Attention placebo**	3	67
4	TAU	410	**TAU**	4	535
5	Enhanced TAU	125		4	
6	Exercise	334	**Exercise***	5	334
7	Mirtazapine	27	**Mirtazapine**	6	27
8	Amitriptyline	392	**TCA**	7	1043
9	Imipramine	493		7	
10	Lofepramine	110		7	
11	Desipramine	7		7	
12	Any TCA	41		7	
13	Citalopram	609	**SSRI**	8	2631
14	Escitalopram	496		8	
15	Fluoxetine	638		8	
16	Sertraline	781		8	
17	Any SSRI	107		8	
18	Any AD	136	**Any AD***	9	136
19	Psychodynamic counselling	65	**Short-term psychodynamic psychotherapies***	10	200
20	Short-term psychodynamic psychotherapy individual	135		10	
21	Cognitive bibliotherapy with support	58	**Self-help with support***	11	199
22	Computerised-CBT (CCBT) with support	141		11	
23	Cognitive bibliotherapy	73	**Self-help without support**	12	306
24	Computerised-CBT (CCBT)	128		12	
25	Online positive psychological intervention	95		12	
26	Self-examination therapy	10		12	
27	Psychoeducational group programme	40	**Psychoeducational interventions ***	13	40
28	Interpersonal psychotherapy (IPT)	209	**Interpersonal psychotherapy (IPT)***	14	209
29	Emotion-focused therapy (EFT)	48	**Counselling**	15	73
30	Non-directive counselling	10		15	
31	Relational client-centred therapy	15		15	
32	CBT individual (under 15 sessions)	105	**Cognitive and cognitive behavioural therapies**	16	1096
33	CBT individual (over 15 sessions)	711		16	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
34	CBT group (under 15 sessions)	105		16	
35	Problem solving	157		16	
36	Third-wave cognitive therapy individual	18		16	
37	Behavioural activation	324	**Behavioural therapies**	17	424
38	Behavioural therapy (Lewinsohn 1976)	10		17	
39	Coping with Depression course (group)	77		17	
40	Coping with Depression course (individual)	13		17	
41	Any SSRI + Enhanced TAU	96	**Combined (AD + TAU)***	18	96
42	CBT individual (over 15 sessions) + amitriptyline	11	**Combined (Cognitive and cognitive behavioural therapies + AD)**	19	40
43	Problem solving + any SSRI	29		19	
44	Interpersonal psychotherapy (IPT) + imipramine	8	**Combined (IPT + AD)**	20	61
45	Interpersonal psychotherapy (IPT) + any AD	53		20	
46	Short-term psychodynamic psychotherapy individual + Any AD	65	**Combined (Short-term psychodynamic psychotherapies + AD)**	21	88
47	Short-term psychodynamic psychotherapy individual + any SSRI	23		21	
48	Interpersonal psychotherapy (IPT) + Pill placebo	8	**Combined (psych + placebo)***	22	8
49	Aerobic exercise (supervised) + sertraline	44	**Combined (Exercise + AD/CBT)**	23	62
50	Exercise + CBT individual (under 15 sessions)	18		23	

1 **Variance borrowed from another class as described in section 17.2.3*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 23: Response (completers). Network diagram of all studies included in analysis by intervention



Note: Disconnected interventions are 22 and 24.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 24: Response (completers). Network diagram of all studies included in analysis by class



The analysis suggested an increased odds of response in completers compared to Pill placebo for Exercise, Amitriptyline, Imipramine, Lofepramine, any TCA, Citalopram, Fluoxetine, Sertraline, Any SSRI, Any AD, Short-term psychodynamic psychotherapy individual, Cognitive bibliotherapy, Interpersonal psychotherapy (IPT), all Cognitive and cognitive behavioural therapies, Behavioural activation, Behavioural therapy (Lewinsohn 1976), Coping with Depression course (individual), Interpersonal psychotherapy (IPT) + any AD and Short-term psychodynamic psychotherapy individual + Any AD.

There was no evidence of a reduction in odds of response compared to Pill placebo, although a possible reduction is suggested for Waitlist.

The classes with an increased odds of response are TCAs, SSRIs, Cognitive and Cognitive Behavioural Therapies, Behavioural Therapies and Combined IPT + AD (Figure 25 and Figure 26).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 25: Log-odds ratios and 95% credible intervals of response in completers for every intervention compared to Pill placebo



Figure 26: Log-odds ratios and 95% credible intervals of response in completers for every class compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Combined (IPT + AD) is the highest ranked class at 2nd (95% CrI 1st to 15th). The highest ranked intervention is IPT + any AD with a posterior median rank of 2nd (95% CrI 1st to 23rd). The lowest ranked intervention is waitlist at 41st (95% CrI 39th to 41st). The lowest ranked active intervention is Online Positive Psychological Intervention at 36th (95% CrI 13th to 40th) (Appendix 5). The lowest ranked active class is Psychoeducational Interventions at 14th (1st to 20th) (Table 10 and Appendix 3). Large uncertainty is evident from the wide credible intervals.

Table 10: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Combined (IPT + AD)	2	(1, 15)
Combined (Short-term psychodynamic psychotherapies + AD)	5	(1, 18)
Mirtazapine	6	(1, 19)
Behavioural therapies	6	(1, 15)
Exercise	7	(1, 18)
Cognitive and cognitive behavioural therapies	7	(2, 14)
TCA	8	(2, 16)
SSRI	9	(3, 16)
Short-term psychodynamic psychotherapies	10	(2, 18)
Self-help with support	10	(1, 19)
Self-help without support	10	(2, 18)
Interpersonal psychotherapy (IPT)	10	(1, 19)
Combined (Cognitive and cognitive behavioural therapies + AD)	11	(2, 19)
Counselling	12	(2, 19)
Combined (Exercise + AD/CBT)	13	(2, 19)
Psychoeducational interventions	14	(1, 20)
TAU	15	(9, 19)
Attention placebo	16	(5, 20)
Pill placebo	17	(13, 19)
Waitlist	20	(18, 20)

Update 2017

17.3.1.69 Outcome: response in those randomised

The response analysis was also carried out in all patients randomised, including those who discontinued treatment. After excluding trials with zero events in all arms, 52 trials reported response. Out of the remaining studies 10 reported change from baseline (but not response) and 68 reported baseline and final scores (but not response or change from baseline). This meant that 130 trials of 48 interventions and 24 classes were included in the analysis for this outcome (Table 11, Figure 27 and Figure 28).

No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Moderate between trials heterogeneity was found relative to the size of the intervention effect estimates,($\tau = 0.56$ (95% CrI 0.45 to 0.68)).

Table 11: Table of interventions, classes and number of patients (N) included in response in those randomised analysis

	Intervention	N	Class		N
1	Pill placebo	2439	**Pill placebo**	1	2439

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
2	Waitlist	1039	**Waitlist**	2	1039
3	Attention placebo	381	**Attention placebo**	3	381
4	TAU	1790	**TAU**	4	1949
5	Enhanced TAU	159		4	
6	Exercise	945	**Exercise**	5	945
7	Mirtazapine	45	**Mirtazapine**	6	45
8	Amitriptyline	527	**TCA**	7	1292
9	Imipramine	639		7	
10	Lofepramine	93		7	
11	Desipramine	33		7	
12	Citalopram	715	**SSRI**	8	3547
13	Escitalopram	616		8	
14	Fluoxetine	948		8	
15	Sertraline	1238		8	
16	Any SSRI	30		8	
17	Any AD	355	**Any AD***	9	355
18	Short-term psychodynamic psychotherapy group	22	**Short-term psychodynamic psychotherapies***	10	491
19	Short-term psychodynamic psychotherapy individual	469		10	
20	Long-term psychodynamic psychotherapy individual	128	**Long-term psychodynamic psychotherapies***	11	128
21	Cognitive bibliotherapy with support	246	**Self-help with support**	12	544
22	Computerised psychodynamic therapy with support	74		12	
23	Computerised-CBT (CCBT) with support	224		12	
24	Cognitive bibliotherapy	605	**Self-help without support**	13	1736
25	Computerised-CBT (CCBT)	988		13	
26	Online positive psychological intervention	143		13	
27	Psychoeducational group programme	268	**Psychoeducational interventions ***	14	268
28	Interpersonal psychotherapy (IPT)	234	**Interpersonal psychotherapy (IPT)***	15	234
29	Directive counselling	74	**Counselling**	16	406
30	Non-directive counselling	332		16	
31	CBT individual (under 15 sessions)	383	**Cognitive and cognitive behavioural therapies**	17	2147
32	CBT individual (over 15 sessions)	1270		17	
33	CBT group (under 15 sessions)	231		17	
34	CBT group (over 15 sessions)	21		17	
35	Rational emotive behaviour therapy (REBT)	57		17	
36	Third-wave cognitive therapy individual	118		17	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
37	Third-wave cognitive therapy group	67		17	
38	Behavioural activation	491	**Behavioural therapies**	18	764
39	Coping with Depression course (group)	248		18	
40	Behavioural therapy (Lewinsohn 1976)	25		18	
41	Any SSRI + Enhanced TAU	112	**Combined (AD + TAU)***	19	112
42	CBT individual (over 15 sessions) + any TCA	36	**Combined (Cognitive and cognitive behavioural therapies + AD)**	20	36
43	Interpersonal psychotherapy (IPT) + imipramine	13	**Combined (IPT + AD)**	21	76
44	Interpersonal psychotherapy (IPT) + any AD	63		21	
45	Short-term psychodynamic psychotherapy individual + Any AD	198	**Combined (Short-term psychodynamic psychotherapies + AD)**	22	295
46	Short-term psychodynamic psychotherapy individual + any SSRI	97		22	
47	Interpersonal psychotherapy (IPT) + Pill placebo	12	**Combined (psych + placebo)***	23	12
48	Aerobic exercise (supervised) + sertraline	79	**Combined (Exercise + AD/CBT)**	24	79

**Variance borrowed from another class as described in section 17.2.3*

Figure 27: Response in those randomised. Network diagram of all studies included in analysis by intervention



Note: Disconnected treatments are 43, 47, 16, and 46.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 28: Response in those randomised. Network diagram of all studies included in analysis by class



The analysis suggested an increased odds of response compared to Pill placebo with Exercise, Amitriptyline, Citalopram, Fluoxetine, Sertraline, any AD, Short-term psychodynamic psychotherapy individual, Long-term psychodynamic psychotherapy individual, Computerised-CBT (CCBT) with support, CBT individual (under 15 sessions), CBT individual (over 15 sessions), CBT group (under 15 sessions), Rational emotive behaviour therapy (REBT), Third-wave cognitive therapy individual, Behavioural activation, Behavioural therapy, IPT + imipramine, IPT + any AD, Short-term psychodynamic psychotherapy individual + Any AD, Short-term psychodynamic psychotherapy individual + any SSRI, and Aerobic exercise (supervised) + sertraline. Waitlist had a statistically significant reduction in odds of response compared to Pill placebo. The classes with an increased odds of response are SSRIs, Cognitive and Cognitive behavioural therapies, Behavioural therapies, Combined IPT + AD, Combined (Short-term psychodynamic psychotherapies + AD), and Combined (Exercise + AD/CBT) (Figure 29 and Figure 30).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 29: Log-odds ratios and 95% credible intervals of response for every intervention compared to Pill placebo



Figure 30: Log-odds ratios and 95% credible intervals of response for every class compared to Pill placebo.



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Combined (IPT + AD) is the highest ranked class at 3rd (95% CrI 1st to 12th). The highest ranked intervention is IPT + any AD with a posterior median rank of 3rd (95% CrI 1st to 14th). The lowest ranked intervention is waitlist at 40th (95% CrI 40th to 41st). The lowest ranked active intervention is Online positive psychological intervention at 34rd (95% CrI 16th to 41th). The lowest ranked active class is Self-help without support at 15th (7th to 20th) (Table 10 and Appendix 3).

Table 10: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Combined (IPT + AD)	3	(1 - 12)
Combined (Exercise + AD/CBT)	4	(1 - 15)
Combined (Short-term psychodynamic psychotherapies + AD)	5	(1 - 14)
Long-term psychodynamic psychotherapies	6	(1 - 18)
Mirtazapine	7	(1 - 19)
Combined (Cognitive and cognitive behavioural therapies + AD)	7	(1 - 19)
Behavioural therapies	8	(3 - 15)
Cognitive and cognitive behavioural therapies	9	(4 - 14)
Self-help with support	10	(3 - 17)
Exercise	10	(2 - 20)
Short-term psychodynamic psychotherapies	11	(4 - 19)
SSRI	12	(6 - 17)
Psychoeducational interventions	13	(4 - 20)
Interpersonal psychotherapy (IPT)	13	(4 - 20)
TCA	13	(6 - 19)
Counselling	14	(5 - 20)
Self-help without support	15	(7 - 20)
Attention placebo	16	(11 - 20)
Pill placebo	17	(14 - 20)
TAU	20	(18 - 21)
Waitlist	21	(20 - 21)

Update 2017

17.3.1.78 Outcome: SMD

As mentioned in the methods section, this analysis also included trials reporting three types of data:

1) Mean change from baseline (CFB), the standard deviation in CFB and the total number of individuals in that arm
2) Baseline and follow-up means, standard deviations, and number of individuals, for each arm of the study
3) Number of individuals responding to treatment in each arm of each study, out of the total number of individuals, defined as those improving by more than a certain percentage from baseline.

This analysis was carried out on all patients randomised. After excluding trials with zero events in all arms, 20 trials reported CFB. Out of the remaining studies 76 reported baseline and follow-up scores (but not CFB) and 10 reported response (but not CFB or baseline and follow-up). This meant that 106 trials of 42 interventions and 21 classes were included in the analysis for this outcome (Table 12, Figure 31 and Figure 32).

National Institute for Health and Care Excellence [2017]. All rights reserved.

Relative to the size of the intervention effect estimates, moderate to low between trial heterogeneity was observed for this outcome ($\tau = 0.22$ (95% CrI 0.17 to 0.29)). No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency.

Table 12: Table of interventions, classes and number of patients (N) included in SMD analysis

	Intervention		Class		N
1	Pill placebo	1564	**Pill placebo**	1	1564
2	Waitlist	1035	**Waitlist**	2	1035
3	Attention placebo	294	**Attention placebo**	3	294
4	TAU	1624	**TAU**	4	1675
5	Enhanced TAU	51		4	
6	Exercise	752	**Exercise**	5	752
7	Amitriptyline	396	**TCA**	6	811
8	Imipramine	289		6	
9	Lofepramine	93		6	
10	Desipramine	33		6	
11	Citalopram	335	**SSRI**	7	2463
12	Escitalopram	616		7	
13	Fluoxetine	579		7	
14	Sertraline	933		7	
15	Any AD	341	**Any AD**	8	341
16	Short-term psychodynamic psychotherapy group	22	**Short-term psychodynamic* psychotherapies**	9	379
17	Short-term psychodynamic psychotherapy individual	357		9	
18	Long-term psychodynamic psychotherapy individual	128	**Long-term psychodynamic psychotherapies***	10	128
19	Cognitive bibliotherapy with support	244	**Self-help with support**	11	514
20	Computerised psychodynamic therapy with support	46		11	
21	Computerised-CBT (CCBT) with support	224		11	
22	Cognitive bibliotherapy	605	**Self-help without support**	12	1721
23	Computerised-CBT (CCBT)	973		12	
24	Online positive psychological intervention	143		12	
25	Psychoeducational group programme	268	**Psychoeducational interventions ***	13	268
26	Interpersonal psychotherapy (IPT)	234	**Interpersonal psychotherapy (IPT)***	14	234
27	Directive counselling	74	**Counselling**	15	406
28	Non-directive counselling	332		15	
29	CBT individual (under 15 sessions)	383	**Cognitive and cognitive behavioural therapies**	16	2026
30	CBT individual (over 15 sessions)	1211		16	
31	CBT group (under 15 sessions)	179		16	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention		Class		N
32	CBT group (over 15 sessions)	21		16	
33	Rational emotive behaviour therapy (REBT)	57		16	
34	Third-wave cognitive therapy individual	118		16	
35	Third-wave cognitive therapy group	67		16	
36	Behavioural activation	491	**Behavioural therapies**	17	717
37	Coping with Depression course (group)	226		17	
38	CBT individual (over 15 sessions) + any TCA	36	**Combined (Cognitive and cognitive behavioural therapies + AD)**	18	36
39	Interpersonal psychotherapy (IPT) + any AD	63	**Combined (IPT + AD)**	19	63
40	Short-term psychodynamic psychotherapy individual + Any AD	95	**Combined (Short-term psychodynamic psychotherapies + AD)**	20	165
41	Short-term psychodynamic psychotherapy individual + Any SSRI	70		20	
42	Aerobic exercise (supervised) + sertraline	79	**Combined (Exercise + AD/CBT)**	21	79

**Variance borrowed from another class as described in section 17.2.3*

Figure 31: SMD. Network diagram of all studies included in analysis by intervention



Note: Intervention 41 is disconnected

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 32: SMD. Network diagram of all studies included in analysis by class



The analysis suggested that Exercise, Amitriptyline, Sertraline, any AD, Long-term psychodynamic psychotherapy individual, Cognitive bibliotherapy with support, Computerised psychodynamic therapy with support, CCBT with support, Cognitive bibliotherapy, CCBT, CBT individual (under 15 sessions), CBT individual (over 15 sessions), CBT group (under 15 sessions), REBT, Third-wave cognitive therapy individual, Behavioural Activation, IPT + any AD, Short-term psychodynamic psychotherapy individual + Any AD and Aerobic exercise (supervised) + sertraline result in a lower standardised mean difference in depression compared to Pill placebo whereas Waitlist results in a standardised mean difference increase compared to Placebo.

The only classes showing a standardised mean difference reduction in depression compared to Placebo are Self-help with support, Cognitive and Cognitive Behavioural Therapies and Combined (IPT + AD) (Figure 33 and Figure 34).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 33: SMD for every intervention compared to Pill placebo



Figure 34: SMD for every class compared to Pill placebo



Combined (IPT + AD) is the highest ranked class at 2nd (95% CrI 1st to 13th). The highest ranked intervention is IPT + any AD with a posterior median rank of 2nd (95% CrI 1st to 5th). The lowest ranked intervention is waitlist at 38th (95% CrI 37th to 38th). The lowest ranked active intervention is Online positive psychological intervention at 35th (95% CrI 17th to 38th). The lowest ranked active class is Counselling at 13th (3rd to 20th) (Table 13 and Appendix 3).

Table 13: Posterior median rank and 95% credible intervals by class

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Class	Posterior Median rank	95% CrIs
Combined (IPT + AD)	2	(1, 13)
Combined (Short-term psychodynamic psychotherapies + AD)	3	(1, 17)
Long-term psychodynamic psychotherapies	5	(1, 17)
Self-help with support	5	(1, 14)
Combined (Exercise + AD/CBT)	6	(1, 20)
Combined (Cognitive and cognitive behavioural therapies + AD)	7	(1, 20)
Cognitive and cognitive behavioural therapies	8	(4, 13)
Behavioural therapies	8	(2, 19)
Exercise	10	(1, 20)
Psychoeducational interventions	10	(2, 20)
SSRIs	11	(4, 19)
Short-term psychodynamic psychotherapies	11	(4, 19)
Interpersonal psychotherapy (IPT)	11	(3, 20)
TCAs	12	(5, 19)
Self-help without support	12	(4, 20)
Counselling	13	(3, 20)
Pill placebo	15	(11, 18)
Attention placebo	15	(10, 19)
TAU	18	(14, 19)
Waitlist	20	(17, 20)

Update 2017

17.3.21 Population: more severe depression

17.3.2.12 Outcome: discontinuation

After excluding trials with zero events in all arms, 121 trials of 44 interventions and 22 classes were included for this outcome (Table 14, Figure 35 and Figure 36).

There was no evidence of inconsistency when the inconsistency model was fitted (Appendix 3). Relative to the size of the intervention effect estimates, moderate between trial heterogeneity was observed for this outcome ($\tau = 0.52$ (95% CrI 0.40 to 0.65)).

Table 14: Table of interventions, classes and number of patients (N) included in discontinuation analysis

	Intervention	N	Class		N
1	Pill placebo	4721	**Pill placebo**	1	4721
2	Waitlist	406	**Waitlist**	2	406
3	Attention placebo	80	**Attention placebo**	3	80
4	TAU	1084	**TAU**	4	1084
5	Exercise	98	**Exercise***	5	118
6	Yoga	20		5	
7	Mirtazapine	738	**Mirtazapine**	6	738
8	Amitriptyline	1689	**TCA**	7	3782

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
9	Imipramine	1857		7	
10	Lofepramine	109		7	
11	Any TCA	127		7	
12	Citalopram	1569	**SSRI**	8	6204
13	Escitalopram	1754		8	
14	Fluoxetine	2151		8	
15	Sertraline	730		8	
16	Any AD	51	**Any AD***	9	51
17	Short-term psychodynamic psychotherapy individual	172	**Short-term psychodynamic psychotherapies***	10	172
18	Long-term psychodynamic psychotherapy individual	79	**Long-term psychodynamic psychotherapies***	11	79
19	Cognitive bibliotherapy with support	141	**Self-help with support***	12	344
20	Computerised-CBT (CCBT) with support	203		12	
21	Cognitive bibliotherapy	50	**Self-help***	13	720
22	Computerised-CBT (CCBT)	670		13	
23	Psychoeducational group programme	228	**Psychoeducational interventions ***	14	228
24	Interpersonal psychotherapy (IPT)	145	**Interpersonal psychotherapy (IPT)***	15	145
25	Emotion-focused therapy (EFT)	19	**Counselling**	16	157
26	Non-directive counselling	67		16	
27	Relational client-centred therapy	19		16	
28	Counselling (any type)	52		16	
29	CBT individual (under 15 sessions)	156	**Cognitive and cognitive behavioural therapies**	17	580
30	CBT individual (over 15 sessions)	168		17	
31	CBT group (under 15 sessions)	80		17	
32	Problem solving	134		17	
33	Third-wave cognitive therapy group	30		17	
34	Third-wave cognitive therapy individual	12		17	
35	Behavioural activation (BA)	116	**Behavioural therapies***	18	116
36	CBT individual (over 15 sessions) + any SSRI	60	**Combined (Cognitive and cognitive behavioural therapies + AD)**	19	155
37	CBT individual (over 15 sessions) + imipramine	25		19	
38	CBT individual (over 15 sessions) + nortriptyline	19		19	
39	CBT individual (under 15 sessions) + amineptine	51		19	

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
40	Interpersonal psychotherapy (IPT) + any TCA	49	**Combined (IPT + AD)***	20	49
41	Interpersonal psychotherapy (IPT) + Pill placebo	47	**Combined (psych + placebo)**	21	116
42	CBT individual (over 15 sessions) + Pill placebo	18		21	
43	CBT individual (under 15 sessions) + Pill placebo	51		21	
44	Long-term psychodynamic psychotherapy individual + fluoxetine	76	**Long-term psychodynamic psychotherapy individual + any SSRI***	22	76

**Variance borrowed from another class as described in section 17.2.3*

Figure 35: Discontinuation. Network diagram of all studies included in analysis by intervention



Note: Disconnected interventions are 16, 25, 28, 27, 39 and 43.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 36: Discontinuation. Network diagram of all studies included in analysis by class



The interventions which decreased the odds of discontinuation compared to Pill placebo were Waitlist, CBT individual (over 15 sessions) + any SSRI, and CBT individual (under 15 sessions) + amineptine. Psychoeducational group programme was associated with an increase in discontinuation. Within classes, Waitlist and Combined (CBT+AD) resulted in a decrease in odds of discontinuation and no class resulted in an increase (Figure 37 and Figure 38).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 37: Log-odds ratios and 95% credible intervals of discontinuation for every intervention compared to Pill placebo



Figure 38: Log-odds ratios and 95% credible intervals of discontinuation for every class compared to Pill placebo



Exercise is the highest ranked class at 2nd (95% CrI 1st to 17th). The highest ranked intervention is Yoga with a posterior median rank of 3rd (95% CrI 1st to 35th). The lowest ranked intervention is Psychoeducational group programme at 40th (95% CrI 37th to 40th). The

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

lowest ranked class is Psychoeducational interventions at 20th (16th to 20th) (Table 15 and Appendix 5).

Table 15: Posterior median rank and 95% credible intervals by class

Class	Posterior median rank	95% CrIs
Exercise	2	(1, 17)
Long-term psychodynamic psychotherapies	5	(1, 18)
Self-help with support	5	(1, 16)
Counselling	5	(1, 18)
Combined (Cognitive and cognitive behavioural therapies + AD)	5	(1, 14)
Waitlist	6	(2, 12)
TAU	6	(2, 12)
Short-term psychodynamic psychotherapies	7	(1, 18)
Attention placebo	10	(2, 18)
Cognitive and cognitive behavioural therapies	10	(4, 17)
Self-help	12	(3, 19)
Interpersonal psychotherapy (IPT)	12	(2, 19)
Mirtazapine	13	(5, 18)
Combined (IPT + AD)	13	(2, 19)
TCA	14	(7, 19)
Long-term psychodynamic psychotherapy individual + any SSRI	14	(2, 20)
SSRI	15	(7, 19)
Pill placebo	16	(10, 19)
Behavioural therapies	18	(3, 20)
Psychoeducational interventions	20	(16, 20)

Update 2017

17.3.2.24 Outcome: discontinuation due to SE

After excluding trials with zero events in all arms and those which did not report both discontinuation and discontinuation due to SE, 48 trials of 15 interventions and 8 classes were included for this outcome (Table 16, Figure 39 and Figure 40).

There was no evidence of inconsistency with higher posterior mean residual deviance and DIC values in the inconsistency model (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Relative to the size of the intervention effect estimates, moderate to high between trial heterogeneity was observed for this outcome $(\tau = 0.54\ (95\%\ \text{CrI}\ 0.07\ \text{to}\ 0.95))$.

Table 16: Table of interventions, classes and number of patients (N) included in discontinuation due to SE analysis

	Intervention	N	Class		N
1	Pill placebo	955	**Pill placebo**	1	955
2	Mirtazapine	120	**Mirtazapine**	2	120
3	Amitriptyline	271	**TCA**	3	805

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
4	Imipramine	502		3	
5	Lofepramine	29		3	
6	Any TCA	3		3	
7	Citalopram	150	**SSRI**	4	614
8	Escitalopram	100		4	
9	Fluoxetine	321		4	
10	Sertraline	43		4	
11	CBT individual (under 15 sessions)	2	**Cognitive and cognitive behavioural therapies**	5	9
12	CBT individual (over 15 sessions)	7		5	
13	CBT individual (over 15 sessions) + imipramine	10	**Combined (Cognitive and cognitive behavioural therapies + AD)**	6	10
14	Long-term psychodynamic psychotherapy individual	6	**Long-term psychodynamic psychotherapies**	7	6
15	Long-term psychodynamic psychotherapy individual + fluoxetine	14	**Long-term psychodynamic psychotherapy individual + any SSRI**	8	14

Figure 39: Discontinuation due to SE. Network diagram of every study included in analysis by intervention



Note: Without using a class model interventions 6 and 11 would be disconnected from the rest of the network.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 40: Discontinuation due to SE. Network diagram of every study included in analysis by class



The analysis suggested that Mirtazapine, Amitriptyline, Imipramine, Lofepramine, any TCA, Citalopram, Escitalopram Fluoxetine and Sertraline result in a significant increase in odds of discontinuation due to SE compared to Pill placebo. No interventions result in a decrease (Figure 41). The classes which result in an increase in discontinuation due to SE are Mirtazapine, TCAs and SSRIs (Figure 42).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 41: Log-odds ratios and 95% credible intervals for every intervention compared to Pill placebo



Figure 42: Log-odds ratios and 95% credible intervals for every class compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Long-term psychodynamic psychotherapy individual + any SSRI and Cognitive and Cognitive behavioural therapies are the highest ranked classes at 2nd (95% CrI 1st to 7th) and 2nd (95% CrI 1st to 8th). The highest ranked intervention is Long-term psychodynamic psychotherapy individual + fluoxetine with a posterior median rank of 2nd (95% CrI 1st to 11th). This should be interpreted with caution however as only 14 people were randomised to this intervention (Table 16). The lowest ranked intervention is Long-term psychodynamic psychotherapy individual at 12th (95% CrI 3rd to 13st). The lowest ranked class is Long-term psychodynamic psychotherapies at 8th (2nd to 8th) (Table 17 and Appendix 5). The wide credible intervals suggest considerable uncertainty in these estimates.

Table 17: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Cognitive and cognitive behavioural therapies	2	(1, 8)
Long-term psychodynamic psychotherapy individual + any SSRI	2	(1, 7)
Pill placebo	3	(1, 4)
Combined (Cognitive and cognitive behavioural therapies + AD)	3	(1, 8)
SSRI	5	(3, 7)
Mirtazapine	6	(4, 8)
TCA	7	(4, 8)
Long-term psychodynamic psychotherapies	8	(2, 8)

Update 2017

17.3.2.3 Outcome: remission in responders

After excluding trials with zero events in all arms and those which did not report both remission and response, only 19 trials of 13 interventions and 8 classes remained to be included in the analysis for this outcome (Table 18). The network was disconnected with Pill placebo, TCAs and SSRIs being separate from the other interventions (Figure 43 and Figure 44).

Table 18: Table of interventions, classes and number of patients (N) included in remission analysis

	Intervention	N	Class		N
1	Pill placebo	460	Pill placebo	1	460
2	TAU	41	TAU	2	41
3	Exercise	21	Exercise	3	21
4	Amitriptyline	47	TCA	4	203
5	Imipramine	156		4	
6	Citalopram	315	SSRI	5	1599
7	Escitalopram	662		5	
8	Fluoxetine	457		5	
9	Sertraline	165		5	
10	Intensive clinical management	77	Psychoeducational interventions	6	77
11	Behavioural activation (BA)	11	Behavioural therapies	7	79
12	Social rhythm therapy (SRT)	68		7	
13	Short-term psychodynamic psychotherapy individual	44	Short-term psychodynamic psychotherapies	8	44

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 43: Remission. Network diagram of every study included in analysis by intervention



Figure 44: Remission. Network diagram of every study included in analysis by class



Looking at the relative effects of TCAs and SSRIs compared to Pill placebo in the subnetwork where they have been compared (subnetwork 1), no evidence of effectiveness can be seen for any intervention or class (Figure 45 and Figure 46). The same is true for subnetwork 2 where Exercise, Psychoeducational interventions, Behavioural therapies and Short-term psychodynamic psychotherapies have been compared to TAU (Figure 47 and Figure 48).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 45: Subnetwork 1. Log-odds ratios and 95% credible intervals for interventions connected to Pill placebo



Figure 46: Subnetwork 1. Log-odds ratios and 95% credible intervals for classes compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 47: Subnetwork 2. Log-odds ratios and 95% credible intervals for interventions compared to TAU



Figure 48: Subnetwork 2. Log-odds ratios and 95% credible intervals for classes compared to TAU



Due to the disconnectedness of the network no ranking of interventions or classes could be carried out.

17.3.2.4 Outcome: remission in those randomised

After excluding trials with zero events in all arms 23 trials of 19 interventions and 12 classes remained to be included in the analysis for this outcome (Table 19, Figure 49 and Figure 50).

No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Relative to the size of the intervention effect estimates, high between trial heterogeneity was observed for this outcome $(\tau = 0.66\ (95\%\ \text{CrI}\ 0.43\ \text{to}\ 1.05))$.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Table 19: Table of interventions, classes and number of patients (N) included in remission in those randomised analysis

	Intervention	N	Class		N
1	Pill placebo	1076	**Pill placebo**	1	1076
2	Waitlist	195	**Waitlist**	2	195
3	Mirtazapine	66	**Mirtazapine**	3	66
4	Amitriptyline	281	**TCA**	4	620
5	Imipramine	323		4	
6	Any TCA	16		4	
7	Citalopram	737	**SSRI**	5	3097
8	Escitalopram	1056		5	
9	Fluoxetine	1032		5	
10	Sertraline	272		5	
11	Computerised-CBT (CCBT) with support	149	**Self-help with support**	6	149
12	Interpersonal psychotherapy (IPT)	75	**Interpersonal psychotherapy (IPT)**	7	75
13	CBT individual (over 15 sessions)	122	**Cognitive and cognitive behavioural therapies**	8	171
14	Problem solving	49		8	
15	CBT individual (over 15 sessions) + imipramine	25	**Combined (Cognitive and cognitive behavioural therapies + AD)**	9	43
16	CBT individual (over 15 sessions) + nortriptyline	18		9	
17	CBT individual (over 15 sessions) + Pill placebo	17	**Combined (psych + placebo)**	10	17
18	Long-term psychodynamic psychotherapy individual	90	**Long-term psychodynamic psychotherapies**	11	90
19	Long-term psychodynamic psychotherapy individual + fluoxetine	91	**Long-term psychodynamic psychotherapy individual + any SSRI**	12	91

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 49: Remission in those randomised. Network diagram of every study included in analysis by intervention



Note: Interventions 2, 11, and 14 are disconnected from the rest of the network.

Figure 50: Remission in those randomised. Network diagram of every study included in analysis by class



The analysis suggested an increased odds of remission compared to Pill placebo with Long-term psychodynamic psychotherapy individual and Long-term psychodynamic psychotherapy individual + fluoxetine. No interventions had a statistically significant reduction in odds of remission compared to Pill placebo (Figure 51). The classes with an increased odds of response are Long-term psychodynamic psychotherapies and Long-term psychodynamic psychotherapy individual + any SSRI (Figure 52).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 51: Log-odds ratios and 95% credible intervals of remission in those randomised for every intervention compared to Pill placebo



Figure 52: Log-odds ratios and 95% credible intervals of remission in those randomised for every class compared to Pill placebo



Long-term psychodynamic psychotherapies and Long-term psychodynamic psychotherapy individual + any SSRI are the highest ranked classes at 1st (95% CrI 1st to 6th) and 2nd (95% CrI 1st to 7th), respectively. The highest ranked intervention is Long-term psychodynamic psychotherapy individual with a posterior median rank of 1st (95% CrI 1st to 6th). The lowest

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

ranked intervention is Waitlist. The lowest ranked active class is Self-help with support at 10th (2nd to 11th) (Table 20 and Appendix 5).

Table 20: Remission in those randomised. Posterior median rank and 95% credible intervals

Intervention	Posterior median rank	95% CrIs
Long-term psychodynamic psychotherapies	1	(1 - 6)
Long-term psychodynamic psychotherapy individual + any SSRI	2	(1 - 7)
Combined (Cognitive and cognitive behavioural therapies + AD)	3	(1 - 8)
Interpersonal psychotherapy (IPT)	5	(1 - 11)
Cognitive and cognitive behavioural therapies	5	(2 - 9)
TCAs	6	(3 - 10)
Pill placebo	7	(4 - 10)
Mirtazapine	7	(2 - 11)
SSRIs	7	(3 - 10)
Self-help with support	10	(2 - 11)
Waitlist	11	(6 - 11)

17.3.2.55 Outcome: response (completers)

After excluding trials with zero events in all arms, 62 trials reported response. Out of the remaining studies, 5 reported change from baseline in completers (but not response) and 14 reported baseline and final scores in completers (but not response or change from baseline). This meant that 81 trials of 29 interventions and 16 classes were included in the analysis for this outcome (Table 21, Figure 54 and Figure 55).

No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Relative to the size of the intervention effect estimates, high between trial heterogeneity was observed for this outcome $(\tau = 0.57\ (95\%\ \mathrm{CrI}\ 0.43\ \text{to}\ 0.74))$.

Update 2017

Table 21: Table of interventions, classes and number of patients (N) included in response in completers analysis

	Intervention	N	Class	Class	N
1	Pill placebo	2702	Pill placebo	1	2702
2	Waitlist	16	Waitlist	2	16
3	Attention placebo	58	Attention placebo	3	58
4	TAU	312	TAU	4	312
5	Exercise	77	Exercise	5	95
6	Yoga	18		5	
7	Mirtazapine	496	Mirtazapine	6	496
8	Amitriptyline	870	TCAs	7	1804
9	Imipramine	832		7	
10	Lofepramine	34		7	
11	Any TCA	68		7	
12	Citalopram	1044	SSRIs	8	4560
13	Escitalopram	1632		8	

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class	Class	N
14	Fluoxetine	1278		8	
15	Sertraline	606		8	
16	Any AD	43	Any AD*	9	43
17	Short-term psychodynamic psychotherapy individual	140	Short-term psychodynamic psychotherapies*	10	140
18	Cognitive bibliotherapy	38	Self-help	11	38
19	Non-directive counselling	62	Counselling	12	101
20	Counselling (any type)	39		12	
21	CBT individual (under 15 sessions)	142	Cognitive and cognitive behavioural therapies	13	225
22	CBT individual (over 15 sessions)	27		13	
23	CBT group (under 15 sessions)	26		13	
24	Third-wave cognitive therapy group	19		13	
25	Third-wave cognitive therapy individual	11		13	
26	Behavioural activation (BA)	16	Behavioural therapies*	14	16
27	CBT individual (over 15 sessions) + any SSRI	43	Combined (Cognitive and cognitive behavioural therapies + AD)	15	57
28	CBT individual (over 15 sessions) + nortriptyline	14		15	
29	CBT individual (over 15 sessions) + Pill placebo	17	Combined (psych + placebo)*	16	17

1 **Variance borrowed from another class as described in section 17.2.3*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 53: Response in completers. Network diagram of every study included in analysis by intervention



Note: Disconnected interventions are 16, 20, 23 and 24.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 54: Response in completers. Network diagram of every study included in analysis by class



The analysis suggested an increased odds of response compared to Pill placebo with Exercise, Mirtazapine, Amitriptyline, Imipramine, Lofepramine, any TCA, Escitalopram, Fluoxetine, Sertraline, Short-term psychodynamic psychotherapy individual, Behavioural activation, and CBT individual (over 15 sessions) + nortriptyline. No interventions had a decreased odds of response compared to Pill placebo (Figure 55). The classes with an increased odds of response are Mirtazapine, TCAs, SSRIs and Behavioural Therapies (Figure 56).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 55: Log-odds ratios and 95% credible intervals for every intervention compared to Pill placebo



Figure 56: Log-odds ratios and 95% credible intervals for every class compared to Pill placebo



Behavioural therapies are the highest ranked class at 1st (95% CrI 1st to 8th). The highest ranked interventions are Behavioural activation (2nd, 95% CrI 1st to 13th) and Exercise (2nd, 95% CrI 1st to 18th). The lowest ranked intervention is Waitlist. The lowest ranked active intervention is CBT individual (over 15 sessions) at 21st (95% CrIs 10th to 26th). The lowest

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

ranked active class is Self-help at 10th (2nd to 14th) (Table 22 and Appendix 5). There is a lot of uncertainty in these estimates as is evident from the wide credible intervals.

Table 22: Posterior median rank and 95% credible intervals by class

Class	Posterior Median rank	95% CrIs
Behavioural therapies	1	(1, 8)
Exercise	2	(1, 11)
Combined (Cognitive and cognitive behavioural therapies + AD)	4	(1, 11)
Short-term psychodynamic psychotherapies	5	(1, 12)
Counselling	5	(1, 13)
TCA	6	(2, 11)
Mirtazapine	8	(3, 12)
Cognitive and cognitive behavioural therapies	8	(3, 13)
Attention placebo	9	(3, 14)
TAU	9	(5, 13)
SSRI	10	(4, 13)
Self-help	10	(2, 14)
Pill placebo	13	(8, 14)
Waitlist	14	(6, 14)

17.3.2.64 Outcome: response in those randomised

Update 2017

After excluding trials with zero events in all arms, 63 trials reported response. Out of the remaining studies, 6 reported change from baseline in those randomised (but not response) and 27 reported baseline and final scores in those randomised (but not response or change from baseline). This meant that 96 trials of 33 interventions and 19 classes were included in the analysis for this outcome (Table 23, Figure 57 and Figure 58).

No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency. Relative to the size of the intervention effect estimates, high between-trial heterogeneity was observed for this outcome $(\tau = 0.70\ (95\%\ \text{CrI}\ 0.57\ \text{to}\ 0.87))$.

Table 23: Table of interventions, classes and number of patients (N) included in response in those randomised analysis

	Intervention	N	Class		N
1	Pill placebo	3725	**Pill placebo**	1	3725
2	Waitlist	60	**Waitlist**	2	60
3	Attention placebo	80	**Attention placebo**	3	80
4	TAU	830	**TAU**	4	830
5	Exercise	50	**Exercise***	5	50
6	Mirtazapine	645	**Mirtazapine**	6	645
7	Amitriptyline	1206	**TCA**	7	2419
8	Imipramine	1151		7	
9	Lofepramine	46		7	
10	Any TCA	16		7	
11	Citalopram	1255	**SSRI**	8	5874

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Intervention	N	Class		N
12	Escitalopram	1950		8	
13	Fluoxetine	1810		8	
14	Sertraline	859		8	
15	Computerised-CBT (CCBT) with support	54	**Self-help with support***	9	54
16	Cognitive bibliotherapy	50	**Self-help***	10	757
17	Computerised-CBT (CCBT)	707		10	
18	Intensive clinical management	111	**Psychoeducational interventions***	11	111
19	Interpersonal psychotherapy (IPT)	95	**Interpersonal psychotherapy (IPT)***	12	95
20	Emotion-focused therapy (EFT)	19	**Counselling**	13	120
21	Non-directive counselling	82		13	
22	Relational client-centred therapy	19		13	
23	CBT individual (under 15 sessions)	173	**Cognitive and cognitive behavioural therapies**	14	391
24	CBT individual (over 15 sessions)	156		14	
25	CBT group (under 15 sessions)	41		14	
26	Third-wave cognitive therapy individual	21		14	
27	Behavioural activation (BA)	126	**Behavioural therapies***	15	236
28	Social rhythm therapy (SRT)	110		15	
29	CBT individual (under 15 sessions) + citalopram	40	**Combined (Cognitive and cognitive behavioural therapies + AD)**	16	58
30	CBT individual (over 15 sessions) + nortriptyline	18		16	
31	Exercise + Fluoxetine	41	**Combined (Exercise + AD/CBT)**	17	41
32	CBT individual (over 15 sessions) + Pill placebo	17	**Combined (psych + placebo)***	18	17
33	Short-term psychodynamic psychotherapy individual	120	**Short-term psychodynamic psychotherapies***	19	120

1 **Variance borrowed from another class as described in section 17.2.3*

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 57: Response in those randomised. Network diagram of every study included in analysis by intervention



Note: Disconnected interventions are 18 and 28.

Figure 58: Response in those randomised. Network diagram of every study included in analysis by class



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

The analysis suggested an increased odds of response compared to Pill placebo with Mirtazapine, Amitriptyline, Imipramine, Lofepramine, Escitalopram, Fluoxetine, Sertraline, and Exercise + Fluoxetine. Waitlist, Attention placebo, TAU, Exercise, Computerised-CBT (CCBT) with support, Cognitive bibliotherapy, Computerised-CBT (CCBT), Non-directive counselling, Relational client-centred therapy, CBT individual (under 15 sessions) and Short-term psychodynamic psychotherapy individual had a statistically significant reduction in response compared to Pill placebo (Figure 59). The classes with an increased odds of response are Mirtazapine, TCAs and Combined (Exercise + AD/CBT) (Figure 60). The classes with a decreased odds of response are Waitlist, Attention placebo, TAU, Exercise, Self-help, Counselling and Short-term psychodynamic psychotherapies.

Figure 59: Log-odds ratios and 95% credible intervals for every intervention compared to Pill placebo



Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 60: Log-odds ratios and 95% credible intervals for every class compared to Pill placebo



Combined (Exercise +AD/CBT) is the highest ranked class at 1st (95% CrI 1st to 2nd). The highest ranked intervention is Exercise + Fluoxetine with a posterior median rank of 1st (95% CrI 1st to 3rd). The lowest ranked intervention is TAU at 28th (95% CrI 25th to 30th). The lowest ranked active intervention is Cognitive bibliotherapy. The lowest ranked active class is Self-help at 15th (10th to 18th) (Table 24 and Appendix 5).

Table 24: Posterior median rank and 95% credible intervals by class

Class	Posterior median rank	95% CrIs
Combined (Exercise + AD/CBT)	1	(1 - 2)
TCA	3	(2 - 6)
Combined (Cognitive and cognitive behavioural therapies + AD)	4	(1 - 8)
Mirtazapine	4	(2 - 7)
SSRI	5	(2 - 8)
Cognitive and cognitive behavioural therapies	7	(3 - 10)
Pill placebo	7	(5 - 10)
Interpersonal psychotherapy (IPT)	8	(2 - 14)
Psychoeducational interventions	10	(2 - 18)
Behavioural therapies	10	(4 - 17)
Self-help with support	12	(7 - 18)
Counselling	13	(8 - 18)
Short-term psychodynamic psychotherapies	13	(8 - 18)
Exercise	14	(9 - 18)
Self-help	15	(10 - 18)

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Class	Posterior median rank	95% CrIs
Waitlist	15	(11 - 18)
Attention placebo	15	(10 - 18)
TAU	16	(14 - 18)

17.3.2.71 Outcome: SMD

After excluding trials with zero events in all arms, 15 trials reported CFB. Out of the remaining studies 40 reported baseline and follow-up scores (but not CFB) and 13 reported response (but not CFB or baseline and follow-up). This meant that 68 trials of 32 interventions and 18 classes were included in the analysis for this outcome (Table 25, Figure 61 and Figure 62).

Relative to the size of the intervention effect estimates, moderate between trial heterogeneity was observed for this outcome $(\tau = 0.40\ (95\%\ \text{CrI}\ 0.31\ \text{to}\ 0.52))$. No meaningful differences were observed in posterior mean residual deviance or between study heterogeneity suggesting that there was no evidence of inconsistency (Appendix 3). Reported results are therefore based on the random-effects NMA model, assuming consistency.

Table 25: Table of interventions, classes and number of patients (N) included in SMD analysis

	Intervention	N	Class		N
1	Pill placebo	2229	**Pill placebo**	1	2229
2	Waitlist	60	**Waitlist**	2	60
3	Attention placebo	80	**Attention placebo**	3	80
4	TAU	825	**TAU**	4	825
5	Exercise	50	**Exercise***	5	50
6	Mirtazapine	326	**Mirtazapine**	6	326
7	Amitriptyline	545	**TCA**	7	1260
8	Imipramine	653		7	
9	Lofepramine	46		7	
10	Any TCA	16		7	
11	Citalopram	1034	**SSRI**	8	4696
12	Escitalopram	1841		8	
13	Fluoxetine	1276		8	
14	Sertraline	545		8	
15	Computerised-CBT (CCBT) with support	54	**Self-help with support***	9	54
16	Cognitive bibliotherapy	50	**Self-help***	10	757
17	Computerised-CBT (CCBT)	707		10	
18	Interpersonal psychotherapy (IPT)	95	**Interpersonal psychotherapy (IPT)***	11	95
19	Emotion-focused therapy (EFT)	19	**Counselling**	12	120
20	Non-directive counselling	82		12	
21	Relational client-centred therapy	19		12	
22	CBT individual (under 15 sessions)	173	**Cognitive and cognitive behavioural therapies**	13	391

Update 2017

	Intervention	N	Class		N
23	CBT individual (over 15 sessions)	156		13	
24	CBT group (under 15 sessions)	41		13	
25	Third-wave cognitive therapy individual	21		13	
26	Behavioural activation (BA)	126	**Behavioural therapies***	14	126
27	CBT individual (under 15 sessions) + citalopram	40	**Combined (Cognitive and cognitive behavioural therapies + AD)**	15	58
28	CBT individual (over 15 sessions) + nortriptyline	18		15	
29	Exercise + Fluoxetine	41	**Combined (Exercise + AD/CBT)**	16	41
30	CBT individual (over 15 sessions) + Pill placebo	17	**Combined (psych + placebo)**	17	17
31	Short-term psychodynamic psychotherapy individual	115	**Short-term psychodynamic psychotherapies**	18	115

Variance borrowed from another class as described in section 17.2.3

Figure 61: SMD. Network diagram of every study included in analysis by intervention



Note: Disconnected interventions are 19 and 21.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 62: SMD. Network diagram of every study included in analysis by class



The analysis suggested that Amitriptyline, Imipramine, Escitalopram, Fluoxetine, CBT group (under 15 sessions), Third-wave cognitive therapy individual, and Exercise + Fluoxetine result in a lower standardised mean difference in depression compared to Pill placebo. Waitlist, Attention placebo, and TAU result in a higher standardised mean difference. No class had a lower standardised mean difference in depression. Waitlist, Attention placebo and TAU were classes with a higher standardized mean difference (Figure 63 and Figure 64).

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Figure 63: SMD and 95% credible intervals for every intervention compared to Pill placebo



Figure 64: SMD and 95% credible intervals for every class compared to Pill placebo



Update 2017

Cognitive and Cognitive behavioural therapies is the highest ranked class at 2nd (95% CrI 1st to 8th). The highest ranked intervention is CBT group (under 15 sessions) with a posterior median rank of 1st (95% CrI 1st to 2nd). The lowest ranked intervention is Waitlist at 28th (95% CrI 20th to 29th). The lowest ranked active intervention is Cognitive bibliotherapy. The lowest ranked active class is Self-help without support at 13th (6th to 17th) (Table 26 and Appendix 5).

National Institute for Health and Care Excellence [2017]. All rights reserved.

Table 26: Posterior median rank and 95% credible intervals by class

Class	Posterior median rank	95% CrIs
Cognitive and cognitive behavioural therapies	2	(1, 8)
Combined (Exercise + AD/CBT)	2	(1, 10)
TCAs	4	(1, 9)
Combined (Cognitive and cognitive behavioural therapies + AD)	4	(1, 11)
Mirtazapine	6	(2, 11)
SSRIs	6	(2, 11)
Pill placebo	8	(5, 12)
Interpersonal psychotherapy (IPT)	8	(1, 16)
Behavioural therapies	9	(1, 17)
Self-help with support	11	(1, 17)
Counselling	11	(3, 17)
Short-term psychodynamic psychotherapies	12	(3, 17)
Exercise	13	(5, 17)
Self-help	13	(6, 17)
Attention placebo	14	(10, 17)
TAU	14	(11, 17)
Waitlist	15	(11, 17)

17.42 Assumptions and limitations

- We assumed that our methods for converting baseline and final and response data to CFB would give reliable estimates of CFB. These equations are based on a mathematical relationship with the assumption of normality of the underlying continuous data. As mentioned in the methods section we checked these assumptions by looking at the observed data for studies reporting all outcomes. It is not possible to know if this agreement also applies to the other studies.
- Similarly we assumed that the method we used to convert SMD to response gave reliable estimates of response. This method is well known and recommended by the Cochrane Collaboration, although it may not always perform well (Meister et al. 2015.).
- The observed correlation between baseline and follow-up was assumed to be 0.5. This value was used following convention, as we failed to find consistency in estimates of these correlations for any scale in the literature. We tested this assumption in sensitivity analysis using an estimate of 0.3 and found no impact on the results.
- For the SMD analysis we needed to make an assumption about the relationship between the standard deviation at baseline and standard deviation at follow-up. From looking at the data we had, we assumed that these were equal. This was also tested in sensitivity analysis using the regression equation to transform the baseline standard deviation with no impact on results.
- We assumed the existence of class effects and modelled the data in this way. We tested this by running fixed class effect models and noted their comparability to random class effect models. We therefore conclude that there is evidence of agreement of relative treatment effects across elements of the same class.
- As we had several classes with only 1 or 2 interventions we needed to make some assumptions about the variance of those classes. The assumptions we made are highlighted in the report. These were informed by clinical opinion from members of the guideline committee.

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.5 References

Brooks S, Gelman A. Alternative methods for monitoring convergence of iterative simulations. Journal of Computatinal and Graphical Statistics 1998;7:434-55

Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005 2005;331:897-900

Chinn S. A simple method for converting an odds ratio to effect size for use in metaanalysis. Statistics in Medicine. 2000;19:3127–31

Cohen J. Statistical power analysis for the behavioral sciences. Academic Press, New York, 1969

Cooper H., Hedges LV, Valentine JC. 2009. The Handbook of Research Synthesis and Meta-analysis, New York, Russel Sage Foundation

Dias S, Ades A, Sutton A, Welton N. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Medical Decision Making 2013;33:607-17.

Dias S, Welton N, Sutton A, Ades A. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials NICE Decision Support Unit Evidence Synthesis Technical Support Document 2 2011; August 2011

Gelman A, Rubin D. Inferences from iterative simulation using multiple sequences. Statistical Science 1992;7:457-72.

Higgins JPT, and Whitehead A. 1996. Borrowing strength from external trials in a meta-analysis.Statist.Med.,15:2733–2749.Doi:10.1002/(Sici)1097-0258(19961230)15:24<2733::Aid-Sim562>3.0.Co;2-0

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org

Lewinsohn PM, Biglan A, Zeiss AM. 1976. Behavioral treatment of depression. In P.O. Davidson (Ed.), The behavioral management of anxiety, depression and pain. Brunner/Mazel, New York

Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004 2004;23:3105-3124.

Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book. Boca Raton, FL: CRC Press; 2013.

Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS -- a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000 2000;10:325-337.

Meister R., Von Wolff A. Kriston L. 2015. Odds ratios of treatment response were well approximated from continuous rating scale scores for meta-analysis. Journal of Clinical Epidemiology, 68, 740-751

Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3(2):http://dx.doi.org/10.1002/jrsm.37.

Spiegelhalter DJ, Best,NG, Carlin BP and van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society 2002;B,64:583-616

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Sweeting M, Sutton A, Lambert P. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-75.

Welton N, Sutton A, Cooper N, Abrams K, Ades A. 2012 Evidence synthesis for decision making in healthcare: Wiley

17.6 Appendix 1: WinBUGS code

17.6.1 Sample WinBUGS code – SMD analysis

```
# Normal likelihood, identity link: SMD with arm-based means
# Random effects model for multi-arm trials
model{                                  # *** PROGRAM STARTS
for(i in 1:ns){                         #   LOOP THROUGH STUDIES
  w[i,1] <- 0   # adjustment for multi-arm trials is zero for control arm
  delta[i,1] <- 0                       # treatment effect is zero for control arm
  mu[i] ~ dnorm(0,.0001)                # vague priors for all trial baselines
 }
# (1) CFB DATA
for(i in 1:nsCFB){
  # calculate pooled.sd and adjustment for SMD
  df[i] <- sum(nCFB[i,1:naCFB[i]]) - naCFB[i] # denominator for pooled.var
  Pooled.var[i] <- sum(nvar[i,1:naCFB[i]])/df[i]
  Pooled.sd[i] <- sqrt(Pooled.var[i]) # pooled sd for study i, for SMD
#  H[i] <- 1 - 3/(4*df[i]-1)           # use Hedges' g
  H[i] <- 1                             # use Cohen's d (ie no adjustment)
  for (k in 1:naCFB[i]){
    se[i,k] <- sdCFB[i,k]/sqrt(nCFB[i,k])
    var[i,k] <- pow(se[i,k],2)          # calcultate variances
    prec[i,k] <- 1/var[i,k]             # set precisions
    y[i,k] ~ dnorm(phi[i,k], prec[i,k]) # normal likelihood
    phi[i,k] <- theta[i,k] * (Pooled.sd[i]/H[i]) # theta is stand mean
    theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor, delta is SMD
    dev[i,k] <- (y[i,k]-phi[i,k])*(y[i,k]-phi[i,k])*prec[i,k]
    nvar[i,k] <- (nCFB[i,k]-1) * pow(sdCFB[i,k],2) # for pooled.sd
   }
  # summed residual deviance contribution for this trial
  resdev[i] <- sum(dev[i,1:naCFB[i]])
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
 }
# (2) BASELINE + FOLLOW-UP DATA (no CFB)
for(i in 1:nsBF){                    #   LOOP THROUGH STUDIES
  # calculate pooled.sd and adjustment for SMD
  df[i+nsCFB] <- sum(n[i,1:na[i]]) - na[i] # denominator for pooled.var
  Pooled.var[i+nsCFB] <- sum(nvarBF[i,1:na[i]])/df[i+nsCFB]
  Pooled.sd[i+nsCFB] <- sqrt(Pooled.var[i])# pooled sd for study i, for SMD
#  H[i] <- 1 - 3/(4*df[i]-1)           # use Hedges' g
  H[i+nsCFB] <- 1                    # use Cohen's d (ie no adjustment)
  for (k in 1:na[i]){
    yBF[i,k] <- yF[i,k] - yB[i,k]     # calculate mean CFB
    seF[i,k] <- sdF[i,k]/sqrt(n[i,k]) # se at followup
    seB[i,k] <- sdB[i,k]/sqrt(n[i,k]) # se at baseline
    # variance of mean CFB, assuming correlation corr[i]
    var[i+nsCFB,k] <- pow(seF[i,k],2)+ pow(seB[i,k],2)
-2*(seF[i,k]*seB[i,k]*corr[i])
    prec[i+nsCFB,k] <- 1/var[i+nsCFB,k] # set CFB precisions
    yBF[i,k] ~ dnorm(phi[i+nsCFB,k], prec[i+nsCFB,k]) # normal likelihood
    # theta is standardised mean
    phi[i+nsCFB,k] <- theta[i+nsCFB,k] * (Pooled.sd[i+nsCFB]/H[i+nsCFB])
    # model for linear predictor, delta is SMD
    theta[i+nsCFB,k] <- mu[i+nsCFB] + delta[i+nsCFB,k]
    # residual deviance contribution
    dev[i+nsCFB,k] <- (yBF[i,k]-phi[i+nsCFB,k]) * (yBF[i,k]-phi[i+nsCFB,k])
* prec[i+nsCFB,k]
    # variance of CFB, assuming correlation corrBF[i] (var is sd squared)
    varBF[i,k] <- pow(sdF[i,k],2) + pow(sdB[i,k],2)
- 2*(sdF[i,k]*sdB[i,k]*corr[i])
    nvarBF[i,k] <- (n[i,k]-1) * varBF[i,k] # for pooled.sd
   }
  # summed residual deviance contribution for this trial
  resdev[i+nsCFB] <- sum(dev[i+nsCFB,1:na[i]])
 }
# (3) RESPONSE DATA (no CFB or BL+follow-up)
for(i in 1:nsR){                    #   LOOP THROUGH STUDIES
  # calculate pooled.sd and adjustment for SMD
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
  df[i+nsCFB+nsBF] <- sum(nR[i,1:naR[i]]) - naR[i] # denominator for
pooled.var

  Pooled.var[i+nsCFB+nsBF] <- sum(nvarR[i,1:naR[i]])/df[i+nsCFB+nsBF]

  Pooled.sd[i+nsCFB+nsBF] <- sqrt(Pooled.var[i])# pooled sd for study i,
for SMD #  H[i] <- 1 - 3/(4*df[i]-1)          # use Hedges' g

  H[i+nsCFB+nsBF] <- 1               # use Cohen's d (ie no adjustment)

  for (k in 1:naR[i]){

    r[i,k] ~ dbin(R[i,k], nR[i,k])   # binomial likelihood

    R[i,k] <- phi.adj[i,k]

    x[i,k] <- -(q[i]*yBR[i,k]+ phi[i+nsCFB+nsBF,k])/(sdBR[i,k] *
sqrt(1+(1-q[i])*(1-q[i]-2*corrR[i])))

    # adjust link function phi(x) for extreme values that can give
numerical

    # errors when x< -5, phi(x)=0, when x> 5, phi(x)=1

    phi.adj[i,k] <- (step(5+x[i,k]) * step(x[i,k]-5)

           + step(5-x[i,k])* step(x[i,k]+5) * phi(x[i,k]))*(1-
equals(x[i,k],5))

           + equals(x[i,k],5)   # correct for x=5

    # theta is standardised mean

    phi[i+nsCFB+nsBF,k] <- theta[i+nsCFB+nsBF,k]

                * (Pooled.sd[i+nsCFB+nsBF]/H[i+nsCFB+nsBF])

    # model for linear predictor, delta is SMD

    theta[i+nsCFB+nsBF,k] <- mu[i+nsCFB+nsBF] + delta[i+nsCFB+nsBF,k]

    # residual deviance contribution

    rhat[i,k] <- R[i,k] * nR[i,k]

    dev[i+nsCFB+nsBF,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))

        + (nR[i,k]-r[i,k]) * (log(nR[i,k]-r[i,k]) - log(nR[i,k]-
rhat[i,k])))
# Sensitivity analysis
#    sdR[i,k] <-  0.693 + sdBR[i,k] * 3.266  # sd for response
    sdR[i,k] <-  sdBR[i,k]          # sd for response
    nvarR[i,k] <- (nR[i,k]-1) * pow(sdR[i,k],2) # for pooled.sd
   }
  # summed residual deviance contribution for this trial
  resdev[i+nsCFB+nsBF] <- sum(dev[i+nsCFB+nsBF,1:naR[i]])
 }
#
# RE MODEL (CFB data)
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
for(i in 1:nsCFB){                    # LOOP THROUGH STUDIES WITH CFB DATA
  for (k in 2:naCFB[i]){              # LOOP THROUGH ARMS
    # trial-specific RE distributions
    delta[i,k] ~ dnorm(md[i,k], taud[i,k])
    md[i,k] <- d[tCFB[i,k]] - d[tCFB[i,1]] + sw[i,k]
    # precision of RE distributions (with multi-arm trial correction)
    taud[i,k] <- tau *2*(k-1)/k
    #adjustment, multi-arm RCTs
    w[i,k] <- delta[i,k] - d[tCFB[i,k]] + d[tCFB[i,1]]
    # cumulative adjustment for multi-arm trials
    sw[i,k] <-sum(w[i,1:k-1])/(k-1)
   }
 }
# RE MODEL (BL and F-up data)
for(i in 1:nsBF){                     # LOOP THROUGH STUDIES WITH BL+FUP
DATA
  for (k in 2:na[i]){                 # LOOP THROUGH ARMS
    # trial-specific RE distributions
    delta[i+nsCFB,k] ~ dnorm(md[i+nsCFB,k], taud[i+nsCFB,k])
    md[i+nsCFB,k] <- d[t[i,k]] - d[t[i,1]] + sw[i+nsCFB,k]
    # precision of RE distributions (with multi-arm trial correction)
    taud[i+nsCFB,k] <- tau *2*(k-1)/k
    #adjustment, multi-arm RCTs
    w[i+nsCFB,k] <- delta[i+nsCFB,k] - d[t[i,k]] + d[t[i,1]]
  # cumulative adjustment for multi-arm trials
    sw[i+nsCFB,k] <-sum(w[i+nsCFB,1:k-1])/(k-1)
   }
 }
# RE MODEL (Response data)
for(i in 1:nsR){                      # LOOP THROUGH STUDIES WITH RESPONSE
DATA
  for (k in 2:naR[i]){                # LOOP THROUGH ARMS
    # trial-specific RE distributions
    delta[i+nsCFB+nsBF,k] ~ dnorm(md[i+nsCFB+nsBF,k], taud[i+nsCFB+nsBF,k])
    md[i+nsCFB+nsBF,k] <- d[tR[i,k]] - d[tR[i,1]] + sw[i+nsCFB+nsBF,k]
    # precision of RE distributions (with multi-arm trial correction)
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
    taud[i+nsCFB+nsBF,k] <- tau *2*(k-1)/k
    #adjustment, multi-arm RCTs
    w[i+nsCFB+nsBF,k] <- delta[i+nsCFB+nsBF,k] - d[tR[i,k]] + d[tR[i,1]]
    # cumulative adjustment for multi-arm trials
    sw[i+nsCFB+nsBF,k] <-sum(w[i+nsCFB+nsBF,1:k-1])/(k-1)
  }
 }
#
totresdev <- sum(resdev[])              # Total Residual Deviance (all
data)
# Partial Residual Deviance
totresdev.p[1] <- sum(resdev[1:nsCFB])                    # CFB data
totresdev.p[2] <- sum(resdev[nsCFB+1:nsCFB+nsBF])         # BL + Fup data
totresdev.p[3] <- sum(resdev[nsCFB+nsBF+1:nsCFB+nsBF+nsR]) # Response data
#
# Priors and model assumptions (classes)
d[1]<-0                        # treatment effect is zero for control arm
# no class treatments, vague prior for treatment effects
for (k in 2:5){ d[k] ~ dnorm(0, .0001) }
#
# single treatment classes, borrowing variance
#d[15] ~ dnorm(m[D[15]], prec2[9])  # variance from SSRI/TCA
#y <- (1/prec2[8]) + (1/prec2[7])
#prec2[9] <- 1/y
# variance from CBT
for (k in 16:18){ d[k] ~ dnorm(m[D[k]], prec2[16]) }
for (k in 25:26){ d[k] ~ dnorm(m[D[k]], prec2[16]) }
#
# treatment effects from Class, estimate variance
for (k in 6:15){  d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 19:24){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 27:nt){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
#
# no class treatments: class effect = treat effect
m[1] <- 0
m[2] <- d[2]
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
m[3] <- d[3]
m[4] <- d[4]
#
# priors for mean class effect
for (k in 5:nc){ m[k] ~ dnorm(0, .0001)  }
for (k in 1:nc){
  sd2[k] ~ dnorm(0,tau2)I(0,)          # prior for class precision
  prec2[k] <- pow(sd2[k], -0.5)
}
#
tau2 <- pow(0.19,-2)
sdev ~ dunif(0,20)                     # vague prior for between-trial SD
tau <- pow(sdev,-2)                    # between-trial precision
# all pairwise differences
for (c in 1:(nt-1)) {  for (k in (c+1):nt)  { diff[c,k] <- d[k] - d[c] }  }
# rank treatments
for(k in 1:4){ dR[k] <- d[k] }
for(k in 5:6){ dR[k] <- d[k+1] }
dR[7] <- d[9]
for(k in 8:11){ dR[k] <- d[k+3] }
for(k in 12:ntR){ dR[k] <- d[k+4] }
#
for (k in 1:nt)  {
  rk[k]  <- rank(d[],k)
  best[k]  <- equals(rk[k],1)    # Smallest is best (i.e. rank 1)
  # prob treat k is h-th best, prob[1,k]=best[k]
  for (h in 1:nt) { prob[h,k] <- equals(rk[k],h) }
 }
for (k in 1:ntR){
#  rk2[k] <- ntR+1-rank(dR[],k)     # assumes events are "good"
  rk2[k] <- rank(dR[],k)      # assumes events are "bad"
  best2[k]  <- equals(rk2[k],1)    # Smallest is best (i.e. rank 1)
  # prob treat k is h-th best, prob[1,k]=best[k]
  for (h in 1:ntR) { prob2[h,k] <- equals(rk2[k],h) }
 }
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
# pairwise SMDs for all possible class comparisons
for (c in 1:(nt-1)) {
  for (k in (c+1):nc)  {
    diffClass[c,k] <- (m[k]-m[c])
   }
 }
# rank classes
for(k in 1:7){ mR[k] <- m[k]  }
for(k in 8:ncR){ mR[k] <- m[k+1]  }
for (k in 1:nc){
  rkClass[k] <- rank(m[],k)   # assumes events are "good"
  bestClass[k] <- equals(rkClass[k],1) # Smallest is best (i.e. rank 1)
  # prob class k is h-th best, prob[1,k]=best[k]
  for (h in 1:nc){ probClass[h,k] <- equals(rkClass[k],h) }
 }
for (k in 1:ncR)  {
  rkClass2[k]  <- rank(mR[],k)
  bestClass2[k]  <- equals(rkClass2[k],1)    # Smallest is best (i.e. rank
1)
  # prob class k is h-th best, prob[1,k]=best[k]
  for (h in 1:ncR) { probClass2[h,k] <- equals(rkClass2[k],h) }
 }
}                                  # *** PROGRAM ENDS

```

17.6.25 Sample WinBUGS code – Response analysis

```
# Random effects model for multi-arm trials
model{                             # *** PROGRAM STARTS
for(i in 1:ns){                    #   LOOP THROUGH ALL STUDIES
  w[i,1] <- 0   # adjustment for multi-arm trials is zero for control arm
  # RESPONSE DATA
  delta[i,1] <- 0                  # treatment effect is zero for control
arm
  mu[i] ~ dnorm(0,.0001)           # vague priors for all trial baselines
  # CONTINUOUS DATA
  deltaX[i,1] <- 0                 # treatment effect is zero for control
arm
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
  muX[i] ~ dnorm(0,.0001)          # vague priors for all trial baselines
 }
#
# RESPONSE DATA
for(i in 1:nsR){                   # LOOP THROUGH STUDIES WITH RESPONSE
DATA
  for (k in 1:naR[i]){             # LOOP THROUGH ARMS
    r[i,k] ~ dbin(p[i,k],nR[i,k])  # binomial likelihood
    logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
    rhat[i,k] <- p[i,k] * nR[i,k]  # expected value of the numerators
    #Deviance contribution
    dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
          +  (nR[i,k]-r[i,k]) * (log(nR[i,k]-r[i,k]) - log(nR[i,k]-
rhat[i,k])))
   }
  # Summed residual deviance contribution for this trial
  resdev[i] <- sum(dev[i,1:naR[i]])
 }
#
# (1) CFB DATA
for(i in 1:nsCFB){                 # LOOP THROUGH STUDIES WITH CFB DATA
  # calculate pooled.sd and adjustment for SMD
  df[i] <- sum(nCFB[i,1:naCFB[i]]) - naCFB[i] # denominator for pooled.var
  Pooled.var[i] <- sum(nvar[i,1:naCFB[i]])/df[i]
  Pooled.sd[i] <- sqrt(Pooled.var[i]) # pooled sd for study i, for SMD
  # H[i] <- 1 - 3/(4*df[i]-1)       # use Hedges' g
  H[i] <- 1                        # use Cohen's d (ie no adjustment)
  for (k in 1:naCFB[i]){           # LOOP THROUGH ARMS
    se[i,k] <- sdCFB[i,k]/sqrt(nCFB[i,k]) # calculate st error of CFB
    var[i,k] <- pow(se[i,k],2)     # calcultate variances of CFB
    prec[i,k] <- 1/var[i,k]        # set precisions of CFB
    y[i,k] ~ dnorm(phi[i,k], prec[i,k]) # normal likelihood
    phi[i,k] <- theta[i,k] * (Pooled.sd[i]/H[i]) # theta is stand mean
    # model for linear predictor, deltaX is SMD
    theta[i,k] <- muX[i] + deltaX[i,k]
    dev[i+nsR,k] <- (y[i,k]-phi[i,k])*(y[i,k]-phi[i,k])*prec[i,k]
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
    nvar[i,k] <- (nCFB[i,k]-1) * pow(sdCFB[i,k],2) # for pooled.sd
   }
  # summed residual deviance contribution for this trial
  resdev[i+nsR] <- sum(dev[i+nsR,1:naCFB[i]])
 }
# (2) BASELINE + FOLLOW-UP DATA (no CFB)
for(i in 1:nsBF){                  # LOOP THROUGH STUDIES WITH BL + F-UP
DATA
  # calculate pooled.sd and adjustment for SMD
  df[i+nsCFB] <- sum(n[i,1:na[i]]) - na[i] # denominator for pooled.var
  Pooled.var[i+nsCFB] <- sum(nvarBF[i,1:na[i]])/df[i+nsCFB]
  Pooled.sd[i+nsCFB] <- sqrt(Pooled.var[i+nsCFB])# pooled sd for study
i,for SMD   # H[i+nsCFB] <- 1 - 3/(4*df[i]-1) # use Hedges' g
  H[i+nsCFB] <- 1                   # use Cohen's d (ie no adjustment)
  for (k in 1:na[i]){               # LOOP THROUGH ARMS
    yBF[i,k] <- yF[i,k] - yB[i,k]   # calculate mean CFB
    seF[i,k] <- sdF[i,k]/sqrt(n[i,k]) # se at followup
    seB[i,k] <- sdB[i,k]/sqrt(n[i,k]) # se at baseline
    # variance of mean CFB, assuming correlation corr[i]
    var[i+nsCFB,k] <- pow(seF[i,k],2)+ pow(seB[i,k],2)
-2*(seF[i,k]*seB[i,k]*corrBF[i])
    prec[i+nsCFB,k] <- 1/var[i+nsCFB,k] # set CFB precisions
    yBF[i,k] ~ dnorm(phi[i+nsCFB,k], prec[i+nsCFB,k]) # normal likelihood
    # theta is standardised mean
    phi[i+nsCFB,k] <- theta[i+nsCFB,k] * (Pooled.sd[i+nsCFB]/H[i+nsCFB])
    # model for linear predictor, deltaX is SMD
    theta[i+nsCFB,k] <- muX[i+nsCFB] + deltaX[i+nsCFB,k]
    # residual deviance contribution
    dev[i+nsR+nsCFB,k] <- (yBF[i,k]-phi[i+nsCFB,k]) * (yBF[i,k]-
phi[i+nsCFB,k])                          * prec[i+nsCFB,k]
    # variance of CFB, assuming correlation corrBF[i] (var is sd squared)
    varBF[i,k] <- pow(sdF[i,k],2) + pow(sdB[i,k],2)
                - 2*(sdF[i,k]*sdB[i,k]*corrBF[i])
    nvarBF[i,k] <- (n[i,k]-1) * varBF[i,k] # for pooled.sd
   }
  # summed residual deviance contribution for this trial
  resdev[i+nsR+nsCFB] <- sum(dev[i+nsR+nsCFB,1:na[i]])
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
 }
#
# RE MODEL (Response data)
for(i in 1:nsR){                    # LOOP THROUGH STUDIES WITH RESPONSE
DATA
  for (k in 2:naR[i]){              # LOOP THROUGH ARMS
    delta[i,k] ~ dnorm(md[i,k], taud[i,k]) # trial-specific LOR
distributions
    # mean of LOR distributions (with multi-arm trial correction)
    md[i,k] <-  d[tR[i,k]] - d[tR[i,1]] + sw[i,k]
    # precision of LOR distributions (with multi-arm trial correction)
    taud[i,k] <- tau *2*(k-1)/k
    # adjustment for multi-arm RCTs
    w[i,k] <- (delta[i,k] - d[tR[i,k]] + d[tR[i,1]])
    # cumulative adjustment for multi-arm trials
    sw[i,k] <- sum(w[i,1:k-1])/(k-1)
   }
 }
# RE MODEL (CFB data)
for(i in 1:nsCFB){                  # LOOP THROUGH STUDIES WITH CFB DATA
  for (k in 2:naCFB[i]){            # LOOP THROUGH ARMS
    # convert SMD to LOR
    deltaX[i,k] <- delta[i+nsR,k]*((sqrt(3))/-3.1416)
    # trial-specific RE distributions
    delta[i+nsR,k] ~ dnorm(md[i+nsR,k], taud[i+nsR,k])
    md[i+nsR,k] <- d[tCFB[i,k]] - d[tCFB[i,1]] + sw[i+nsR,k]
    # precision of RE distributions (with multi-arm trial correction)
    taud[i+nsR,k] <- tau *2*(k-1)/k
    # adjustment, multi-arm RCTs
    w[i+nsR,k] <- delta[i+nsR,k] - d[tCFB[i,k]] + d[tCFB[i,1]]
    # cumulative adjustment for multi-arm trials
    sw[i+nsR,k] <-sum(w[i+nsR,1:k-1])/(k-1)
   }
 }
# RE MODEL (BL and F-up data)
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
for(i in 1:nsBF){                  # LOOP THROUGH STUDIES WITH BL + F-UP DATA
  for (k in 2:na[i]){              # LOOP THROUGH ARMS
    # convert SMD to LOR
    deltaX[i+nsCFB,k] <- delta[i+nsR+nsCFB,k]*((sqrt(3))/-3.1416)
    # trial-specific RE distributions
    delta[i+nsCFB+nsR,k] ~ dnorm(md[i+nsCFB+nsR,k], taud[i+nsCFB+nsR,k])
    md[i+nsCFB+nsR,k] <- d[t[i,k]] - d[t[i,1]] + sw[i+nsCFB+nsR,k]
    # precision of RE distributions (with multi-arm trial correction)
    taud[i+nsCFB+nsR,k] <- tau *2*(k-1)/k
    #adjustment, multi-arm RCTs
    w[i+nsCFB+nsR,k] <- delta[i+nsR+nsCFB,k] - d[t[i,k]] + d[t[i,1]]
    # cumulative adjustment for multi-arm trials
    sw[i+nsCFB+nsR,k] <-sum(w[i+nsCFB+nsR,1:k-1])/(k-1)
   }
 }
#
# Calculate residual deviance
totresdev <- sum(resdev[])             # Total Residual Deviance (all data)
totresdev.p[1] <- sum(resdev[1:nsR])  # Response data
totresdev.p[2] <- sum(resdev[nsR+1:nsR+nsCFB]) # CFB data
totresdev.p[3] <- sum(resdev[nsR+nsCFB+1:nsCFB+nsBF+nsR]) # BL + FL data
d[1] <- 0                    # treatment effect is zero for reference treatment
m[1] <- 0                    # treatment effect is zero for reference class
#
# Priors and model assumptions (classes)
# no class treatments
d[2] ~ dnorm(0, .0001)          # vague prior for treatment effects
d[3] ~ dnorm(0, .0001)          # vague prior for treatment effects
d[4] ~ dnorm(0, .0001)          # vague prior for treatment effects
d[5] ~ dnorm(0, .0001)          # vague prior for treatment effects
d[7] ~ dnorm(0, .0001)          # vague prior for treatment effects
#
# single treatment classes, borrowing variance
d[6] ~ dnorm(m[D[6]], prec2[15])   # variance from counselling
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
d[18] ~ dnorm(m[D[18]], prec2[9])  # variance from SSRI/TCA
x <- (1/prec2[8]) + (1/prec2[7])
prec2[9] <- 1/x
d[19] ~ dnorm(m[D[19]], prec2[16]) # variance from CBT
d[20] ~ dnorm(m[D[20]], prec2[16]) # variance from CBT
d[21] ~ dnorm(m[D[21]], prec2[16]) # variance from CBT
d[22] ~ dnorm(m[D[22]], prec2[16]) # variance from CBT
d[27] ~ dnorm(m[D[27]], prec2[16]) # variance from CBT
d[28] ~ dnorm(m[D[28]], prec2[16]) # variance from CBT
d[41] ~ dnorm(m[D[41]], prec2[9])  # variance from SSRI/TCA
d[48] ~ dnorm(m[D[48]], prec2[16]) # variance from CBT
#
# treatment effects from Class, estimate variance
for (k in 8:17){  d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 23:26){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 29:40){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 42:47){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
for (k in 49:50){ d[k] ~ dnorm(m[D[k]], prec2[D[k]]) }
#
# no class treatments: class effect = treat effect
m[2] <- d[2]
m[3] <- d[3]
m[4] <- d[4]
m[6] <- d[7]
# priors for mean class effect
m[5] ~ dnorm(0, .0001)
for (k in 7:nc){ m[k] ~ dnorm(0, .0001) }
# priors for class precision
tau2 <- pow(0.19,-2)
for (k in 1:8){
  sd2[k] ~ dnorm(0,tau2)I(0,)   # informative prior for within-class st dev
  prec2[k] <- pow(sd2[k], -0.5) # within-class precision
 }
for (k in 10:nc){
  sd2[k] ~ dnorm(0,tau2)I(0,)   # informative prior for within-class st dev
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
  prec2[k] <- pow(sd2[k], -0.5) # within-class precision
}
#
sdev ~ dunif(0,5)               # vague prior for between-trial SD
tau <- pow(sdev,-2)             # between-trial precision
# pairwise ORs and LORs for all possible treatment comparisons
for (c in 1:(nt-1)){
  for (k in (c+1):nt){
    or[c,k] <- exp(d[k] - d[c])
    lor[c,k] <- (d[k]-d[c])
   }
 }
# rank treatments
for(k in 1:4){  dR[k] <- d[k] }
dR[5] <- d[6]
dR[6] <- d[7]
dR[7] <- d[8]
dR[8] <- d[10]
dR[9] <- d[13]
dR[10] <- d[14]
dR[11] <- d[15]
dR[12] <- d[16]
dR[13] <- d[19]
dR[14] <- d[20]
dR[15] <- d[21]
dR[16] <- d[22]
dR[17] <- d[23]
dR[18] <- d[24]
dR[19] <- d[25]
dR[20] <- d[26]
dR[21] <- d[27]
dR[22] <- d[28]
dR[23] <- d[29]
dR[24] <- d[30]
dR[25] <- d[31]
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
dR[26] <- d[32]
dR[27] <- d[33]
dR[28] <- d[34]
dR[29] <- d[35]
dR[30] <- d[36]
dR[31] <- d[37]
dR[32] <- d[38]
dR[33] <- d[39]
dR[34] <- d[40]
dR[35] <- d[42]
dR[36] <- d[44]
dR[37] <- d[45]
dR[38] <- d[46]
dR[39] <- d[47]
dR[40] <- d[49]
dR[41] <- d[50]
for (k in 1:nt){
rk[k] <- nt+1-rank(d[],k)          # assumes events are "good"
#  rk[k] <- rank(d[],k)           # assumes events are "bad"
  best[k]  <- equals(rk[k],1)     # Smallest is best (i.e. rank 1)
  # prob treat k is h-th best, prob[1,k]=best[k]
  for (h in 1:nt) { prob[h,k] <- equals(rk[k],h) }
 }
for (k in 1:ntR){
  rk2[k] <- ntR+1-rank(dR[],k)        # assumes events are "good"
#  rk2[k] <- rank(dR[],k)             # assumes events are "bad"
  best2[k]  <- equals(rk2[k],1)  # Smallest is best (i.e. rank 1)
  # prob treat k is h-th best, prob[1,k]=best[k]
  for (h in 1:ntR) { prob2[h,k] <- equals(rk2[k],h) }
 }
# pairwise ORs and LORs for all possible class comparisons
for (c in 1:(nt-1)) {
  for (k in (c+1):nc)  {
    orClass[c,k] <- exp(m[k] - m[c])
    lorClass[c,k] <- (m[k]-m[c])
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

```
   }
 }
# rank classes
for(k in 1:8){ mR[k] <- m[k] }
mR[9] <- m[10]
mR[10] <- m[11]
mR[11] <- m[12]
mR[12] <- m[13]
mR[13] <- m[14]
mR[14] <- m[15]
mR[15] <- m[16]
mR[16] <- m[17]
mR[17] <- m[19]
mR[18] <- m[20]
mR[19] <- m[21]
mR[20] <- m[23]
for (k in 1:nc){
  rkClass[k] <- nc+1-rank(m[],k)    # assumes events are "good"
  bestClass[k] <- equals(rkClass[k],1) # Smallest is best (i.e. rank 1)
  # prob class k is h-th best, prob[1,k]=best[k]
  for (h in 1:nc){ probClass[h,k] <- equals(rkClass[k],h) }
 }
for (k in 1:ncR)  {
  rkClass2[k]  <- ncR+1-rank(mR[],k)
  bestClass2[k]  <- equals(rkClass2[k],1)    # Smallest is best (i.e. rank
1)
  # prob class k is h-th best, prob[1,k]=best[k]
  for (h in 1:ncR) { probClass2[h,k] <- equals(rkClass2[k],h) }
 }
}                                    # *** PROGRAM ENDS
```

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.7 Appendix 2: Correlations

17.7.1 Data from trials

Study	Intervention	Scale	Number of items	Mean baseline completers	SD baseline completers	Mean endpoint completers	SD endpoint completers	Mean change completers	SD change completers	N_Rand	N_Compl	Correlation
Beasley 1991b	Fluoxetine	HAMD	17	27.1	5.1	15.2	9.7	-11.8	9.7	235	233	0.26
	Imipramine	HAMD	17	27.7	5.4	16.3	9.8	-11.4	9.7	238	233	0.29
	Placebo	HAMD	17	27.4	5.6	20.1	9.2	-7.3	9	225	222	0.34
Schneider 2003	Sertraline	HAMD	17	21.4	2.7	13	6.2	-8.4	6.1	371	284	0.25
	Placebo	HAMD	17	21.2	2.5	14.5	6.2	-6.8	6.2	376	311	0.20
Callaghan 2011	Exercise	BDI-ii	21	26.5	10.7	18.1	13	-8.5	9.8	22	19	0.67
	Exercise	BDI-ii	21	30.5	12	29.6	13.9	-0.9	6.6	21	19	0.88

Update 2017

Study	Intervention	Scale	Number of items	Mean baseline ITT	SD baseline ITT	Mean endpoint ITT	SD endpoint ITT	Mean change ITT	SD change ITT	N_Rand	N_Compl	Correlation
Ou 2011	Escitalopram	HAMD	17	23	4	8.6	7.2	14.7	8.2	120	101	0.01
	Citalopram	HAMD	17	22.9	4.4	9.1	7.5	13.8	7.5	120	102	0.29
Schneider 2003	Sertraline	HAMD	17	21.4	2.7	14	6.5	-7.4	6.3	371	284	0.28
	Placebo	HAMD	17	21.4	2.6	14.8	6.3	-6.6	6.4	376	311	0.17
Tollefson 1994	Fluoxetine	HAMD	17	21.6	3.9	11.6	7.6	-10	6.7	62	49	0.47
	Imipramine	HAMD	17	21.3	3.8	12.2	7.9	-9.1	8	62	28	0.21
Versiani 1999a	Fluoxetine	HAMD	21	28.4	4.8	10.5	8.9	-17.9	7.4	77	65	0.56

National Institute for Health and Care Excellence [2017]. All rights reserved.

Study	Intervention	Scale	Number of items	Mean baseline ITT	SD baseline ITT	Mean endpoint ITT	SD endpoint ITT	Mean change ITT	SD change ITT	N_Rand	N_Compl	Correlation
	Amitriptyline	HAMD	21	27.8	4.8	8.7	7.7	-19.1	8.1	80	65	0.23
Spring 1992	Amitriptyline	HAMD	21	25.2	2.8	8.5	5.3	-16.7	6	10	10	0.00
	Placebo	HAMD	21	24.8	4.5	13.1	9.8	-11.7	9	15	15	0.40
ITT = intention-to-treat (data derived from those randomised)												

17.7.21 IAPT psych

			PHQ-9 Baseline		PHQ-9 Endpoint		Correlation	
Intervention	**PHQ range**	**n**	**mean**	**sd**	**mean**	**sd**	***r***	***p***
High Intensity (Only receiving HI treatment during episode of care)	PHQ: 5 - 17	2814	11.48	3.56	7.65	5.60	0.3405	<0.001
	PHQ: 5 - 9 (GAD <=9)	561	7.03	1.33	5.17	4.54	0.1143	0.0067
	PHQ: 10 - 17	1906	13.51	2.27	8.70	5.77	0.2364	<0.001
	PHQ: 10+	3817	17.70	4.88	11.72	7.31	0.4743	<0.001
	PHQ: 18+	1911	21.87	2.75	14.72	7.45	0.2727	<0.001
Low Intensity (Only receiving LI treatment during episode of care)	PHQ: 5 - 17	5329	11.36	3.60	7.66	5.19	0.3922	<0.001
	PHQ: 5 - 9 (GAD <=9)	1117	6.92	1.38	5.11	3.73	0.2151	<0.001
	PHQ: 10 - 17	3535	13.49	2.24	8.86	5.39	0.2358	<0.001
	PHQ: 10+	5872	16.50	4.37	10.89	6.53	0.4486	<0.001
	PHQ: 18+	2337	21.05	2.47	13.94	6.90	0.2791	<0.001
Cognitive Behavioural Therapy	PHQ: 5 - 17	2758	11.52	3.58	7.50	5.64	0.3455	<0.001
	PHQ: 5 - 9 (GAD <=9)	506	7.03	1.29	4.92	4.35	0.1093	0.0139
	PHQ: 10 - 17	1862	13.57	2.28	8.58	5.82	0.2396	<0.001
	PHQ: 10+	3772	17.74	4.82	11.35	7.31	0.4454	<0.001
	PHQ: 18+	1910	21.80	2.72	14.06	7.59	0.2721	<0.001
Guided Self-Help	PHQ: 5 - 17	3164	11.18	3.64	7.22	5.06	0.3903	<0.001
	PHQ: 5 - 9 (GAD <=9)	663	6.86	1.38	4.84	3.51	0.2566	<0.001
	PHQ: 10 - 17	2033	13.45	2.26	8.46	5.31	0.2239	<0.001
	PHQ: 10+	3175	16.13	4.26	10.25	6.40	0.4243	<0.001

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

			PHQ-9 Baseline		PHQ-9 Endpoint		Correlation	
	PHQ: 18+	1142	20.91	2.39	13.43	6.91	0.2193	<0.001
Pure Self-Help	PHQ: 5 - 17	44	10.18	3.99	7.00	4.77	0.209	0.1734
	PHQ: 5 - 9 (GAD <=9)	15	6.73	1.39	6.87	5.49	0.4172	0.1218
	PHQ: 10 - 17	23	13.48	2.41	7.48	4.35	0.1204	0.5843
	PHQ: 10+	30	14.90	3.46	9.23	5.47	0.5739	<0.001
	PHQ: 18+	7	19.57	1.81	15.00	4.97	0.759	0.0478
Either Self-Help	PHQ: 5 - 17	3202	11.16	3.65	7.22	5.05	0.3875	<0.001
	PHQ: 5 - 9 (GAD <=9)	676	6.86	1.38	4.88	3.57	0.2582	<0.001
	PHQ: 10 - 17	2053	13.45	2.26	8.45	5.30	0.2236	<0.001
	PHQ: 10+	3200	16.12	4.25	10.23	6.39	0.4253	<0.001
	PHQ: 18+	1147	20.90	2.39	13.43	6.90	0.22	<0.001
Behavioural Activation	PHQ: 5 - 17	119	12.39	3.63	9.27	5.73	0.5059	<0.001
	PHQ: 5 - 9 (GAD <=9)	22	6.59	1.14	4.91	3.32	0.1531	0.4964
	PHQ: 10 - 17	94	13.88	2.38	10.44	5.70	0.3571	<0.001
	PHQ: 10+	236	18.50	4.52	13.34	6.81	0.4715	<0.001
	PHQ: 18+	142	21.55	2.60	15.26	6.82	0.3472	<0.001
cCBT	PHQ: 5 - 17	157	11.35	3.82	6.83	4.97	0.4583	<0.001
	PHQ: 5 - 9 (GAD <=9)	34	6.53	1.42	3.97	2.69	-0.3052	0.0792
	PHQ: 10 - 17	103	13.68	2.30	8.33	5.25	0.2748	0.005
	PHQ: 10+	145	15.64	3.86	9.17	5.92	0.3369	<0.001
	PHQ: 18+	42	20.45	2.43	11.24	6.97	0.2656	0.0891
Counselling	PHQ: 5 - 17	316	11.31	3.45	7.86	5.66	0.392	<0.001
	PHQ: 5 - 9 (GAD <=9)	76	7.14	1.34	5.16	4.03	0.2052	0.0754
	PHQ: 10 - 17	214	13.26	2.23	9.10	5.95	0.2658	<0.001
	PHQ: 10+	382	16.85	4.76	11.58	7.02	0.4696	<0.001
	PHQ: 18+	168	21.42	2.78	14.73	7.03	0.2766	<0.001
Notes								
LI and HI criteria = recorded as receiving only this step of care during treatment episode								

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	PHQ-9 Baseline	PHQ-9 Endpoint	Correlation
Method for designating interventions: a case is allocated to an intervention in this analysis IF they had at least 2 sessions of that intervention recorded AND no more than 2 sessions of any other intervention.			
Counselling, behavioural activation and cCBT: might be quite varied in nature at delivery. Counselling seems to be delivered across LI and HI, but also a lot of step-ups.			
For low severity group GAD<=9 was included as well so wasn't just an anxiety group, but anxiety was not considered in other bands.			
Low intensity: self-help, self-help with support, psychoeducational interventions; include exercise too. All other psych interventions: high intensity			

17.7.31 PHQ9

		PHQ-9 T1		PHQ-9 T2		Correlation	
Sample (criteria)	**n**	**mean**	**sd**	**mean**	**sd**	***r***	***p***
Caseness PHQ (>=10)	13405	17.11	4.62	11.56	6.91	0.455	<0.001
Caseness PHQ (>=10) + Low intensity received	5872	16.5	4.37	10.89	6.53	0.4486	<0.001
Caseness PHQ (>=10) + High intensity received	3817	17.7	4.88	11.72	7.31	0.4743	<0.0

Update 2017

17.7.42 STAR*D COMED drugs

Study	Intervention	Severity	Number of participants	Correlation (baseline and endpoint)
STAR-D	Citalopram	All participants	970	r = 0.1107 (p<0.001)
		HAM-D <=23	643	r = 0.04 (p=0.3087)
		HAM>=24	327	r = -0.0372 (p=0.1849)
CO-MED	Escit + Plb	All participants		r = (p=)
		HAM-D <=23		r = (p=)
		HAM>=24		r = (p=)
CO-MED	Escit + Bupro	All participants		r = (p=)
		HAM-D <=23		r = (p=)
		HAM>=24		r = (p=)
CO-MED	Venla + Mirtz	All participants		r = (p=)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Study	Intervention	Severity	Number of participants	Correlation (baseline and endpoint)
		HAM-D <=23		r = (p=)
		HAM>=24		r = (p=)

1

Study	Intervention	Severity	Number of participants	Correlation (baseline and endpoint)
STAR-D	Citalopram	All participants	3593	r = 0.3765 (p<0.001)
		QIDS <=16	2109	r = 0.2546 (p<0.001)
		QIDS >=17	1484	r = 0.2077 (p<0.001)
CO-MED	Escit + Plb	All participants	196	r = 0.2544 (p<0.001)
		QIDS <=16	124	r = 0.157 (p=0.0816)
		QIDS >=17	72	r = 0.0295 (p=0.8058)
CO-MED	Escit + Bupro	All participants	190	r = 0.2887 (p<0.001)
		QIDS <=16	107	r = 0.232 (p=0.0162)
		QIDS >=17	83	r = 0.1903 (p=0.0849)
CO-MED	Venla + Mirtz	All participants	191	r = 0.2595 (p<0.001)
		QIDS <=16	102	r = 0.2116 (p=0.0328)
		QIDS >=17	89	r = -0.077 (p=0.4728)

Update 2017

17.7.52 AHEAD

			HADs-D Baseline		HADs-D Endpoint		Correlation	
Intervention	PHQ range	n	mean	sd	mean	sd	*r*	*p*
SSRI	HAD-D: 8+	60	11.65	2.77	6.05	4.74	0.2737	0.0343
	HAD-D: 8 - 15	56	11.27	2.45	6.16	4.86	0.3756	0.0043
	HAD-D: 16+	4	17.00	0.82	4.50	2.08	0.3922	0.6078
Tricyclic	HAD-D: 8+	46	11.85	3.04	6.24	4.51	0.1016	0.5016
	HAD-D: 8 - 15	41	11.17	2.44	6.12	4.31	0.0454	0.7778
	HAD-D: 16+	5	17.40	1.14	7.20	6.38	0.4674	0.4273
Lofepramine (is tricyclic)	HAD-D: 8+	54	11.54	2.58	6.52	4.59	0.107	0.4414

National Institute for Health and Care Excellence [2017]. All rights reserved.

			HADs-D Baseline		HADs-D Endpoint		Correlation	
	HAD-D: 8 - 15	49	10.94	1.81	6.35	4.58	0.0328	0.8227
	HAD-D: 16+	5	17.40	1.14	8.20	4.87	-0.018	0.9771

1

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.81 Appendix 3: NMA model fit statistics

17.8.12 Population: less severe depression

17.8.1.13 Outcome: discontinuation

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.56 (0.45 – 0.68)	393.1	397	2170.37
RE – inconsistency	0.46 (0.33 – 0.62)	408.3	397	2187.21
RE – random class effect: bias adjustment	0.53 (0.42 – 0.65)	389.9	397	2172.29

17.8.1.24 Outcome: discontinuation due to SE

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.62 (0.05 – 1.31)	62.98	62	288.47
RE – inconsistency	0.69 (0.05 - 1.57)	65.9	62	285.49

17.8.1.35 Outcome: remission in responders

Model	SD	Totresdev	Datapoints	DIC
FE – random class effect	-	33.84	32	165.74
FE – fixed class effect	-	34.95	32	151.11
FE – inconsistency	-	34.47	32	153.42

17.8.1.46 Outcome: remission in those randomised

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.49 (0.33 - 0.69)	153.5	151	925.29
RE – inconsistency	0.37 (0.05 - 0.71)	154.7	151	913.30

17.8.1.57 Outcome: response in completers

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.46 (0.29 - 0.64)	214.8	205	1030.63
RE – inconsistency	0.41 (0.19 - 0.64)	214.5	205	1044.96
RE – random class effect: bias adjustment	0.17 (0.007 – 0.39)	206.8	205	1012.60
FE – random class effect: bias adjustment		211.6	205	1011.95

17.8.1.68 Outcome: response in those randomised

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.56 (0.45 - 0.68)	306.7	298	1440.77
RE – inconsistency	0.59 (0.46 - 0.76)	305.7	298	1428.76

17.8.1.79 Outcome: SMD

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.22 (0.17 - 0.29)	260.8	246	946.83
RE – inconsistency	0.18 (0.09 - 0.26)	262.7	246	962.37
RE – random class effect: bias adjustment	0.17 (0.1 – 0.24)	258.0	246	991.71

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.8.21 Population: more severe depression

17.8.2.12 Outcome: discontinuation

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.52 (0.40 – 0.65)	274.6	268	1546.82
RE – inconsistency	0.47 (0.35 - 0.62)	276.9	268	1563.09
RE – random class effect: bias adjustment	0.47 (0.35 – 0.60)	263.6	268	1542.54

17.8.2.23 Outcome: discontinuation due to side effects

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.54 (0.07 – 0.95)	105.7	103	476.42
RE – inconsistency	0.51 (0.04 -1.04)	107.6	103	485.68

17.8.2.34 Outcome: response in completers

Model	SD	Totresdev	Datapoints	DIC
Class model – RE - random class effect	0.57 (0.43 - 0.74)	181.7	179	1016.30
RE – inconsistency	0.62 (0.46 - 0.82)	181.8	179	1025.39
RE – random class effect: bias adjustment	0.49 (0.31 – 0.67)	179.9	179	1016.04

17.8.2.45 Outcome: remission in those randomised

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.66 (0.43 - 1.05)	55.88	55	362.93
RE – inconsistency	0.84 (0.49 - 1.63)	55.88	55	365.48

17.8.2.56 Outcome: response in those randomised

Model	SD	Totresdev	Datapoints	DIC
RE – random class effect	0.70 (0.57 - 0.87)	215.8	214	1264.62
RE – inconsistency	0.71 (0.57 -0.89)	217.3	214	1231.08

17.8.2.67 Outcome: SMD

Model	SD	Totresdev	Datapoints	DIC
RE - random class effect	0.40 (0.31 - 0.52)	159.5	154	702.47
RE – inconsistency	0.45 (0.34 - 0.60)	157.0	154	705.55
RE – random class effect: bias adjustment	0.09 (0.03 – 0.16)	159.6	154	722.60

17.98 Appendix 4: Results of NMAs: relative effects (LORs or 9 SMDs) of every class compared to every other

10 For class numbering see relevant section of report.

17.9.11 Population: less severe depression

17.9.1.12 Outcome: discontinuation

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-0.5524	-1.118	-0.5519	0.01448

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[1,3]	-0.2191	-0.8987	-0.2199	0.4573
lorClass[1,4]	-0.3086	-0.7845	-0.3079	0.163
lorClass[1,5]	-0.688	-1.87	-0.674	0.4321
lorClass[1,6]	-0.7354	-2.121	-0.7345	0.6509
lorClass[1,7]	0.1045	-0.4893	0.1007	0.7162
lorClass[1,8]	-0.1692	-0.7132	-0.1672	0.3655
lorClass[1,9]	-0.117	-1.693	-0.1181	1.455
lorClass[1,10]	0.05143	-0.9497	0.04707	1.073
lorClass[1,11]	0.3406	-0.5663	0.3378	1.257
lorClass[1,12]	0.06102	-0.8203	0.06392	0.9335
lorClass[1,13]	-0.4174	-1.705	-0.4208	0.8762
lorClass[1,14]	-0.2602	-1.409	-0.2615	0.8945
lorClass[1,15]	-0.9679	-2.382	-0.9615	0.4087
lorClass[1,16]	-0.4106	-0.9871	-0.4113	0.1742
lorClass[1,17]	0.2912	-0.6194	0.2843	1.238
lorClass[1,18]	0.3008	-2.204	0.3036	2.795
lorClass[1,19]	-0.01202	-0.9016	-0.01573	0.8919
lorClass[1,20]	-0.2094	-1.821	-0.2085	1.386
lorClass[1,21]	-0.5203	-1.819	-0.5238	0.7985
lorClass[1,22]	-0.6704	-2.402	-0.6691	1.059
lorClass[1,23]	-0.521	-1.717	-0.5158	0.646
lorClass[2,3]	0.3333	-0.2868	0.3328	0.9588
lorClass[2,4]	0.2438	-0.183	0.2437	0.6706
lorClass[2,5]	-0.1357	-1.309	-0.1215	0.9688
lorClass[2,6]	-0.1831	-1.685	-0.1836	1.316
lorClass[2,7]	0.6569	-0.08658	0.6538	1.414
lorClass[2,8]	0.3832	-0.3271	0.3849	1.087
lorClass[2,9]	0.4354	-1.168	0.4343	2.036
lorClass[2,10]	0.6038	-0.4251	0.6008	1.655
lorClass[2,11]	0.893	0.09217	0.8897	1.711
lorClass[2,12]	0.6134	-0.1578	0.6171	1.367
lorClass[2,13]	0.135	-1.085	0.1342	1.365
lorClass[2,14]	0.2922	-0.9061	0.2928	1.486
lorClass[2,15]	-0.4155	-1.816	-0.4117	0.9623
lorClass[2,16]	0.1418	-0.4651	0.1401	0.7621
lorClass[2,17]	0.8436	-0.0596	0.8391	1.772
lorClass[2,18]	0.8532	-1.647	0.8516	3.351
lorClass[2,19]	0.5404	-0.3944	0.5368	1.496
lorClass[2,20]	0.343	-1.311	0.3424	1.999
lorClass[2,21]	0.03211	-1.313	0.0282	1.403
lorClass[2,22]	-0.118	-1.915	-0.1161	1.675
lorClass[2,23]	0.03143	-1.188	0.03517	1.228
lorClass[3,4]	-0.08949	-0.6973	-0.09095	0.5224
lorClass[3,5]	-0.4689	-1.614	-0.4556	0.6156
lorClass[3,6]	-0.5163	-2.063	-0.5172	1.037

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[3,7]	0.3237	-0.5145	0.3221	1.176
lorClass[3,8]	0.0499	-0.7561	0.04853	0.8473
lorClass[3,9]	0.1022	-1.557	0.1029	1.752
lorClass[3,10]	0.2706	-0.848	0.2666	1.403
lorClass[3,11]	0.5597	-0.3447	0.5559	1.486
lorClass[3,12]	0.2802	-0.6381	0.281	1.186
lorClass[3,13]	-0.1982	-1.516	-0.1994	1.132
lorClass[3,14]	-0.04104	-1.304	-0.0417	1.22
lorClass[3,15]	-0.7487	-2.214	-0.7451	0.6902
lorClass[3,16]	-0.1915	-0.9367	-0.1929	0.561
lorClass[3,17]	0.5103	-0.5006	0.5051	1.549
lorClass[3,18]	0.52	-2.022	0.5203	3.064
lorClass[3,19]	0.2071	-0.8174	0.2032	1.249
lorClass[3,20]	0.00976	-1.701	0.0116	1.722
lorClass[3,21]	-0.3012	-1.706	-0.3048	1.132
lorClass[3,22]	-0.4513	-2.282	-0.4511	1.387
lorClass[3,23]	-0.3018	-1.561	-0.2981	0.9294
lorClass[4,5]	-0.3794	-1.537	-0.3655	0.7104
lorClass[4,6]	-0.4268	-1.89	-0.4271	1.037
lorClass[4,7]	0.4132	-0.2581	0.4084	1.104
lorClass[4,8]	0.1394	-0.496	0.1401	0.7702
lorClass[4,9]	0.1917	-1.38	0.1908	1.758
lorClass[4,10]	0.3601	-0.6064	0.3554	1.349
lorClass[4,11]	0.6492	-0.1742	0.6469	1.482
lorClass[4,12]	0.3697	-0.4254	0.3729	1.143
lorClass[4,13]	-0.1087	-1.326	-0.1097	1.11
lorClass[4,14]	0.04845	-1.095	0.04842	1.19
lorClass[4,15]	-0.6592	-2.012	-0.6549	0.6554
lorClass[4,16]	-0.102	-0.6241	-0.1035	0.4288
lorClass[4,17]	0.5998	-0.2777	0.593	1.514
lorClass[4,18]	0.6094	-1.88	0.6119	3.092
lorClass[4,19]	0.2966	-0.5818	0.2927	1.195
lorClass[4,20]	0.09925	-1.523	0.1004	1.72
lorClass[4,21]	-0.2117	-1.513	-0.2153	1.122
lorClass[4,22]	-0.3618	-2.134	-0.3597	1.4
lorClass[4,23]	-0.2123	-1.407	-0.2086	0.96
lorClass[5,6]	-0.0474	-1.827	-0.05529	1.765
lorClass[5,7]	0.7926	-0.4318	0.7797	2.077
lorClass[5,8]	0.5188	-0.6804	0.5078	1.776
lorClass[5,9]	0.5711	-1.319	0.5674	2.477
lorClass[5,10]	0.7395	-0.695	0.7317	2.217
lorClass[5,11]	1.029	-0.2883	1.018	2.396
lorClass[5,12]	0.7491	-0.5512	0.7414	2.087
lorClass[5,13]	0.2707	-1.342	0.2634	1.916
lorClass[5,14]	0.4279	-1.12	0.4215	2.014

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[5,15]	-0.2798	-1.994	-0.287	1.47
lorClass[5,16]	0.2775	-0.8972	0.2666	1.506
lorClass[5,17]	0.9792	-0.3836	0.9666	2.4
lorClass[5,18]	0.9889	-1.712	0.9846	3.713
lorClass[5,19]	0.676	-0.6932	0.6668	2.091
lorClass[5,20]	0.4787	-1.454	0.4718	2.425
lorClass[5,21]	0.1678	-1.504	0.1601	1.883
lorClass[5,22]	0.01762	-2.036	0.01561	2.089
lorClass[5,23]	0.1671	-1.359	0.1627	1.717
lorClass[6,7]	0.84	-0.6641	0.8387	2.345
lorClass[6,8]	0.5662	-0.9165	0.5651	2.05
lorClass[6,9]	0.6185	-1.465	0.6169	2.703
lorClass[6,10]	0.7869	-0.9271	0.7894	2.499
lorClass[6,11]	1.076	-0.5883	1.079	2.74
lorClass[6,12]	0.7965	-0.8584	0.7986	2.43
lorClass[6,13]	0.3181	-1.562	0.3169	2.214
lorClass[6,14]	0.4753	-1.32	0.4743	2.266
lorClass[6,15]	-0.2324	-2.205	-0.2289	1.713
lorClass[6,16]	0.3249	-1.185	0.3285	1.823
lorClass[6,17]	1.027	-0.6406	1.026	2.696
lorClass[6,18]	1.036	-1.821	1.041	3.877
lorClass[6,19]	0.7234	-0.9347	0.7242	2.387
lorClass[6,20]	0.5261	-1.603	0.5305	2.636
lorClass[6,21]	0.2152	-1.692	0.2129	2.128
lorClass[6,22]	0.06502	-2.133	0.0627	2.278
lorClass[6,23]	0.2145	-1.613	0.2198	2.022
lorClass[7,8]	-0.2738	-1.025	-0.2703	0.4618
lorClass[7,9]	-0.2215	-1.874	-0.2193	1.427
lorClass[7,10]	-0.05312	-1.182	-0.05513	1.078
lorClass[7,11]	0.2361	-0.7962	0.2364	1.269
lorClass[7,12]	-0.04352	-1.054	-0.04035	0.9569
lorClass[7,13]	-0.5219	-1.896	-0.5231	0.8563
lorClass[7,14]	-0.3647	-1.612	-0.3638	0.8777
lorClass[7,15]	-1.072	-2.564	-1.067	0.389
lorClass[7,16]	-0.5151	-1.279	-0.5124	0.2349
lorClass[7,17]	0.1866	-0.851	0.1838	1.249
lorClass[7,18]	0.1963	-2.359	0.202	2.73
lorClass[7,19]	-0.1166	-1.108	-0.1162	0.8767
lorClass[7,20]	-0.3139	-2.007	-0.3096	1.36
lorClass[7,21]	-0.6248	-2.017	-0.6266	0.7829
lorClass[7,22]	-0.775	-2.579	-0.7738	1.012
lorClass[7,23]	-0.6255	-1.926	-0.6198	0.648
lorClass[8,9]	0.05227	-1.575	0.05126	1.685
lorClass[8,10]	0.2207	-0.8671	0.2179	1.329
lorClass[8,11]	0.5098	-0.4877	0.5069	1.519

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[8,12]	0.2303	-0.7402	0.2293	1.203
lorClass[8,13]	-0.2481	-1.591	-0.2498	1.109
lorClass[8,14]	-0.09095	-1.3	-0.0926	1.125
lorClass[8,15]	-0.7986	-2.271	-0.792	0.6388
lorClass[8,16]	-0.2414	-0.9517	-0.2435	0.4744
lorClass[8,17]	0.4604	-0.5468	0.4534	1.5
lorClass[8,18]	0.47	-2.077	0.4737	2.999
lorClass[8,19]	0.1572	-0.8111	0.1555	1.143
lorClass[8,20]	-0.04014	-1.71	-0.03948	1.628
lorClass[8,21]	-0.3511	-1.702	-0.3539	1.016
lorClass[8,22]	-0.5012	-2.301	-0.4995	1.282
lorClass[8,23]	-0.3517	-1.631	-0.346	0.8954
lorClass[9,10]	0.1684	-1.597	0.1642	1.936
lorClass[9,11]	0.4576	-1.289	0.4566	2.214
lorClass[9,12]	0.178	-1.546	0.1772	1.91
lorClass[9,13]	-0.3004	-2.255	-0.3004	1.659
lorClass[9,14]	-0.1432	-2.023	-0.1426	1.735
lorClass[9,15]	-0.8509	-2.885	-0.8501	1.171
lorClass[9,16]	-0.2936	-1.901	-0.2918	1.3
lorClass[9,17]	0.4081	-1.338	0.4065	2.17
lorClass[9,18]	0.4178	-2.497	0.4166	3.318
lorClass[9,19]	0.1049	-1.637	0.1068	1.852
lorClass[9,20]	-0.09242	-2.192	-0.0943	2.019
lorClass[9,21]	-0.4033	-2.314	-0.4066	1.528
lorClass[9,22]	-0.5535	-2.841	-0.5521	1.723
lorClass[9,23]	-0.404	-2.326	-0.4048	1.514
lorClass[10,11]	0.2892	-0.9798	0.2901	1.541
lorClass[10,12]	0.009594	-1.231	0.01343	1.231
lorClass[10,13]	-0.4688	-2.011	-0.4674	1.062
lorClass[10,14]	-0.3116	-1.779	-0.3057	1.137
lorClass[10,15]	-1.019	-2.602	-1.015	0.5525
lorClass[10,16]	-0.462	-1.503	-0.457	0.5534
lorClass[10,17]	0.2398	-1.028	0.2383	1.51
lorClass[10,18]	0.2494	-2.404	0.2485	2.89
lorClass[10,19]	-0.06345	-1.32	-0.06494	1.193
lorClass[10,20]	-0.2608	-2.089	-0.2613	1.569
lorClass[10,21]	-0.5717	-2.087	-0.5736	0.9613
lorClass[10,22]	-0.7219	-2.708	-0.7168	1.241
lorClass[10,23]	-0.5724	-2.082	-0.5688	0.913
lorClass[11,12]	-0.2796	-1.346	-0.2763	0.7698
lorClass[11,13]	-0.758	-2.19	-0.7571	0.6641
lorClass[11,14]	-0.6008	-1.991	-0.5984	0.7807
lorClass[11,15]	-1.308	-2.87	-1.306	0.238
lorClass[11,16]	-0.7512	-1.696	-0.751	0.1916
lorClass[11,17]	-0.04941	-1.211	-0.05146	1.117

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[11,18]	-0.03979	-2.649	-0.03822	2.561
lorClass[11,19]	-0.3526	-1.529	-0.3555	0.8337
lorClass[11,20]	-0.55	-2.352	-0.5536	1.259
lorClass[11,21]	-0.8609	-2.38	-0.8668	0.688
lorClass[11,22]	-1.011	-2.948	-1.011	0.9173
lorClass[11,23]	-0.8616	-2.276	-0.8575	0.5346
lorClass[12,13]	-0.4784	-1.879	-0.4828	0.9321
lorClass[12,14]	-0.3212	-1.683	-0.3193	1.044
lorClass[12,15]	-1.029	-2.571	-1.03	0.4944
lorClass[12,16]	-0.4716	-1.375	-0.4733	0.4401
lorClass[12,17]	0.2302	-0.899	0.226	1.379
lorClass[12,18]	0.2398	-2.339	0.2399	2.819
lorClass[12,19]	-0.07305	-1.221	-0.07687	1.087
lorClass[12,20]	-0.2704	-2.061	-0.2682	1.51
lorClass[12,21]	-0.5813	-2.085	-0.5871	0.9467
lorClass[12,22]	-0.7315	-2.649	-0.7283	1.181
lorClass[12,23]	-0.582	-1.97	-0.5764	0.7914
lorClass[13,14]	0.1572	-1.5	0.1565	1.818
lorClass[13,15]	-0.5505	-2.34	-0.5513	1.234
lorClass[13,16]	0.006763	-1.304	0.005122	1.323
lorClass[13,17]	0.7085	-0.77	0.7052	2.189
lorClass[13,18]	0.7182	-2.031	0.7184	3.445
lorClass[13,19]	0.4053	-1.09	0.4057	1.89
lorClass[13,20]	0.208	-1.799	0.2111	2.202
lorClass[13,21]	-0.1029	-1.863	-0.1048	1.673
lorClass[13,22]	-0.2531	-2.386	-0.251	1.881
lorClass[13,23]	-0.1036	-1.778	-0.1005	1.559
lorClass[14,15]	-0.7077	-2.433	-0.7052	1.023
lorClass[14,16]	-0.1504	-1.35	-0.1528	1.066
lorClass[14,17]	0.5514	-0.8382	0.5474	1.957
lorClass[14,18]	0.561	-2.139	0.5606	3.259
lorClass[14,19]	0.2482	-1.119	0.2466	1.63
lorClass[14,20]	0.0508	-1.881	0.05166	1.98
lorClass[14,21]	-0.2601	-1.932	-0.2623	1.412
lorClass[14,22]	-0.4103	-2.484	-0.4094	1.646
lorClass[14,23]	-0.2608	-1.858	-0.2587	1.321
lorClass[15,16]	0.5573	-0.8254	0.5544	1.956
lorClass[15,17]	1.259	-0.3133	1.254	2.863
lorClass[15,18]	1.269	-1.532	1.268	4.078
lorClass[15,19]	0.9558	-0.6083	0.9531	2.551
lorClass[15,20]	0.7585	-1.293	0.7552	2.84
lorClass[15,21]	0.4476	-1.392	0.4468	2.304
lorClass[15,22]	0.2974	-1.887	0.3	2.484
lorClass[15,23]	0.4469	-1.315	0.44	2.234
lorClass[16,17]	0.7018	-0.2565	0.6973	1.681

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[16,18]	0.7114	-1.801	0.7133	3.204
lorClass[16,19]	0.3986	-0.5123	0.3959	1.33
lorClass[16,20]	0.2012	-1.459	0.2011	1.852
lorClass[16,21]	-0.1097	-1.459	-0.1135	1.262
lorClass[16,22]	-0.2598	-2.064	-0.2573	1.527
lorClass[16,23]	-0.1104	-1.367	-0.1052	1.114
lorClass[17,18]	0.009622	-2.6	0.01403	2.599
lorClass[17,19]	-0.3032	-1.502	-0.3023	0.8896
lorClass[17,20]	-0.5006	-2.317	-0.4964	1.307
lorClass[17,21]	-0.8115	-2.347	-0.8134	0.7239
lorClass[17,22]	-0.9616	-2.909	-0.9596	0.9669
lorClass[17,23]	-0.8122	-2.263	-0.8052	0.6131
lorClass[18,19]	-0.3128	-2.908	-0.3158	2.288
lorClass[18,20]	-0.5102	-3.465	-0.5141	2.446
lorClass[18,21]	-0.8211	-3.602	-0.8215	1.951
lorClass[18,22]	-0.9712	-3.984	-0.9732	2.053
lorClass[18,23]	-0.8218	-3.537	-0.8161	1.893
lorClass[19,20]	-0.1974	-1.998	-0.1935	1.585
lorClass[19,21]	-0.5083	-2.011	-0.5104	1.004
lorClass[19,22]	-0.6584	-2.595	-0.6545	1.264
lorClass[19,23]	-0.5089	-1.97	-0.4993	0.902
lorClass[20,21]	-0.3109	-2.284	-0.3195	1.709
lorClass[20,22]	-0.4611	-2.411	-0.459	1.497
lorClass[20,23]	-0.3116	-2.287	-0.3093	1.648
lorClass[21,22]	-0.1501	-2.289	-0.1484	1.981
lorClass[21,23]	0.00	-1.747	0.007167	1.703
lorClass[22,23]	0.1495	-1.928	0.1504	2.228

Update 2017

17.9.1.21 Outcome: discontinuation due to SE

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-4.365	-11	-3.958	-0.1191
lorClass[1,3]	2.06	0.9623	2.054	3.177
lorClass[1,4]	1.075	0.1316	1.07	2.065
lorClass[1,5]	2.91	-0.9419	2.855	7.086
lorClass[1,6]	-1.457	-3.803	-1.426	0.7044
lorClass[1,7]	2.276	-0.5685	2.237	5.291
lorClass[1,8]	-0.03389	-4.719	0.02804	4.253
lorClass[1,9]	0.2579	-2.646	0.2699	3.07
lorClass[1,10]	1.381	-1.034	1.344	4.002
lorClass[2,3]	6.425	2.079	6.028	13.12
lorClass[2,4]	5.441	1.153	5.041	12.1
lorClass[2,5]	7.275	1.374	6.993	14.9
lorClass[2,6]	2.909	-1.954	2.546	9.946
lorClass[2,7]	6.641	1.513	6.286	13.89
lorClass[2,8]	4.332	-1.996	4.097	12.16

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[2,9]	4.623	0.3786	4.225	11.21
lorClass[2,10]	5.747	0.7242	5.41	12.84
lorClass[3,4]	-0.9845	-2.299	-0.9881	0.3419
lorClass[3,5]	0.8501	-3.064	0.7977	5.095
lorClass[3,6]	-3.517	-6.031	-3.491	-1.163
lorClass[3,7]	0.2161	-2.789	0.1907	3.356
lorClass[3,8]	-2.094	-6.838	-2.032	2.275
lorClass[3,9]	-1.802	-4.803	-1.791	1.109
lorClass[3,10]	-0.6787	-3.354	-0.7056	2.143
lorClass[4,5]	1.835	-1.973	1.779	5.951
lorClass[4,6]	-2.532	-4.841	-2.491	-0.4257
lorClass[4,7]	1.201	-1.574	1.176	4.11
lorClass[4,8]	-1.109	-5.721	-1.041	3.047
lorClass[4,9]	-0.8175	-3.748	-0.7969	1.979
lorClass[4,10]	0.3058	-2.313	0.2825	3.052
lorClass[5,6]	-4.367	-8.967	-4.298	-0.09357
lorClass[5,7]	-0.634	-5.596	-0.6012	4.099
lorClass[5,8]	-2.944	-9.115	-2.858	2.723
lorClass[5,9]	-2.652	-7.68	-2.607	2.068
lorClass[5,10]	-1.529	-6.317	-1.51	3.117
lorClass[6,7]	3.733	1.206	3.678	6.562
lorClass[6,8]	1.423	-3.601	1.49	6.07
lorClass[6,9]	1.715	-1.796	1.709	5.301
lorClass[6,10]	2.838	-0.4342	2.8	6.309
lorClass[7,8]	-2.31	-7.535	-2.235	2.558
lorClass[7,9]	-2.018	-6.059	-1.997	1.917
lorClass[7,10]	-0.8947	-4.737	-0.8843	2.955
lorClass[8,9]	0.2918	-4.86	0.267	5.645
lorClass[8,10]	1.415	-3.52	1.352	6.751
lorClass[9,10]	1.123	-2.592	1.104	4.988

17.9.1.31 Outcome: remission in responders

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-0.9955	-7.67	-0.9329	5.235
lorClass[1,3]	0.5758	-0.7889	0.5634	2.002
lorClass[1,4]	0.3192	-0.1009	0.32	0.7373
lorClass[1,5]	2.241	-1.157	2.165	6.065
lorClass[1,6]	-0.7946	-9.544	-0.8088	7.942
lorClass[1,7]	0.792	-0.9685	0.7724	2.698
lorClass[1,8]	2.09	0.6345	2.053	3.768
lorClass[1,9]	0.4562	-6.47	0.5033	6.987
lorClass[1,10]	7.212	-0.8908	6.172	20.9
lorClass[2,3]	1.571	-4.788	1.516	8.412
lorClass[2,4]	1.315	-4.899	1.254	7.969
lorClass[2,5]	3.237	-3.41	3.137	10.41

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[2,6]	0.2009	-5.63	0.1184	6.531
lorClass[2,7]	1.788	-4.212	1.706	8.213
lorClass[2,8]	3.086	-2.97	3.01	9.564
lorClass[2,9]	1.452	-0.373	1.403	3.569
lorClass[2,10]	8.207	-2.374	7.428	23.08
lorClass[3,4]	-0.2566	-1.624	-0.2439	1.047
lorClass[3,5]	1.665	-1.98	1.599	5.674
lorClass[3,6]	-1.37	-10.24	-1.38	7.478
lorClass[3,7]	0.2162	-1.973	0.2063	2.468
lorClass[3,8]	1.514	-0.4513	1.5	3.578
lorClass[3,9]	-0.1196	-7.165	-0.07788	6.518
lorClass[3,10]	6.636	-1.628	5.605	20.38
lorClass[4,5]	1.922	-1.444	1.845	5.728
lorClass[4,6]	-1.114	-9.847	-1.131	7.624
lorClass[4,7]	0.4728	-1.232	0.4517	2.333
lorClass[4,8]	1.771	0.3827	1.732	3.393
lorClass[4,9]	0.137	-6.765	0.1787	6.669
lorClass[4,10]	6.893	-1.209	5.856	20.58
lorClass[5,6]	-3.036	-12.16	-3.019	5.981
lorClass[5,7]	-1.449	-4.84	-1.365	1.429
lorClass[5,8]	-0.1507	-3.643	-0.07444	2.879
lorClass[5,9]	-1.785	-9.179	-1.691	5.135
lorClass[5,10]	4.971	-4.238	4.061	18.97
lorClass[6,7]	1.587	-6.984	1.602	10.15
lorClass[6,8]	2.885	-5.724	2.891	11.5
lorClass[6,9]	1.251	-5.329	1.313	7.389
lorClass[6,10]	8.007	-4.426	7.375	23.79
lorClass[7,8]	1.298	0.3879	1.288	2.265
lorClass[7,9]	-0.3358	-7.005	-0.2772	5.968
lorClass[7,10]	6.42	-1.95	5.422	20.17
lorClass[8,9]	-1.634	-8.35	-1.583	4.736
lorClass[8,10]	5.122	-3.186	4.106	18.89
lorClass[9,10]	6.756	-4.043	5.974	21.75

17.9.1.41 Outcome: remission in those randomised

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-1.229	-2.23	-1.23	-0.2348
lorClass[1,3]	-0.8874	-1.874	-0.8849	0.0812
lorClass[1,4]	0.0324	-0.6324	0.02854	0.7063
lorClass[1,5]	-0.01185	-1.418	-0.01156	1.398
lorClass[1,6]	0.3672	-0.5439	0.3713	1.26
lorClass[1,7]	0.5956	-0.08559	0.5953	1.281
lorClass[1,8]	0.696	-1.05	0.6957	2.45
lorClass[1,9]	0.5304	-0.6246	0.5332	1.667
lorClass[1,10]	0.5363	-0.6353	0.5329	1.724

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[1,11]	-0.06472	-1.2	-0.06041	1.044
lorClass[1,12]	0.8718	-0.7929	0.8701	2.555
lorClass[1,13]	0.8462	-0.3685	0.8454	2.07
lorClass[1,14]	1.473	-0.3284	1.478	3.278
lorClass[1,15]	0.8182	0.07098	0.8151	1.58
lorClass[1,16]	1.293	0.3852	1.288	2.228
lorClass[1,17]	0.8272	-1.294	0.8285	2.95
lorClass[1,18]	0.5507	-0.6464	0.5485	1.763
lorClass[1,19]	1.323	-0.5229	1.317	3.195
lorClass[1,20]	1.152	-0.3304	1.146	2.685
lorClass[1,21]	0.1303	-1.407	0.1311	1.68
lorClass[2,3]	0.3417	-0.6883	0.3424	1.37
lorClass[2,4]	1.261	0.4193	1.258	2.118
lorClass[2,5]	1.217	-0.3497	1.216	2.788
lorClass[2,6]	1.596	0.4247	1.597	2.76
lorClass[2,7]	1.825	0.7765	1.821	2.896
lorClass[2,8]	1.925	0.05323	1.923	3.81
lorClass[2,9]	1.759	0.4319	1.757	3.099
lorClass[2,10]	1.765	0.6241	1.758	2.939
lorClass[2,11]	1.164	0.05281	1.163	2.278
lorClass[2,12]	2.101	0.3638	2.101	3.842
lorClass[2,13]	2.075	0.6469	2.072	3.513
lorClass[2,14]	2.702	0.8043	2.703	4.628
lorClass[2,15]	2.047	1.05	2.042	3.069
lorClass[2,16]	2.522	1.45	2.517	3.61
lorClass[2,17]	2.056	-0.1373	2.057	4.24
lorClass[2,18]	1.78	0.3767	1.776	3.198
lorClass[2,19]	2.552	0.5696	2.551	4.552
lorClass[2,20]	2.381	0.7236	2.37	4.082
lorClass[2,21]	1.359	-0.3345	1.356	3.064
lorClass[3,4]	0.9198	0.05083	0.9159	1.818
lorClass[3,5]	0.8755	-0.6059	0.8791	2.362
lorClass[3,6]	1.255	0.07426	1.256	2.435
lorClass[3,7]	1.483	0.4682	1.478	2.53
lorClass[3,8]	1.583	-0.3132	1.58	3.488
lorClass[3,9]	1.418	0.07995	1.417	2.755
lorClass[3,10]	1.424	0.3941	1.421	2.481
lorClass[3,11]	0.8227	-0.3131	0.8228	1.954
lorClass[3,12]	1.759	0.004008	1.757	3.539
lorClass[3,13]	1.734	0.3054	1.729	3.176
lorClass[3,14]	2.361	0.4573	2.357	4.304
lorClass[3,15]	1.706	0.6773	1.702	2.763
lorClass[3,16]	2.18	1.066	2.176	3.317
lorClass[3,17]	1.715	-0.4721	1.711	3.921
lorClass[3,18]	1.438	0.03359	1.436	2.862

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[3,19]	2.211	0.2272	2.207	4.229
lorClass[3,20]	2.039	0.3771	2.03	3.742
lorClass[3,21]	1.018	-0.6009	1.018	2.65
lorClass[4,5]	-0.04426	-1.494	-0.04393	1.4
lorClass[4,6]	0.3348	-0.5626	0.3417	1.202
lorClass[4,7]	0.5632	-0.1886	0.5635	1.317
lorClass[4,8]	0.6636	-1.056	0.664	2.382
lorClass[4,9]	0.498	-0.5712	0.4997	1.566
lorClass[4,10]	0.5039	-0.5345	0.4968	1.583
lorClass[4,11]	-0.09712	-1.06	-0.09442	0.8545
lorClass[4,12]	0.8394	-0.7005	0.8381	2.379
lorClass[4,13]	0.8138	-0.3703	0.8074	2.024
lorClass[4,14]	1.441	-0.2899	1.44	3.171
lorClass[4,15]	0.7858	0.1287	0.7832	1.464
lorClass[4,16]	1.261	0.4853	1.256	2.058
lorClass[4,17]	0.7948	-1.209	0.7924	2.799
lorClass[4,18]	0.5183	-0.6559	0.5185	1.697
lorClass[4,19]	1.291	-0.5286	1.291	3.134
lorClass[4,20]	1.119	-0.3395	1.113	2.62
lorClass[4,21]	0.09786	-1.484	0.1019	1.663
lorClass[5,6]	0.379	-1.218	0.3778	1.978
lorClass[5,7]	0.6075	-0.8356	0.6026	2.054
lorClass[5,8]	0.7079	-1.468	0.7075	2.896
lorClass[5,9]	0.5423	-1.195	0.5436	2.272
lorClass[5,10]	0.5481	-1.126	0.5454	2.227
lorClass[5,11]	-0.05286	-1.711	-0.0513	1.597
lorClass[5,12]	0.8836	-1.212	0.8852	2.975
lorClass[5,13]	0.858	-0.9186	0.8578	2.64
lorClass[5,14]	1.485	-0.7445	1.48	3.721
lorClass[5,15]	0.8301	-0.6631	0.8247	2.339
lorClass[5,16]	1.305	-0.2514	1.301	2.873
lorClass[5,17]	0.8391	-1.619	0.8368	3.306
lorClass[5,18]	0.5625	-1.226	0.5606	2.353
lorClass[5,19]	1.335	-0.934	1.331	3.608
lorClass[5,20]	1.164	-0.8043	1.155	3.152
lorClass[5,21]	0.1421	-1.693	0.1441	1.98
lorClass[6,7]	0.2284	-0.7196	0.2221	1.207
lorClass[6,8]	0.3289	-1.529	0.3239	2.212
lorClass[6,9]	0.1632	-1.159	0.164	1.473
lorClass[6,10]	0.1691	-1.145	0.1611	1.528
lorClass[6,11]	-0.4319	-1.707	-0.4301	0.8512
lorClass[6,12]	0.5046	-1.265	0.5058	2.268
lorClass[6,13]	0.479	-0.864	0.4743	1.847
lorClass[6,14]	1.106	-0.7614	1.104	2.978
lorClass[6,15]	0.4511	-0.4897	0.4452	1.425

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[6,16]	0.9258	-0.1514	0.9195	2.036
lorClass[6,17]	0.4601	-1.732	0.4579	2.655
lorClass[6,18]	0.1835	-1.151	0.1817	1.535
lorClass[6,19]	0.9561	-0.9997	0.9493	2.936
lorClass[6,20]	0.7846	-0.8324	0.7758	2.448
lorClass[6,21]	-0.2369	-1.935	-0.2391	1.473
lorClass[7,8]	0.1004	-1.712	0.1014	1.893
lorClass[7,9]	-0.06521	-1.301	-0.06043	1.154
lorClass[7,10]	-0.05933	-1.286	-0.06298	1.187
lorClass[7,11]	-0.6603	-1.848	-0.6528	0.501
lorClass[7,12]	0.2762	-1.424	0.2787	1.975
lorClass[7,13]	0.2506	-0.9913	0.2512	1.503
lorClass[7,14]	0.8778	-0.9647	0.8797	2.718
lorClass[7,15]	0.2226	-0.6029	0.2212	1.055
lorClass[7,16]	0.6974	-0.2866	0.6972	1.674
lorClass[7,17]	0.2316	-1.913	0.2329	2.38
lorClass[7,18]	-0.04494	-1.292	-0.04621	1.213
lorClass[7,19]	0.7277	-1.173	0.7218	2.653
lorClass[7,20]	0.5562	-0.9814	0.5536	2.143
lorClass[7,21]	-0.4653	-2.027	-0.4646	1.093
lorClass[8,9]	-0.1656	-2.088	-0.1638	1.74
lorClass[8,10]	-0.1598	-2.144	-0.1597	1.829
lorClass[8,11]	-0.7608	-2.691	-0.7654	1.173
lorClass[8,12]	0.1757	-2.126	0.1745	2.485
lorClass[8,13]	0.1501	-1.886	0.1495	2.187
lorClass[8,14]	0.7773	-1.607	0.7767	3.178
lorClass[8,15]	0.1222	-1.645	0.1258	1.885
lorClass[8,16]	0.5969	-1.224	0.5949	2.437
lorClass[8,17]	0.1312	-2.499	0.1342	2.773
lorClass[8,18]	-0.1454	-2.156	-0.1441	1.87
lorClass[8,19]	0.6273	-1.674	0.6262	2.945
lorClass[8,20]	0.4558	-1.643	0.4571	2.556
lorClass[8,21]	-0.5658	-2.843	-0.5608	1.699
lorClass[9,10]	0.005877	-1.465	9.42E-04	1.504
lorClass[9,11]	-0.5951	-2.019	-0.5922	0.8318
lorClass[9,12]	0.3414	-1.516	0.3376	2.211
lorClass[9,13]	0.3158	-1.23	0.3131	1.885
lorClass[9,14]	0.943	-1.062	0.946	2.94
lorClass[9,15]	0.2878	-0.8971	0.2839	1.489
lorClass[9,16]	0.7626	-0.4846	0.7535	2.055
lorClass[9,17]	0.2968	-1.967	0.2952	2.561
lorClass[9,18]	0.02027	-1.492	0.01487	1.554
lorClass[9,19]	0.7929	-1.203	0.7875	2.828
lorClass[9,20]	0.6214	-0.9545	0.6129	2.238
lorClass[9,21]	-0.4001	-2.241	-0.4066	1.456

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[10,11]	-0.601	-1.904	-0.5969	0.676
lorClass[10,12]	0.3355	-1.521	0.3374	2.189
lorClass[10,13]	0.3099	-1.262	0.3111	1.869
lorClass[10,14]	0.9371	-1.066	0.9362	2.947
lorClass[10,15]	0.282	-0.9309	0.2828	1.486
lorClass[10,16]	0.7567	-0.5254	0.7601	2.023
lorClass[10,17]	0.291	-1.978	0.2914	2.569
lorClass[10,18]	0.01439	-1.539	0.01609	1.561
lorClass[10,19]	0.787	-1.313	0.7856	2.883
lorClass[10,20]	0.6155	-1.191	0.6151	2.423
lorClass[10,21]	-0.406	-2.21	-0.4018	1.383
lorClass[11,12]	0.9365	-0.8666	0.9353	2.752
lorClass[11,13]	0.9109	-0.597	0.8998	2.457
lorClass[11,14]	1.538	-0.4187	1.54	3.49
lorClass[11,15]	0.883	-0.2391	0.8767	2.038
lorClass[11,16]	1.358	0.1657	1.35	2.599
lorClass[11,17]	0.892	-1.353	0.8933	3.121
lorClass[11,18]	0.6154	-0.8641	0.6121	2.128
lorClass[11,19]	1.388	-0.6436	1.385	3.451
lorClass[11,20]	1.217	-0.5201	1.209	2.975
lorClass[11,21]	0.195	-1.58	0.1874	1.992
lorClass[12,13]	-0.0256	-1.963	-0.03183	1.922
lorClass[12,14]	0.6016	-1.722	0.6037	2.922
lorClass[12,15]	-0.05353	-1.725	-0.05465	1.641
lorClass[12,16]	0.4212	-1.287	0.4152	2.149
lorClass[12,17]	-0.04452	-2.574	-0.0496	2.492
lorClass[12,18]	-0.3211	-2.253	-0.3216	1.614
lorClass[12,19]	0.4515	-1.949	0.4523	2.859
lorClass[12,20]	0.28	-1.832	0.2729	2.43
lorClass[12,21]	-0.7415	-2.93	-0.7379	1.447
lorClass[13,14]	0.6272	-1.427	0.629	2.679
lorClass[13,15]	-0.02793	-1.311	-0.02954	1.256
lorClass[13,16]	0.4468	-0.9249	0.4413	1.83
lorClass[13,17]	-0.01892	-2.338	-0.01269	2.311
lorClass[13,18]	-0.2955	-1.876	-0.296	1.288
lorClass[13,19]	0.4771	-1.645	0.4758	2.61
lorClass[13,20]	0.3056	-1.511	0.2962	2.16
lorClass[13,21]	-0.7159	-2.59	-0.7207	1.178
lorClass[14,15]	-0.6551	-2.447	-0.66	1.145
lorClass[14,16]	-0.1804	-2.041	-0.1823	1.708
lorClass[14,17]	-0.6461	-3.31	-0.6493	2.011
lorClass[14,18]	-0.9227	-2.994	-0.9258	1.141
lorClass[14,19]	-0.1501	-2.616	-0.1536	2.334
lorClass[14,20]	-0.3216	-2.564	-0.3238	1.911
lorClass[14,21]	-1.343	-3.648	-1.343	0.947

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[15,16]	0.4747	-0.4305	0.4711	1.393
lorClass[15,17]	0.009013	-2.116	0.009416	2.114
lorClass[15,18]	-0.2676	-1.426	-0.2648	0.8945
lorClass[15,19]	0.5051	-1.379	0.505	2.395
lorClass[15,20]	0.3336	-1.191	0.3296	1.886
lorClass[15,21]	-0.688	-2.316	-0.6838	0.9477
lorClass[16,17]	-0.4657	-2.612	-0.4651	1.685
lorClass[16,18]	-0.7423	-2.073	-0.7408	0.5817
lorClass[16,19]	0.03033	-1.917	0.03469	1.963
lorClass[16,20]	-0.1412	-1.742	-0.1417	1.474
lorClass[16,21]	-1.163	-2.843	-1.161	0.5145
lorClass[17,18]	-0.2766	-2.612	-0.279	2.042
lorClass[17,19]	0.4961	-2.202	0.4878	3.257
lorClass[17,20]	0.3246	-2.147	0.3177	2.832
lorClass[17,21]	-0.697	-3.243	-0.701	1.843
lorClass[18,19]	0.7726	-1.319	0.7717	2.898
lorClass[18,20]	0.6011	-1.222	0.6015	2.398
lorClass[18,21]	-0.4204	-2.309	-0.4252	1.461
lorClass[19,20]	-0.1715	-2.366	-0.1735	2.029
lorClass[19,21]	-1.193	-3.574	-1.189	1.166
lorClass[20,21]	-1.022	-3.13	-1.012	1.046

17.9.1.51 Outcome: response in completers

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-0.965	-1.941	-0.9669	0.02883
lorClass[1,3]	0.2451	-0.9463	0.2417	1.457
lorClass[1,4]	0.3484	-0.3774	0.3479	1.084
lorClass[1,5]	1.108	-0.321	1.103	2.555
lorClass[1,6]	1.18	-0.3864	1.169	2.806
lorClass[1,7]	0.9746	0.2786	0.9758	1.657
lorClass[1,8]	0.8953	0.3221	0.8946	1.472
lorClass[1,9]	1.35	-0.4839	1.349	3.187
lorClass[1,10]	0.8683	-0.2425	0.8642	1.996
lorClass[1,11]	0.7965	-0.8407	0.7964	2.456
lorClass[1,12]	0.8297	-0.5	0.8298	2.175
lorClass[1,13]	0.39	-1.477	0.3872	2.28
lorClass[1,14]	0.8461	-0.4581	0.8425	2.166
lorClass[1,15]	0.6701	-0.7522	0.6749	2.067
lorClass[1,16]	1.142	0.3545	1.139	1.951
lorClass[1,17]	1.188	0.1197	1.185	2.269
lorClass[1,18]	1.504	-0.9899	1.502	3.993
lorClass[1,19]	0.737	-0.6004	0.7356	2.088
lorClass[1,20]	1.92	0.2289	1.919	3.616
lorClass[1,21]	1.262	-0.1216	1.263	2.649
lorClass[1,22]	0.463	-1.318	0.4604	2.26

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[1,23]	0.555	-0.7586	0.5547	1.873
lorClass[2,3]	1.21	-0.07053	1.211	2.499
lorClass[2,4]	1.313	0.3513	1.315	2.268
lorClass[2,5]	2.073	0.5726	2.068	3.584
lorClass[2,6]	2.145	0.2895	2.141	4.035
lorClass[2,7]	1.94	0.7988	1.942	3.065
lorClass[2,8]	1.86	0.7682	1.862	2.936
lorClass[2,9]	2.315	0.3832	2.316	4.237
lorClass[2,10]	1.833	0.5892	1.832	3.086
lorClass[2,11]	1.762	0.3767	1.761	3.154
lorClass[2,12]	1.795	0.8728	1.794	2.719
lorClass[2,13]	1.355	-0.2613	1.357	2.968
lorClass[2,14]	1.811	0.3196	1.815	3.283
lorClass[2,15]	1.635	0.2046	1.638	3.051
lorClass[2,16]	2.107	1.124	2.109	3.086
lorClass[2,17]	2.153	1.189	2.149	3.142
lorClass[2,18]	2.469	-0.05376	2.47	4.984
lorClass[2,19]	1.702	0.1739	1.702	3.235
lorClass[2,20]	2.885	1.057	2.885	4.71
lorClass[2,21]	2.227	0.6933	2.227	3.769
lorClass[2,22]	1.428	-0.5625	1.426	3.43
lorClass[2,23]	1.52	0.08552	1.52	2.952
lorClass[3,4]	0.1033	-1.03	0.1039	1.231
lorClass[3,5]	0.8627	-0.6145	0.8616	2.356
lorClass[3,6]	0.9345	-1.06	0.9326	2.936
lorClass[3,7]	0.7295	-0.6072	0.7309	2.054
lorClass[3,8]	0.6502	-0.6369	0.6516	1.923
lorClass[3,9]	1.105	-0.9928	1.105	3.186
lorClass[3,10]	0.6232	-0.8369	0.6215	2.091
lorClass[3,11]	0.5514	-1.294	0.5486	2.401
lorClass[3,12]	0.5846	-0.9799	0.5842	2.155
lorClass[3,13]	0.1449	-1.91	0.1414	2.202
lorClass[3,14]	0.601	-1.047	0.6017	2.243
lorClass[3,15]	0.4251	-1.285	0.4301	2.124
lorClass[3,16]	0.8972	-0.3354	0.8974	2.131
lorClass[3,17]	0.943	-0.4659	0.9398	2.367
lorClass[3,18]	1.259	-1.371	1.26	3.892
lorClass[3,19]	0.492	-1.212	0.4959	2.175
lorClass[3,20]	1.675	-0.3187	1.677	3.65
lorClass[3,21]	1.017	-0.7171	1.019	2.744
lorClass[3,22]	0.2179	-1.91	0.2203	2.347
lorClass[3,23]	0.31	-1.193	0.3086	1.819
lorClass[4,5]	0.7594	-0.6213	0.7577	2.138
lorClass[4,6]	0.8313	-0.895	0.8236	2.597
lorClass[4,7]	0.6262	-0.2993	0.6276	1.545

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[4,8]	0.5469	-0.316	0.5493	1.401
lorClass[4,9]	1.001	-0.8463	1.002	2.84
lorClass[4,10]	0.5199	-0.517	0.5149	1.583
lorClass[4,11]	0.4482	-1.168	0.447	2.094
lorClass[4,12]	0.4814	-0.8295	0.4805	1.807
lorClass[4,13]	0.04165	-1.815	0.03866	1.921
lorClass[4,14]	0.4977	-0.7715	0.4933	1.791
lorClass[4,15]	0.3218	-1.1	0.3236	1.73
lorClass[4,16]	0.7939	0.03852	0.7901	1.569
lorClass[4,17]	0.8397	-0.2275	0.8362	1.918
lorClass[4,18]	1.156	-1.311	1.155	3.621
lorClass[4,19]	0.3887	-0.9881	0.3887	1.765
lorClass[4,20]	1.572	-0.1697	1.571	3.305
lorClass[4,21]	0.914	-0.5037	0.9129	2.336
lorClass[4,22]	0.1147	-1.766	0.1121	2.012
lorClass[4,23]	0.2067	-1.105	0.2072	1.512
lorClass[5,6]	0.07188	-2.061	0.06716	2.226
lorClass[5,7]	-0.1331	-1.684	-0.1307	1.409
lorClass[5,8]	-0.2125	-1.726	-0.2092	1.282
lorClass[5,9]	0.242	-1.986	0.2433	2.455
lorClass[5,10]	-0.2395	-1.891	-0.2394	1.422
lorClass[5,11]	-0.3112	-2.308	-0.3127	1.69
lorClass[5,12]	-0.278	-2.032	-0.2762	1.476
lorClass[5,13]	-0.7177	-2.91	-0.7176	1.483
lorClass[5,14]	-0.2617	-2.069	-0.2625	1.559
lorClass[5,15]	-0.4376	-2.338	-0.4278	1.422
lorClass[5,16]	0.03452	-1.43	0.03596	1.501
lorClass[5,17]	0.08034	-1.542	0.08237	1.706
lorClass[5,18]	0.3966	-2.329	0.3994	3.128
lorClass[5,19]	-0.3707	-2.231	-0.3699	1.494
lorClass[5,20]	0.8121	-1.317	0.8119	2.934
lorClass[5,21]	0.1546	-1.737	0.1582	2.048
lorClass[5,22]	-0.6447	-2.896	-0.644	1.615
lorClass[5,23]	-0.5527	-2.252	-0.552	1.142
lorClass[6,7]	-0.205	-1.968	-0.1979	1.511
lorClass[6,8]	-0.2843	-2.002	-0.2772	1.384
lorClass[6,9]	0.1701	-2.267	0.1735	2.586
lorClass[6,10]	-0.3114	-2.265	-0.3048	1.615
lorClass[6,11]	-0.3831	-2.69	-0.3791	1.894
lorClass[6,12]	-0.3499	-2.443	-0.3461	1.718
lorClass[6,13]	-0.7896	-3.256	-0.7914	1.687
lorClass[6,14]	-0.3336	-2.391	-0.331	1.709
lorClass[6,15]	-0.5095	-2.65	-0.5049	1.585
lorClass[6,16]	-0.03736	-1.838	-0.03161	1.729
lorClass[6,17]	0.008457	-1.937	0.0135	1.914

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[6,18]	0.3247	-2.642	0.3272	3.29
lorClass[6,19]	-0.4426	-2.542	-0.4374	1.626
lorClass[6,20]	0.7403	-1.591	0.7479	3.046
lorClass[6,21]	0.08276	-2.035	0.08475	2.187
lorClass[6,22]	-0.7166	-3.133	-0.7142	1.673
lorClass[6,23]	-0.6246	-2.711	-0.6167	1.422
lorClass[7,8]	-0.07932	-0.9061	-0.07964	0.7467
lorClass[7,9]	0.3751	-1.533	0.3745	2.295
lorClass[7,10]	-0.1063	-1.345	-0.1098	1.149
lorClass[7,11]	-0.1781	-1.904	-0.1794	1.565
lorClass[7,12]	-0.1449	-1.589	-0.1462	1.314
lorClass[7,13]	-0.5846	-2.533	-0.5893	1.39
lorClass[7,14]	-0.1285	-1.549	-0.1296	1.301
lorClass[7,15]	-0.3045	-1.826	-0.3018	1.189
lorClass[7,16]	0.1677	-0.7974	0.1656	1.149
lorClass[7,17]	0.2135	-0.9868	0.2125	1.424
lorClass[7,18]	0.5297	-2.028	0.5257	3.09
lorClass[7,19]	-0.2376	-1.682	-0.2394	1.21
lorClass[7,20]	0.9453	-0.8286	0.9429	2.713
lorClass[7,21]	0.2878	-1.192	0.2884	1.77
lorClass[7,22]	-0.5116	-2.35	-0.5137	1.355
lorClass[7,23]	-0.4196	-1.858	-0.4207	1.018
lorClass[8,9]	0.4545	-1.437	0.4547	2.353
lorClass[8,10]	-0.02702	-1.227	-0.03061	1.19
lorClass[8,11]	-0.09877	-1.798	-0.1014	1.62
lorClass[8,12]	-0.06557	-1.47	-0.06736	1.355
lorClass[8,13]	-0.5053	-2.431	-0.5062	1.437
lorClass[8,14]	-0.04922	-1.436	-0.05369	1.348
lorClass[8,15]	-0.2251	-1.723	-0.2208	1.245
lorClass[8,16]	0.247	-0.658	0.2439	1.177
lorClass[8,17]	0.2928	-0.8707	0.29	1.468
lorClass[8,18]	0.609	-1.923	0.6097	3.143
lorClass[8,19]	-0.1582	-1.555	-0.1596	1.246
lorClass[8,20]	1.025	-0.7406	1.023	2.779
lorClass[8,21]	0.3671	-1.062	0.3678	1.8
lorClass[8,22]	-0.4323	-2.284	-0.4346	1.425
lorClass[8,23]	-0.3402	-1.733	-0.341	1.053
lorClass[9,10]	-0.4815	-2.434	-0.4793	1.463
lorClass[9,11]	-0.5532	-2.878	-0.5534	1.772
lorClass[9,12]	-0.52	-2.645	-0.5221	1.598
lorClass[9,13]	-0.9597	-3.459	-0.9619	1.539
lorClass[9,14]	-0.5037	-2.635	-0.4999	1.622
lorClass[9,15]	-0.6796	-2.829	-0.6775	1.461
lorClass[9,16]	-0.2075	-2.063	-0.2074	1.65
lorClass[9,17]	-0.1617	-2.119	-0.161	1.8

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[9,18]	0.1546	-2.856	0.1532	3.173
lorClass[9,19]	-0.6127	-2.773	-0.6126	1.547
lorClass[9,20]	0.5701	-1.613	0.5717	2.738
lorClass[9,21]	-0.08737	-2.24	-0.08908	2.068
lorClass[9,22]	-0.8867	-3.353	-0.8842	1.577
lorClass[9,23]	-0.7947	-2.953	-0.7977	1.38
lorClass[10,11]	-0.07176	-1.87	-0.07375	1.742
lorClass[10,12]	-0.03855	-1.567	-0.04081	1.508
lorClass[10,13]	-0.4783	-2.51	-0.4785	1.55
lorClass[10,14]	-0.02221	-1.601	-0.01936	1.548
lorClass[10,15]	-0.1981	-1.785	-0.1945	1.379
lorClass[10,16]	0.274	-0.8807	0.2771	1.432
lorClass[10,17]	0.3198	-0.9929	0.3221	1.631
lorClass[10,18]	0.636	-1.988	0.6353	3.251
lorClass[10,19]	-0.1312	-1.747	-0.1297	1.48
lorClass[10,20]	1.052	-0.8259	1.053	2.923
lorClass[10,21]	0.3941	-1.141	0.3946	1.931
lorClass[10,22]	-0.4052	-2.465	-0.4058	1.649
lorClass[10,23]	-0.3132	-1.912	-0.3118	1.275
lorClass[11,12]	0.0332	-1.366	0.03159	1.449
lorClass[11,13]	-0.4065	-2.533	-0.4046	1.7
lorClass[11,14]	0.04955	-1.932	0.05044	2.009
lorClass[11,15]	-0.1264	-2.073	-0.1253	1.811
lorClass[11,16]	0.3457	-1.295	0.3472	1.979
lorClass[11,17]	0.3916	-1.131	0.3917	1.91
lorClass[11,18]	0.7078	-2.135	0.7089	3.546
lorClass[11,19]	-0.05947	-2.079	-0.05406	1.94
lorClass[11,20]	1.123	-1.124	1.129	3.341
lorClass[11,21]	0.4659	-1.538	0.4667	2.477
lorClass[11,22]	-0.3335	-2.729	-0.3362	2.056
lorClass[11,23]	-0.2415	-2.204	-0.2377	1.703
lorClass[12,13]	-0.4397	-2.308	-0.4362	1.407
lorClass[12,14]	0.01635	-1.734	0.02206	1.729
lorClass[12,15]	-0.1596	-1.848	-0.1555	1.504
lorClass[12,16]	0.3125	-1.027	0.3148	1.635
lorClass[12,17]	0.3584	-0.934	0.3562	1.659
lorClass[12,18]	0.6746	-2.011	0.6765	3.346
lorClass[12,19]	-0.09267	-1.875	-0.09007	1.684
lorClass[12,20]	1.09	-0.9453	1.09	3.123
lorClass[12,21]	0.4327	-1.335	0.4301	2.21
lorClass[12,22]	-0.3667	-2.544	-0.3648	1.814
lorClass[12,23]	-0.2747	-1.975	-0.2739	1.419
lorClass[13,14]	0.4561	-1.735	0.4571	2.625
lorClass[13,15]	0.2801	-1.855	0.2736	2.431
lorClass[13,16]	0.7523	-1.133	0.7513	2.625

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[13,17]	0.7981	-1.082	0.7954	2.682
lorClass[13,18]	1.114	-1.885	1.12	4.087
lorClass[13,19]	0.347	-1.885	0.3483	2.564
lorClass[13,20]	1.53	-0.9059	1.528	3.972
lorClass[13,21]	0.8724	-1.336	0.8651	3.094
lorClass[13,22]	0.07301	-2.48	0.06998	2.639
lorClass[13,23]	0.165	-1.985	0.1671	2.304
lorClass[14,15]	-0.1759	-1.953	-0.1726	1.604
lorClass[14,16]	0.2962	-1.087	0.2981	1.68
lorClass[14,17]	0.342	-1.188	0.3397	1.883
lorClass[14,18]	0.6582	-2.071	0.6591	3.384
lorClass[14,19]	-0.109	-1.879	-0.108	1.646
lorClass[14,20]	1.074	-0.9675	1.075	3.115
lorClass[14,21]	0.4163	-1.38	0.4151	2.22
lorClass[14,22]	-0.383	-2.563	-0.382	1.804
lorClass[14,23]	-0.291	-2.048	-0.2883	1.451
lorClass[15,16]	0.4721	-0.9361	0.4672	1.911
lorClass[15,17]	0.5179	-0.9903	0.5129	2.054
lorClass[15,18]	0.8342	-1.918	0.8374	3.592
lorClass[15,19]	0.06689	-1.741	0.06463	1.895
lorClass[15,20]	1.25	-0.8069	1.248	3.323
lorClass[15,21]	0.5922	-1.234	0.5908	2.428
lorClass[15,22]	-0.2071	-2.428	-0.2089	2.029
lorClass[15,23]	-0.1151	-1.923	-0.1156	1.705
lorClass[16,17]	0.04582	-1.031	0.04606	1.123
lorClass[16,18]	0.3621	-2.076	0.3655	2.807
lorClass[16,19]	-0.4052	-1.796	-0.4029	0.9732
lorClass[16,20]	0.7776	-0.9789	0.7781	2.519
lorClass[16,21]	0.1201	-1.333	0.121	1.569
lorClass[16,22]	-0.6792	-2.593	-0.6794	1.233
lorClass[16,23]	-0.5872	-1.952	-0.586	0.7708
lorClass[17,18]	0.3162	-2.271	0.3144	2.897
lorClass[17,19]	-0.451	-2.022	-0.4504	1.118
lorClass[17,20]	0.7318	-1.142	0.7351	2.596
lorClass[17,21]	0.0743	-1.513	0.07357	1.667
lorClass[17,22]	-0.7251	-2.771	-0.7248	1.32
lorClass[17,23]	-0.633	-2.183	-0.6315	0.9078
lorClass[18,19]	-0.7673	-3.524	-0.7648	1.971
lorClass[18,20]	0.4156	-2.507	0.4107	3.36
lorClass[18,21]	-0.2419	-3.006	-0.2457	2.529
lorClass[18,22]	-1.041	-4.059	-1.046	2.006
lorClass[18,23]	-0.9493	-3.609	-0.9516	1.721
lorClass[19,20]	1.183	-0.8877	1.182	3.248
lorClass[19,21]	0.5253	-1.271	0.5259	2.313
lorClass[19,22]	-0.274	-2.467	-0.2754	1.934

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[19,23]	-0.182	-1.972	-0.1813	1.603
lorClass[20,21]	-0.6575	-2.718	-0.6593	1.403
lorClass[20,22]	-1.457	-3.579	-1.456	0.6568
lorClass[20,23]	-1.365	-3.433	-1.364	0.7027
lorClass[21,22]	-0.7994	-3.015	-0.7981	1.418
lorClass[21,23]	-0.7073	-2.53	-0.7075	1.114
lorClass[22,23]	0.09202	-2.096	0.09255	2.274

17.9.1.61 Outcome: response in those randomised

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-0.7629	-1.375	-0.7601	-0.1702
lorClass[1,3]	0.138	-0.51	0.1369	0.7859
lorClass[1,4]	-0.3647	-0.9036	-0.3651	0.1693
lorClass[1,5]	0.8311	-0.467	0.828	2.157
lorClass[1,6]	1.364	-0.2035	1.353	2.988
lorClass[1,7]	0.5355	-0.1837	0.5346	1.258
lorClass[1,8]	0.6469	0.05286	0.6422	1.262
lorClass[1,9]	1.681	-0.03967	1.677	3.411
lorClass[1,10]	0.6795	-0.3759	0.6837	1.726
lorClass[1,11]	1.458	-0.09267	1.46	2.997
lorClass[1,12]	0.8751	-0.09363	0.8765	1.833
lorClass[1,13]	0.3177	-0.6031	0.3213	1.22
lorClass[1,14]	0.542	-0.7465	0.5448	1.804
lorClass[1,15]	0.5432	-0.744	0.5406	1.852
lorClass[1,16]	0.3996	-0.713	0.3999	1.518
lorClass[1,17]	0.979	0.3244	0.98	1.631
lorClass[1,18]	1.135	0.1886	1.134	2.087
lorClass[1,19]	0.9331	-1.597	0.9337	3.433
lorClass[1,20]	1.363	-0.4393	1.364	3.162
lorClass[1,21]	2.509	0.5552	2.508	4.463
lorClass[1,22]	1.788	0.36	1.789	3.202
lorClass[1,23]	2.63	-0.5668	2.624	5.896
lorClass[1,24]	2.065	0.3363	2.061	3.81
lorClass[2,3]	0.9009	0.3245	0.8999	1.487
lorClass[2,4]	0.3982	-0.02703	0.3979	0.8254
lorClass[2,5]	1.594	0.2831	1.593	2.915
lorClass[2,6]	2.127	0.4537	2.116	3.863
lorClass[2,7]	1.298	0.4383	1.296	2.163
lorClass[2,8]	1.41	0.6371	1.407	2.209
lorClass[2,9]	2.444	0.7224	2.443	4.168
lorClass[2,10]	1.442	0.4165	1.442	2.476
lorClass[2,11]	2.221	0.7033	2.222	3.737
lorClass[2,12]	1.638	0.8109	1.641	2.451
lorClass[2,13]	1.081	0.2885	1.082	1.859
lorClass[2,14]	1.305	0.1167	1.303	2.501

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[2,15]	1.306	0.03937	1.301	2.6
lorClass[2,16]	1.162	0.08765	1.163	2.239
lorClass[2,17]	1.742	1.142	1.741	2.347
lorClass[2,18]	1.898	1.008	1.895	2.808
lorClass[2,19]	1.696	-0.8046	1.69	4.179
lorClass[2,20]	2.126	0.3071	2.129	3.942
lorClass[2,21]	3.272	1.327	3.271	5.219
lorClass[2,22]	2.551	1.086	2.556	3.983
lorClass[2,23]	3.393	0.2116	3.389	6.658
lorClass[2,24]	2.828	1.032	2.824	4.641
lorClass[3,4]	-0.5027	-1.07	-0.5021	0.06495
lorClass[3,5]	0.6931	-0.5944	0.691	1.992
lorClass[3,6]	1.226	-0.4727	1.217	2.973
lorClass[3,7]	0.3975	-0.5065	0.3958	1.306
lorClass[3,8]	0.5089	-0.3139	0.5072	1.332
lorClass[3,9]	1.543	-0.2115	1.543	3.301
lorClass[3,10]	0.5415	-0.5674	0.5449	1.635
lorClass[3,11]	1.32	-0.2606	1.321	2.886
lorClass[3,12]	0.7371	-0.1609	0.7401	1.628
lorClass[3,13]	0.1797	-0.7295	0.1839	1.07
lorClass[3,14]	0.404	-0.8805	0.4055	1.679
lorClass[3,15]	0.4052	-0.9085	0.4008	1.738
lorClass[3,16]	0.2616	-0.8853	0.2625	1.406
lorClass[3,17]	0.841	0.1211	0.8403	1.564
lorClass[3,18]	0.9973	0.02329	0.994	1.979
lorClass[3,19]	0.7951	-1.744	0.792	3.308
lorClass[3,20]	1.225	-0.6327	1.23	3.065
lorClass[3,21]	2.371	0.3837	2.369	4.334
lorClass[3,22]	1.65	0.1584	1.653	3.128
lorClass[3,23]	2.492	-0.721	2.491	5.783
lorClass[3,24]	1.927	0.1107	1.923	3.754
lorClass[4,5]	1.196	-0.09411	1.194	2.502
lorClass[4,6]	1.728	0.07534	1.716	3.443
lorClass[4,7]	0.9002	0.08543	0.9006	1.721
lorClass[4,8]	1.012	0.2798	1.011	1.755
lorClass[4,9]	2.046	0.3481	2.047	3.745
lorClass[4,10]	1.044	0.05323	1.046	2.031
lorClass[4,11]	1.823	0.3182	1.825	3.315
lorClass[4,12]	1.24	0.3531	1.242	2.116
lorClass[4,13]	0.6824	-0.1344	0.6884	1.47
lorClass[4,14]	0.9068	-0.2888	0.908	2.099
lorClass[4,15]	0.9079	-0.3061	0.9033	2.146
lorClass[4,16]	0.7643	-0.2512	0.7644	1.785
lorClass[4,17]	1.344	0.7983	1.344	1.883
lorClass[4,18]	1.5	0.6566	1.497	2.361

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[4,19]	1.298	-1.196	1.298	3.765
lorClass[4,20]	1.728	-0.06454	1.728	3.517
lorClass[4,21]	2.874	0.9514	2.871	4.798
lorClass[4,22]	2.153	0.7268	2.157	3.553
lorClass[4,23]	2.995	-0.1743	2.991	6.24
lorClass[4,24]	2.43	0.6488	2.427	4.223
lorClass[5,6]	0.5326	-1.504	0.5308	2.596
lorClass[5,7]	-0.2956	-1.756	-0.2969	1.153
lorClass[5,8]	-0.1842	-1.593	-0.1843	1.218
lorClass[5,9]	0.8504	-1.245	0.8518	2.944
lorClass[5,10]	-0.1516	-1.74	-0.147	1.429
lorClass[5,11]	0.6272	-1.325	0.6306	2.574
lorClass[5,12]	0.044	-1.461	0.04665	1.539
lorClass[5,13]	-0.5134	-1.995	-0.5079	0.9545
lorClass[5,14]	-0.289	-2.022	-0.2904	1.42
lorClass[5,15]	-0.2879	-2.026	-0.2905	1.464
lorClass[5,16]	-0.4315	-2.056	-0.4309	1.191
lorClass[5,17]	0.1479	-1.225	0.1508	1.508
lorClass[5,18]	0.3042	-1.218	0.306	1.819
lorClass[5,19]	0.1021	-2.678	0.1035	2.862
lorClass[5,20]	0.5322	-1.649	0.5325	2.705
lorClass[5,21]	1.678	-0.6123	1.685	3.95
lorClass[5,22]	0.9571	-0.9305	0.9637	2.821
lorClass[5,23]	1.799	-1.607	1.797	5.255
lorClass[5,24]	1.234	-0.9018	1.232	3.36
lorClass[6,7]	-0.8281	-2.593	-0.8161	0.8921
lorClass[6,8]	-0.7167	-2.452	-0.7113	0.9709
lorClass[6,9]	0.3178	-2.039	0.3193	2.655
lorClass[6,10]	-0.6841	-2.613	-0.6746	1.195
lorClass[6,11]	0.09469	-2.144	0.1014	2.296
lorClass[6,12]	-0.4886	-2.365	-0.4825	1.358
lorClass[6,13]	-1.046	-2.906	-1.039	0.7689
lorClass[6,14]	-0.8216	-2.884	-0.8104	1.192
lorClass[6,15]	-0.8204	-2.896	-0.8146	1.225
lorClass[6,16]	-0.9641	-2.93	-0.9568	0.9541
lorClass[6,17]	-0.3846	-2.136	-0.3772	1.309
lorClass[6,18]	-0.2283	-2.11	-0.2171	1.604
lorClass[6,19]	-0.4305	-3.43	-0.4325	2.544
lorClass[6,20]	-3.40E-04	-2.438	0.009218	2.395
lorClass[6,21]	1.146	-1.386	1.149	3.653
lorClass[6,22]	0.4246	-1.731	0.4295	2.543
lorClass[6,23]	1.266	-2.332	1.271	4.872
lorClass[6,24]	0.7018	-1.661	0.7051	3.068
lorClass[7,8]	0.1114	-0.7763	0.1103	0.9996
lorClass[7,9]	1.146	-0.6717	1.141	2.983

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[7,10]	0.144	-1.076	0.1454	1.348
lorClass[7,11]	0.9228	-0.7415	0.924	2.575
lorClass[7,12]	0.3396	-0.8063	0.3388	1.493
lorClass[7,13]	-0.2178	-1.326	-0.2159	0.8839
lorClass[7,14]	0.006536	-1.41	0.009279	1.416
lorClass[7,15]	0.007703	-1.414	0.003867	1.426
lorClass[7,16]	-0.1359	-1.411	-0.1344	1.129
lorClass[7,17]	0.4435	-0.4531	0.4433	1.331
lorClass[7,18]	0.5998	-0.5174	0.5983	1.726
lorClass[7,19]	0.3976	-2.201	0.395	2.974
lorClass[7,20]	0.8278	-0.9958	0.8301	2.65
lorClass[7,21]	1.974	-0.0613	1.97	4.01
lorClass[7,22]	1.253	-0.3031	1.258	2.789
lorClass[7,23]	2.094	-1.147	2.09	5.395
lorClass[7,24]	1.53	-0.3214	1.527	3.405
lorClass[8,9]	1.035	-0.7486	1.034	2.817
lorClass[8,10]	0.03259	-1.14	0.03699	1.184
lorClass[8,11]	0.8114	-0.8156	0.8118	2.427
lorClass[8,12]	0.2282	-0.8718	0.2313	1.309
lorClass[8,13]	-0.3292	-1.373	-0.3241	0.6995
lorClass[8,14]	-0.1049	-1.493	-0.1009	1.254
lorClass[8,15]	-0.1037	-1.484	-0.1077	1.298
lorClass[8,16]	-0.2473	-1.472	-0.245	0.9744
lorClass[8,17]	0.3321	-0.4984	0.3353	1.15
lorClass[8,18]	0.4884	-0.5757	0.4873	1.562
lorClass[8,19]	0.2862	-2.298	0.2846	2.85
lorClass[8,20]	0.7164	-1.151	0.717	2.586
lorClass[8,21]	1.862	-0.137	1.862	3.863
lorClass[8,22]	1.141	-0.3087	1.145	2.573
lorClass[8,23]	1.983	-1.225	1.976	5.284
lorClass[8,24]	1.419	-0.3805	1.418	3.234
lorClass[9,10]	-1.002	-2.899	-0.9999	0.8742
lorClass[9,11]	-0.2231	-2.451	-0.2185	1.982
lorClass[9,12]	-0.8064	-2.695	-0.8101	1.074
lorClass[9,13]	-1.364	-3.202	-1.365	0.4806
lorClass[9,14]	-1.139	-3.19	-1.139	0.8943
lorClass[9,15]	-1.138	-3.166	-1.136	0.8734
lorClass[9,16]	-1.282	-3.232	-1.278	0.6717
lorClass[9,17]	-0.7025	-2.435	-0.7053	1.03
lorClass[9,18]	-0.5461	-2.4	-0.5461	1.3
lorClass[9,19]	-0.7483	-3.739	-0.7426	2.234
lorClass[9,20]	-0.3182	-2.733	-0.3182	2.085
lorClass[9,21]	0.8279	-1.485	0.8273	3.143
lorClass[9,22]	0.1067	-1.896	0.1067	2.113
lorClass[9,23]	0.9484	-2.493	0.9489	4.432

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[9,24]	0.384	-2.04	0.3851	2.806
lorClass[10,11]	0.7788	-0.9266	0.7796	2.47
lorClass[10,12]	0.1956	-1.087	0.193	1.485
lorClass[10,13]	-0.3618	-1.598	-0.3598	0.8626
lorClass[10,14]	-0.1375	-1.67	-0.1374	1.392
lorClass[10,15]	-0.1363	-1.676	-0.1397	1.431
lorClass[10,16]	-0.2799	-1.614	-0.2813	1.055
lorClass[10,17]	0.2995	-0.7433	0.3014	1.346
lorClass[10,18]	0.4558	-0.7794	0.4499	1.712
lorClass[10,19]	0.2536	-2.392	0.2572	2.877
lorClass[10,20]	0.6838	-1.311	0.6811	2.685
lorClass[10,21]	1.83	-0.2547	1.824	3.935
lorClass[10,22]	1.109	-0.5511	1.111	2.773
lorClass[10,23]	1.95	-1.346	1.946	5.313
lorClass[10,24]	1.386	-0.6078	1.385	3.371
lorClass[11,12]	-0.5833	-2.288	-0.5851	1.119
lorClass[11,13]	-1.141	-2.807	-1.143	0.5289
lorClass[11,14]	-0.9163	-2.81	-0.9192	0.9839
lorClass[11,15]	-0.9151	-2.82	-0.9198	1.011
lorClass[11,16]	-1.059	-2.835	-1.058	0.7139
lorClass[11,17]	-0.4793	-2.013	-0.4797	1.051
lorClass[11,18]	-0.323	-1.994	-0.3242	1.364
lorClass[11,19]	-0.5252	-3.372	-0.5221	2.303
lorClass[11,20]	-0.09503	-2.391	-0.1005	2.207
lorClass[11,21]	1.051	-1.338	1.049	3.45
lorClass[11,22]	0.3299	-1.692	0.3313	2.335
lorClass[11,23]	1.172	-2.301	1.166	4.712
lorClass[11,24]	0.6071	-1.693	0.6071	2.915
lorClass[12,13]	-0.5574	-1.66	-0.5555	0.5381
lorClass[12,14]	-0.333	-1.744	-0.3351	1.081
lorClass[12,15]	-0.3319	-1.81	-0.3361	1.165
lorClass[12,16]	-0.4755	-1.795	-0.4768	0.8563
lorClass[12,17]	0.1039	-0.8741	0.1022	1.083
lorClass[12,18]	0.2603	-0.9084	0.2568	1.458
lorClass[12,19]	0.05807	-2.558	0.05477	2.667
lorClass[12,20]	0.4882	-1.493	0.4895	2.457
lorClass[12,21]	1.634	-0.4634	1.635	3.722
lorClass[12,22]	0.9131	-0.7377	0.9167	2.536
lorClass[12,23]	1.755	-1.524	1.75	5.093
lorClass[12,24]	1.19	-0.7554	1.19	3.146
lorClass[13,14]	0.2244	-1.151	0.2204	1.613
lorClass[13,15]	0.2255	-1.195	0.2205	1.691
lorClass[13,16]	0.0819	-1.18	0.07889	1.348
lorClass[13,17]	0.6613	-0.2484	0.6566	1.582
lorClass[13,18]	0.8176	-0.2925	0.8118	1.953

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[13,19]	0.6155	-1.978	0.6129	3.187
lorClass[13,20]	1.046	-0.8968	1.046	2.982
lorClass[13,21]	2.192	0.1333	2.191	4.254
lorClass[13,22]	1.471	-0.1435	1.475	3.061
lorClass[13,23]	2.312	-0.9607	2.31	5.638
lorClass[13,24]	1.748	-0.1713	1.745	3.678
lorClass[14,15]	0.001166	-1.691	-0.00614	1.724
lorClass[14,16]	-0.1425	-1.686	-0.1429	1.408
lorClass[14,17]	0.437	-0.8453	0.4372	1.729
lorClass[14,18]	0.5933	-0.8412	0.5872	2.049
lorClass[14,19]	0.3911	-2.358	0.3883	3.12
lorClass[14,20]	0.8213	-1.319	0.8158	2.969
lorClass[14,21]	1.967	-0.2739	1.965	4.222
lorClass[14,22]	1.246	-0.5883	1.247	3.073
lorClass[14,23]	2.088	-1.29	2.089	5.525
lorClass[14,24]	1.523	-0.5957	1.52	3.654
lorClass[15,16]	-0.1436	-1.726	-0.1386	1.422
lorClass[15,17]	0.4358	-0.8848	0.4414	1.719
lorClass[15,18]	0.5921	-0.8658	0.593	2.05
lorClass[15,19]	0.3899	-2.364	0.3942	3.12
lorClass[15,20]	0.8201	-1.303	0.8175	2.96
lorClass[15,21]	1.966	-0.2455	1.969	4.183
lorClass[15,22]	1.245	-0.5637	1.245	3.043
lorClass[15,23]	2.087	-1.259	2.077	5.493
lorClass[15,24]	1.522	-0.6259	1.521	3.653
lorClass[16,17]	0.5794	-0.5257	0.5801	1.684
lorClass[16,18]	0.7358	-0.5712	0.7349	2.051
lorClass[16,19]	0.5336	-2.122	0.5404	3.172
lorClass[16,20]	0.9637	-1.091	0.9676	3.002
lorClass[16,21]	2.11	-0.0303	2.105	4.269
lorClass[16,22]	1.389	-0.3384	1.389	3.101
lorClass[16,23]	2.23	-1.092	2.223	5.601
lorClass[16,24]	1.666	-0.3548	1.665	3.699
lorClass[17,18]	0.1563	-0.7872	0.1555	1.113
lorClass[17,19]	-0.04586	-2.553	-0.04502	2.446
lorClass[17,20]	0.3843	-1.443	0.3827	2.209
lorClass[17,21]	1.53	-0.4082	1.529	3.493
lorClass[17,22]	0.8092	-0.6591	0.8112	2.256
lorClass[17,23]	1.651	-1.538	1.648	4.917
lorClass[17,24]	1.086	-0.72	1.081	2.917
lorClass[18,19]	-0.2022	-2.814	-0.2047	2.403
lorClass[18,20]	0.228	-1.72	0.2311	2.171
lorClass[18,21]	1.374	-0.6819	1.375	3.425
lorClass[18,22]	0.6529	-0.9732	0.6568	2.252
lorClass[18,23]	1.495	-1.758	1.49	4.817

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[18,24]	0.9301	-1.009	0.9283	2.892
lorClass[19,20]	0.4302	-2.614	0.4224	3.486
lorClass[19,21]	1.576	-1.528	1.571	4.723
lorClass[19,22]	0.8551	-1.976	0.8503	3.703
lorClass[19,23]	1.697	-2.331	1.681	5.789
lorClass[19,24]	1.132	-1.905	1.134	4.163
lorClass[20,21]	1.146	-1.446	1.143	3.729
lorClass[20,22]	0.4249	-1.818	0.4307	2.645
lorClass[20,23]	1.267	-2.327	1.257	4.926
lorClass[20,24]	0.7022	-1.767	0.7014	3.19
lorClass[21,22]	-0.7212	-2.943	-0.7153	1.461
lorClass[21,23]	0.1205	-2.444	0.1189	2.72
lorClass[21,24]	-0.4439	-3.022	-0.4408	2.149
lorClass[22,23]	0.8417	-2.506	0.8356	4.248
lorClass[22,24]	0.2773	-1.934	0.2806	2.502
lorClass[23,24]	-0.5644	-4.237	-0.5636	3.064

17.9.1.71 Outcome: SMD

	Mean	2.5%	Median	97.5%
diffClass[1,2]	0.3833	0.1108	0.3833	0.6552
diffClass[1,3]	0.01734	-0.2916	0.01879	0.3201
diffClass[1,4]	0.1845	-0.07021	0.1831	0.4455
diffClass[1,5]	-0.3388	-1.57	-0.3395	0.8895
diffClass[1,6]	-0.1929	-0.7614	-0.1944	0.3791
diffClass[1,7]	-0.23	-0.7442	-0.2291	0.2816
diffClass[1,8]	-0.7275	-1.992	-0.7277	0.5394
diffClass[1,9]	-0.2274	-0.885	-0.2288	0.4465
diffClass[1,10]	-0.7474	-1.696	-0.745	0.1916
diffClass[1,11]	-0.7714	-1.523	-0.7682	-0.02902
diffClass[1,12]	-0.186	-0.8945	-0.1891	0.5283
diffClass[1,13]	-0.3461	-1.219	-0.3442	0.5196
diffClass[1,14]	-0.2875	-1.175	-0.285	0.5921
diffClass[1,15]	-0.128	-1.002	-0.1272	0.7519
diffClass[1,16]	-0.4563	-0.8475	-0.4549	-0.07149
diffClass[1,17]	-0.4277	-1.285	-0.4305	0.436
diffClass[1,18]	-0.53	-1.877	-0.5313	0.8181
diffClass[1,19]	-1.483	-2.859	-1.481	-0.1004
diffClass[1,20]	-1.141	-2.497	-1.14	0.2126
diffClass[1,21]	-0.5853	-1.87	-0.5856	0.704
diffClass[2,3]	-0.3659	-0.6457	-0.3657	-0.08655
diffClass[2,4]	-0.1988	-0.4005	-0.1992	0.003694
diffClass[2,5]	-0.7221	-1.954	-0.7219	0.5043
diffClass[2,6]	-0.5761	-1.172	-0.5774	0.02415
diffClass[2,7]	-0.6132	-1.169	-0.613	-0.05627
diffClass[2,8]	-1.111	-2.37	-1.111	0.1481

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
diffClass[2,9]	-0.6106	-1.251	-0.6142	0.04532
diffClass[2,10]	-1.131	-2.064	-1.129	-0.206
diffClass[2,11]	-1.155	-1.876	-1.149	-0.4533
diffClass[2,12]	-0.5692	-1.244	-0.571	0.1105
diffClass[2,13]	-0.7294	-1.577	-0.7279	0.1116
diffClass[2,14]	-0.6708	-1.543	-0.6678	0.1981
diffClass[2,15]	-0.5112	-1.373	-0.5108	0.3498
diffClass[2,16]	-0.8396	-1.205	-0.84	-0.4727
diffClass[2,17]	-0.811	-1.656	-0.8119	0.04288
diffClass[2,18]	-0.9133	-2.26	-0.9156	0.4353
diffClass[2,19]	-1.867	-3.237	-1.863	-0.4894
diffClass[2,20]	-1.524	-2.878	-1.527	-0.173
diffClass[2,21]	-0.9686	-2.268	-0.968	0.3336
diffClass[3,4]	0.1672	-0.1141	0.1667	0.4523
diffClass[3,5]	-0.3562	-1.589	-0.3567	0.8726
diffClass[3,6]	-0.2102	-0.8274	-0.2106	0.4096
diffClass[3,7]	-0.2473	-0.8238	-0.2471	0.3283
diffClass[3,8]	-0.7448	-2.02	-0.7454	0.5292
diffClass[3,9]	-0.2447	-0.9187	-0.246	0.4415
diffClass[3,10]	-0.7647	-1.724	-0.7613	0.183
diffClass[3,11]	-0.7887	-1.523	-0.786	-0.06002
diffClass[3,12]	-0.2033	-0.9088	-0.2054	0.5123
diffClass[3,13]	-0.3635	-1.241	-0.3624	0.5071
diffClass[3,14]	-0.3048	-1.201	-0.3031	0.5876
diffClass[3,15]	-0.1453	-1.031	-0.145	0.741
diffClass[3,16]	-0.4737	-0.894	-0.4733	-0.054
diffClass[3,17]	-0.445	-1.316	-0.4452	0.4306
diffClass[3,18]	-0.5473	-1.901	-0.5496	0.8144
diffClass[3,19]	-1.501	-2.888	-1.499	-0.1134
diffClass[3,20]	-1.158	-2.528	-1.158	0.2081
diffClass[3,21]	-0.6027	-1.904	-0.6051	0.7096
diffClass[4,5]	-0.5233	-1.75	-0.524	0.704
diffClass[4,6]	-0.3774	-0.9649	-0.3774	0.2108
diffClass[4,7]	-0.4145	-0.9658	-0.4144	0.136
diffClass[4,8]	-0.912	-2.164	-0.9118	0.3363
diffClass[4,9]	-0.4119	-1.042	-0.4159	0.2356
diffClass[4,10]	-0.9319	-1.862	-0.9301	-0.01144
diffClass[4,11]	-0.9559	-1.691	-0.9515	-0.2361
diffClass[4,12]	-0.3705	-1.051	-0.374	0.318
diffClass[4,13]	-0.5306	-1.375	-0.5301	0.3127
diffClass[4,14]	-0.472	-1.336	-0.4698	0.3861
diffClass[4,15]	-0.3125	-1.163	-0.312	0.5386
diffClass[4,16]	-0.6408	-0.9915	-0.6408	-0.2883
diffClass[4,17]	-0.6122	-1.45	-0.6139	0.2327
diffClass[4,18]	-0.7145	-2.053	-0.7163	0.6257

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
diffClass[4,19]	-1.668	-3.033	-1.665	-0.3011
diffClass[4,20]	-1.325	-2.677	-1.325	0.02036
diffClass[4,21]	-0.7698	-2.061	-0.7684	0.5344
diffClass[5,6]	0.1459	-1.185	0.1454	1.479
diffClass[5,7]	0.1089	-1.198	0.1102	1.419
diffClass[5,8]	-0.3887	-2.106	-0.3881	1.338
diffClass[5,9]	0.1114	-1.252	0.1093	1.477
diffClass[5,10]	-0.4086	-1.921	-0.409	1.103
diffClass[5,11]	-0.4325	-1.835	-0.432	0.9623
diffClass[5,12]	0.1528	-1.225	0.1534	1.533
diffClass[5,13]	-0.007299	-1.472	-0.00389	1.456
diffClass[5,14]	0.0513	-1.424	0.05292	1.52
diffClass[5,15]	0.2108	-1.268	0.2097	1.681
diffClass[5,16]	-0.1175	-1.38	-0.1175	1.148
diffClass[5,17]	-0.08888	-1.545	-0.08833	1.367
diffClass[5,18]	-0.1912	-1.972	-0.1916	1.608
diffClass[5,19]	-1.144	-2.952	-1.142	0.687
diffClass[5,20]	-0.8021	-2.599	-0.8004	0.9895
diffClass[5,21]	-0.2465	-1.995	-0.2479	1.502
diffClass[6,7]	-0.03707	-0.7708	-0.03688	0.6988
diffClass[6,8]	-0.5346	-1.893	-0.5338	0.8195
diffClass[6,9]	-0.03449	-0.8678	-0.03543	0.8088
diffClass[6,10]	-0.5545	-1.627	-0.5526	0.513
diffClass[6,11]	-0.5785	-1.487	-0.5769	0.3303
diffClass[6,12]	0.006924	-0.8724	0.006772	0.8857
diffClass[6,13]	-0.1532	-1.163	-0.1521	0.8542
diffClass[6,14]	-0.09462	-1.112	-0.09269	0.9192
diffClass[6,15]	0.0649	-0.9436	0.06392	1.081
diffClass[6,16]	-0.2634	-0.9106	-0.262	0.3858
diffClass[6,17]	-0.2348	-1.23	-0.2349	0.766
diffClass[6,18]	-0.3371	-1.744	-0.3382	1.079
diffClass[6,19]	-1.29	-2.756	-1.289	0.183
diffClass[6,20]	-0.948	-2.403	-0.9489	0.4984
diffClass[6,21]	-0.3924	-1.784	-0.3923	0.9982
diffClass[7,8]	-0.4975	-1.839	-0.4999	0.8508
diffClass[7,9]	0.002579	-0.8027	0.001265	0.8136
diffClass[7,10]	-0.5174	-1.574	-0.5162	0.5301
diffClass[7,11]	-0.5414	-1.43	-0.5394	0.3346
diffClass[7,12]	0.04399	-0.7989	0.04105	0.8961
diffClass[7,13]	-0.1162	-1.099	-0.1131	0.86
diffClass[7,14]	-0.05756	-1.06	-0.05416	0.9379
diffClass[7,15]	0.102	-0.8887	0.1011	1.093
diffClass[7,16]	-0.2264	-0.8431	-0.2263	0.3911
diffClass[7,17]	-0.1977	-1.165	-0.1992	0.778
diffClass[7,18]	-0.3	-1.728	-0.2998	1.125

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
diffClass[7,19]	-1.253	-2.712	-1.251	0.1938
diffClass[7,20]	-0.9109	-2.344	-0.911	0.515
diffClass[7,21]	-0.3554	-1.719	-0.3563	1.01
diffClass[8,9]	0.5001	-0.8714	0.5002	1.87
diffClass[8,10]	-0.01991	-1.555	-0.02043	1.504
diffClass[8,11]	-0.04387	-1.48	-0.04201	1.39
diffClass[8,12]	0.5415	-0.8653	0.5414	1.951
diffClass[8,13]	0.3814	-1.098	0.3785	1.863
diffClass[8,14]	0.44	-1.034	0.4397	1.913
diffClass[8,15]	0.5995	-0.8962	0.5993	2.088
diffClass[8,16]	0.2712	-1.009	0.2696	1.551
diffClass[8,17]	0.2998	-1.178	0.2976	1.785
diffClass[8,18]	0.1975	-1.609	0.1941	2.006
diffClass[8,19]	-0.7558	-2.531	-0.7544	1.008
diffClass[8,20]	-0.4134	-2.168	-0.414	1.34
diffClass[8,21]	0.1422	-1.634	0.1411	1.916
diffClass[9,10]	-0.52	-1.626	-0.5144	0.5607
diffClass[9,11]	-0.544	-1.498	-0.5413	0.3971
diffClass[9,12]	0.04141	-0.8781	0.04262	0.9533
diffClass[9,13]	-0.1187	-1.18	-0.1154	0.9268
diffClass[9,14]	-0.06013	-1.139	-0.05425	0.9803
diffClass[9,15]	0.09939	-0.9259	0.09735	1.118
diffClass[9,16]	-0.229	-0.9327	-0.2254	0.4565
diffClass[9,17]	-0.2003	-1.233	-0.199	0.834
diffClass[9,18]	-0.3026	-1.764	-0.3021	1.159
diffClass[9,19]	-1.256	-2.733	-1.254	0.2231
diffClass[9,20]	-0.9135	-2.381	-0.9119	0.5445
diffClass[9,21]	-0.358	-1.775	-0.3565	1.068
diffClass[10,11]	-0.02396	-1.181	-0.0233	1.132
diffClass[10,12]	0.5614	-0.5589	0.5608	1.69
diffClass[10,13]	0.4013	-0.8361	0.3996	1.645
diffClass[10,14]	0.4599	-0.7889	0.4593	1.715
diffClass[10,15]	0.6194	-0.604	0.6197	1.857
diffClass[10,16]	0.2911	-0.6745	0.29	1.267
diffClass[10,17]	0.3197	-0.9051	0.3199	1.544
diffClass[10,18]	0.2174	-1.394	0.2186	1.823
diffClass[10,19]	-0.7359	-2.357	-0.7385	0.8891
diffClass[10,20]	-0.3935	-2.002	-0.3914	1.218
diffClass[10,21]	0.1621	-1.411	0.1596	1.74
diffClass[11,12]	0.5854	-0.3701	0.5818	1.556
diffClass[11,13]	0.4252	-0.6556	0.4252	1.506
diffClass[11,14]	0.4838	-0.6305	0.4851	1.598
diffClass[11,15]	0.6434	-0.447	0.6419	1.739
diffClass[11,16]	0.315	-0.4667	0.3117	1.107
diffClass[11,17]	0.3437	-0.7436	0.3431	1.438

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
diffClass[11,18]	0.2414	-1.266	0.239	1.756
diffClass[11,19]	-0.7119	-2.25	-0.7132	0.8274
diffClass[11,20]	-0.3695	-1.894	-0.3728	1.152
diffClass[11,21]	0.186	-1.266	0.1826	1.659
diffClass[12,13]	-0.1601	-1.22	-0.1585	0.8867
diffClass[12,14]	-0.1015	-1.182	-0.1009	0.9744
diffClass[12,15]	0.05798	-1.011	0.0602	1.133
diffClass[12,16]	-0.2704	-1.022	-0.2675	0.4728
diffClass[12,17]	-0.2417	-1.294	-0.2425	0.8226
diffClass[12,18]	-0.344	-1.827	-0.3464	1.15
diffClass[12,19]	-1.297	-2.808	-1.295	0.2243
diffClass[12,20]	-0.9549	-2.453	-0.9544	0.5424
diffClass[12,21]	-0.3994	-1.85	-0.3988	1.056
diffClass[13,14]	0.0586	-1.133	0.06164	1.255
diffClass[13,15]	0.2181	-0.9506	0.2164	1.391
diffClass[13,16]	-0.1102	-1.011	-0.1105	0.7914
diffClass[13,17]	-0.08158	-1.244	-0.08516	1.092
diffClass[13,18]	-0.1839	-1.742	-0.1853	1.387
diffClass[13,19]	-1.137	-2.717	-1.138	0.4424
diffClass[13,20]	-0.7948	-2.367	-0.7962	0.7752
diffClass[13,21]	-0.2392	-1.756	-0.2386	1.285
diffClass[14,15]	0.1595	-1.022	0.1574	1.355
diffClass[14,16]	-0.1688	-1.078	-0.1695	0.753
diffClass[14,17]	-0.1402	-1.315	-0.1407	1.047
diffClass[14,18]	-0.2425	-1.801	-0.2415	1.317
diffClass[14,19]	-1.196	-2.772	-1.198	0.3782
diffClass[14,20]	-0.8534	-2.405	-0.8524	0.7103
diffClass[14,21]	-0.2978	-1.827	-0.2976	1.236
diffClass[15,16]	-0.3283	-1.235	-0.3278	0.573
diffClass[15,17]	-0.2997	-1.473	-0.3005	0.874
diffClass[15,18]	-0.402	-1.972	-0.4046	1.174
diffClass[15,19]	-1.355	-2.943	-1.355	0.2284
diffClass[15,20]	-1.013	-2.588	-1.013	0.5616
diffClass[15,21]	-0.4573	-1.987	-0.4579	1.074
diffClass[16,17]	0.02864	-0.8595	0.02631	0.9208
diffClass[16,18]	-0.07366	-1.444	-0.07428	1.292
diffClass[16,19]	-1.027	-2.414	-1.026	0.3665
diffClass[16,20]	-0.6845	-2.061	-0.6846	0.6866
diffClass[16,21]	-0.129	-1.452	-0.1303	1.201
diffClass[17,18]	-0.1023	-1.661	-0.1043	1.458
diffClass[17,19]	-1.056	-2.633	-1.055	0.5222
diffClass[17,20]	-0.7132	-2.285	-0.713	0.8525
diffClass[17,21]	-0.1576	-1.678	-0.1565	1.353
diffClass[18,19]	-0.9533	-2.851	-0.9488	0.9244
diffClass[18,20]	-0.6109	-2.49	-0.6082	1.244

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
diffClass[18,21]	-0.05534	-1.89	-0.05389	1.774
diffClass[19,20]	0.3424	-1.496	0.3446	2.178
diffClass[19,21]	0.8979	-0.9602	0.8957	2.752
diffClass[20,21]	0.5555	-1.295	0.5539	2.406

17.9.21 Population: more severe depression

17.9.2.112 Outcome: discontinuation

	Mean	2.50%	Median	97.50%
lorClass[1,2]	-1.358	-2.72	-1.355	-0.02339
lorClass[1,3]	-0.8677	-2.622	-0.8653	0.8532
lorClass[1,4]	-1.284	-2.609	-1.275	3.77E-04
lorClass[1,5]	-2.127	-4.684	-2.117	0.3678
lorClass[1,6]	-0.3362	-0.7745	-0.3358	0.09925
lorClass[1,7]	-0.2332	-0.8979	-0.2326	0.4319
lorClass[1,8]	-0.126	-0.6765	-0.1272	0.4278
lorClass[1,9]	-2.105	-5.322	-2.111	1.125
lorClass[1,10]	-1.187	-3.079	-1.178	0.6794
lorClass[1,11]	-1.395	-3.233	-1.391	0.4059
lorClass[1,12]	-1.385	-3.059	-1.377	0.2309
lorClass[1,13]	-0.6118	-2.281	-0.5998	0.9932
lorClass[1,14]	1.944	-0.2683	1.95	4.125
lorClass[1,15]	-0.5017	-2.149	-0.5046	1.157
lorClass[1,16]	-1.502	-3.774	-1.502	0.7482
lorClass[1,17]	-0.8479	-2.151	-0.8447	0.4319
lorClass[1,18]	0.5	-2.152	0.4632	3.336
lorClass[1,19]	-1.401	-2.727	-1.398	-0.08386
lorClass[1,20]	-0.4607	-2.425	-0.4542	1.473
lorClass[1,21]	-0.6082	-2.143	-0.6068	0.9215
lorClass[1,22]	-0.3307	-2.147	-0.3332	1.488
lorClass[2,3]	0.4904	-0.9421	0.4921	1.912
lorClass[2,4]	0.07436	-0.7265	0.07403	0.8791
lorClass[2,5]	-0.7685	-3.117	-0.7555	1.501
lorClass[2,6]	1.022	-0.3646	1.018	2.443
lorClass[2,7]	1.125	-0.2032	1.12	2.477
lorClass[2,8]	1.232	-0.1996	1.225	2.705
lorClass[2,9]	-0.7471	-3.84	-0.7443	2.325
lorClass[2,10]	0.1712	-1.386	0.1735	1.726
lorClass[2,11]	-0.03684	-2.298	-0.03842	2.231
lorClass[2,12]	-0.0272	-1.143	-0.02597	1.077
lorClass[2,13]	0.7463	-0.4445	0.7484	1.92
lorClass[2,14]	3.303	1.379	3.298	5.257
lorClass[2,15]	0.8565	-0.7344	0.8472	2.492
lorClass[2,16]	-0.1442	-2.177	-0.1401	1.895
lorClass[2,17]	0.5102	-0.4403	0.5117	1.458
lorClass[2,18]	1.858	-0.5381	1.816	4.494

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[2,19]	-0.0429	-1.353	-0.04494	1.284
lorClass[2,20]	0.8974	-1.083	0.8913	2.898
lorClass[2,21]	0.7499	-0.8155	0.7494	2.321
lorClass[2,22]	1.027	-1.204	1.019	3.304
lorClass[3,4]	-0.416	-1.637	-0.4168	0.8076
lorClass[3,5]	-1.259	-3.357	-1.247	0.7615
lorClass[3,6]	0.5315	-1.238	0.5322	2.327
lorClass[3,7]	0.6345	-1.074	0.6325	2.365
lorClass[3,8]	0.7417	-1.05	0.7373	2.567
lorClass[3,9]	-1.238	-4.412	-1.236	1.938
lorClass[3,10]	-0.3192	-2.174	-0.3207	1.566
lorClass[3,11]	-0.5272	-3.016	-0.5277	1.97
lorClass[3,12]	-0.5176	-2.151	-0.5173	1.131
lorClass[3,13]	0.2559	-1.34	0.2568	1.859
lorClass[3,14]	2.812	0.6814	2.804	4.97
lorClass[3,15]	0.3661	-1.583	0.3571	2.356
lorClass[3,16]	-0.6346	-2.813	-0.632	1.547
lorClass[3,17]	0.01979	-1.334	0.01605	1.39
lorClass[3,18]	1.368	-1.193	1.33	4.17
lorClass[3,19]	-0.5333	-2.198	-0.5358	1.148
lorClass[3,20]	0.407	-1.85	0.405	2.696
lorClass[3,21]	0.2595	-1.631	0.2555	2.175
lorClass[3,22]	0.537	-1.947	0.5307	3.055
lorClass[4,5]	-0.8428	-3.027	-0.8329	1.295
lorClass[4,6]	0.9475	-0.4014	0.9426	2.342
lorClass[4,7]	1.051	-0.2357	1.044	2.365
lorClass[4,8]	1.158	-0.2308	1.149	2.595
lorClass[4,9]	-0.8215	-3.815	-0.8195	2.176
lorClass[4,10]	0.09686	-1.355	0.09314	1.564
lorClass[4,11]	-0.1112	-2.33	-0.1153	2.135
lorClass[4,12]	-0.1016	-1.223	-0.1017	1.026
lorClass[4,13]	0.6719	-0.3858	0.672	1.721
lorClass[4,14]	3.228	1.488	3.22	5.022
lorClass[4,15]	0.7821	-0.8078	0.7701	2.425
lorClass[4,16]	-0.2186	-2.109	-0.2166	1.685
lorClass[4,17]	0.4358	-0.3958	0.436	1.27
lorClass[4,18]	1.784	-0.4827	1.744	4.299
lorClass[4,19]	-0.1173	-1.328	-0.1191	1.118
lorClass[4,20]	0.823	-1.142	0.8154	2.807
lorClass[4,21]	0.6755	-0.8561	0.6755	2.215
lorClass[4,22]	0.9531	-1.259	0.9461	3.203
lorClass[5,6]	1.79	-0.7376	1.78	4.375
lorClass[5,7]	1.893	-0.5795	1.883	4.437
lorClass[5,8]	2.001	-0.5447	1.99	4.605
lorClass[5,9]	0.02131	-3.61	0.007251	3.708

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[5,10]	0.9397	-1.628	0.9287	3.584
lorClass[5,11]	0.7316	-2.342	0.727	3.86
lorClass[5,12]	0.7413	-1.671	0.7324	3.205
lorClass[5,13]	1.515	-0.8515	1.499	3.946
lorClass[5,14]	4.071	1.33	4.061	6.87
lorClass[5,15]	1.625	-1.017	1.616	4.346
lorClass[5,16]	0.6242	-2.185	0.6112	3.484
lorClass[5,17]	1.279	-0.9631	1.271	3.584
lorClass[5,18]	2.627	-0.4916	2.597	5.903
lorClass[5,19]	0.7256	-1.719	0.7191	3.224
lorClass[5,20]	1.666	-1.21	1.66	4.599
lorClass[5,21]	1.518	-1.096	1.513	4.175
lorClass[5,22]	1.796	-1.287	1.785	4.935
lorClass[6,7]	0.103	-0.6625	0.1039	0.8613
lorClass[6,8]	0.2103	-0.4645	0.2094	0.8856
lorClass[6,9]	-1.769	-5.006	-1.772	1.488
lorClass[6,10]	-0.8506	-2.784	-0.841	1.065
lorClass[6,11]	-1.059	-2.942	-1.052	0.7849
lorClass[6,12]	-1.049	-2.763	-1.041	0.6023
lorClass[6,13]	-0.2755	-1.993	-0.2665	1.382
lorClass[6,14]	2.281	0.02791	2.286	4.506
lorClass[6,15]	-0.1654	-1.852	-0.1694	1.541
lorClass[6,16]	-1.166	-3.481	-1.168	1.124
lorClass[6,17]	-0.5117	-1.875	-0.5072	0.8303
lorClass[6,18]	0.8363	-1.852	0.8012	3.693
lorClass[6,19]	-1.065	-2.453	-1.061	0.3095
lorClass[6,20]	-0.1245	-2.132	-0.1189	1.844
lorClass[6,21]	-0.272	-1.855	-0.2705	1.3
lorClass[6,22]	0.005581	-1.852	0.006765	1.865
lorClass[7,8]	0.1072	-0.7286	0.1064	0.9462
lorClass[7,9]	-1.872	-5.071	-1.877	1.349
lorClass[7,10]	-0.9537	-2.828	-0.9478	0.9005
lorClass[7,11]	-1.162	-3.091	-1.156	0.7461
lorClass[7,12]	-1.152	-2.799	-1.143	0.4562
lorClass[7,13]	-0.3786	-2.038	-0.369	1.231
lorClass[7,14]	2.178	-0.01127	2.181	4.362
lorClass[7,15]	-0.2684	-1.893	-0.2724	1.378
lorClass[7,16]	-1.269	-3.527	-1.265	0.9846
lorClass[7,17]	-0.6147	-1.907	-0.6127	0.6532
lorClass[7,18]	0.7332	-1.911	0.699	3.563
lorClass[7,19]	-1.168	-2.493	-1.166	0.1623
lorClass[7,20]	-0.2275	-2.148	-0.2243	1.682
lorClass[7,21]	-0.375	-1.872	-0.3747	1.128
lorClass[7,22]	-0.09745	-2.006	-0.1004	1.818
lorClass[8,9]	-1.979	-5.23	-1.982	1.29

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[8,10]	-1.061	-3.025	-1.056	0.8794
lorClass[8,11]	-1.269	-3.165	-1.263	0.5917
lorClass[8,12]	-1.259	-3.012	-1.25	0.4378
lorClass[8,13]	-0.4858	-2.239	-0.4723	1.2
lorClass[8,14]	2.07	-0.2037	2.074	4.309
lorClass[8,15]	-0.3757	-2.106	-0.3799	1.358
lorClass[8,16]	-1.376	-3.706	-1.374	0.941
lorClass[8,17]	-0.7219	-2.131	-0.7179	0.6574
lorClass[8,18]	0.626	-2.079	0.5952	3.514
lorClass[8,19]	-1.275	-2.701	-1.272	0.1358
lorClass[8,20]	-0.3347	-2.37	-0.3272	1.664
lorClass[8,21]	-0.4822	-2.108	-0.48	1.132
lorClass[8,22]	-0.2047	-2.078	-0.2027	1.668
lorClass[9,10]	0.9184	-2.395	0.9154	4.224
lorClass[9,11]	0.7103	-2.999	0.7128	4.417
lorClass[9,12]	0.72	-2.453	0.7185	3.926
lorClass[9,13]	1.493	-1.664	1.491	4.666
lorClass[9,14]	4.05	0.5783	4.045	7.518
lorClass[9,15]	1.604	-1.757	1.596	4.978
lorClass[9,16]	0.6029	-1.713	0.6013	2.917
lorClass[9,17]	1.257	-1.79	1.254	4.312
lorClass[9,18]	2.605	-1.182	2.59	6.505
lorClass[9,19]	0.7042	-2.519	0.7075	3.897
lorClass[9,20]	1.645	-1.909	1.653	5.205
lorClass[9,21]	1.497	-1.848	1.49	4.812
lorClass[9,22]	1.775	-1.924	1.77	5.476
lorClass[10,11]	-0.2081	-2.818	-0.2102	2.401
lorClass[10,12]	-0.1984	-1.992	-0.198	1.591
lorClass[10,13]	0.5751	-1.207	0.5776	2.336
lorClass[10,14]	3.131	0.8375	3.129	5.43
lorClass[10,15]	0.6852	-1.396	0.6785	2.799
lorClass[10,16]	-0.3155	-2.707	-0.3127	2.06
lorClass[10,17]	0.339	-1.299	0.3418	1.962
lorClass[10,18]	1.687	-1.025	1.66	4.569
lorClass[10,19]	-0.2141	-2.049	-0.2171	1.638
lorClass[10,20]	0.7262	-1.626	0.7204	3.123
lorClass[10,21]	0.5786	-1.446	0.5728	2.619
lorClass[10,22]	0.8562	-1.728	0.8497	3.465
lorClass[11,12]	0.009647	-2.446	0.01117	2.441
lorClass[11,13]	0.7832	-1.678	0.7922	3.197
lorClass[11,14]	3.339	0.4902	3.343	6.182
lorClass[11,15]	0.8933	-1.54	0.8891	3.344
lorClass[11,16]	-0.1074	-3.029	-0.1	2.787
lorClass[11,17]	0.547	-1.674	0.5512	2.751
lorClass[11,18]	1.895	-1.308	1.863	5.25

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[11,19]	-0.00606	-2.237	-0.00178	2.234
lorClass[11,20]	0.9342	-1.718	0.9365	3.579
lorClass[11,21]	0.7867	-1.561	0.7883	3.139
lorClass[11,22]	1.064	-1.112	1.064	3.252
lorClass[12,13]	0.7735	-0.7011	0.7731	2.236
lorClass[12,14]	3.33	1.25	3.326	5.44
lorClass[12,15]	0.8836	-0.9627	0.8736	2.796
lorClass[12,16]	-0.117	-2.318	-0.1182	2.063
lorClass[12,17]	0.5374	-0.7697	0.5384	1.856
lorClass[12,18]	1.885	-0.6443	1.856	4.62
lorClass[12,19]	-0.0157	-1.593	-0.02213	1.601
lorClass[12,20]	0.9246	-1.266	0.9158	3.141
lorClass[12,21]	0.7771	-1.031	0.7699	2.62
lorClass[12,22]	1.055	-1.358	1.043	3.509
lorClass[13,14]	2.556	0.5082	2.547	4.642
lorClass[13,15]	0.1101	-1.752	0.1004	2.022
lorClass[13,16]	-0.8905	-3.06	-0.8859	1.261
lorClass[13,17]	-0.2361	-1.529	-0.236	1.055
lorClass[13,18]	1.112	-1.381	1.071	3.818
lorClass[13,19]	-0.7892	-2.35	-0.7945	0.7986
lorClass[13,20]	0.1511	-2.035	0.1414	2.372
lorClass[13,21]	0.003565	-1.81	-0.00249	1.833
lorClass[13,22]	0.2811	-2.134	0.2695	2.746
lorClass[14,15]	-2.446	-4.827	-2.451	-0.03784
lorClass[14,16]	-3.447	-6.056	-3.435	-0.867
lorClass[14,17]	-2.792	-4.77	-2.786	-0.8566
lorClass[14,18]	-1.444	-4.372	-1.463	1.587
lorClass[14,19]	-3.345	-5.499	-3.343	-1.193
lorClass[14,20]	-2.405	-5.049	-2.404	0.2412
lorClass[14,21]	-2.553	-4.901	-2.548	-0.2111
lorClass[14,22]	-2.275	-5.113	-2.281	0.5719
lorClass[15,16]	-1.001	-3.468	-0.9916	1.432
lorClass[15,17]	-0.3463	-1.967	-0.3331	1.209
lorClass[15,18]	1.002	-1.811	0.98	3.94
lorClass[15,19]	-0.8994	-2.623	-0.8995	0.8026
lorClass[15,20]	0.04094	-2.025	0.04143	2.097
lorClass[15,21]	-0.1066	-1.856	-0.11	1.657
lorClass[15,22]	0.171	-2.267	0.1675	2.615
lorClass[16,17]	0.6544	-1.334	0.6508	2.647
lorClass[16,18]	2.002	-1.006	1.969	5.156
lorClass[16,19]	0.1013	-2.134	0.1018	2.3
lorClass[16,20]	1.042	-1.656	1.037	3.756
lorClass[16,21]	0.8941	-1.517	0.8923	3.293
lorClass[16,22]	1.172	-1.735	1.169	4.083
lorClass[17,18]	1.348	-1.059	1.31	3.998

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[17,19]	-0.5531	-1.819	-0.5558	0.7289
lorClass[17,20]	0.3872	-1.572	0.3831	2.351
lorClass[17,21]	0.2397	-1.278	0.2383	1.76
lorClass[17,22]	0.5173	-1.687	0.5129	2.742
lorClass[18,19]	-1.901	-4.693	-1.87	0.689
lorClass[18,20]	-0.9607	-4.087	-0.9419	2.068
lorClass[18,21]	-1.108	-4.027	-1.08	1.624
lorClass[18,22]	-0.8307	-4.17	-0.811	2.362
lorClass[19,20]	0.9403	-1.066	0.9375	2.974
lorClass[19,21]	0.7928	-0.6811	0.7927	2.258
lorClass[19,22]	1.07	-1.156	1.07	3.317
lorClass[20,21]	-0.1475	-2.123	-0.1418	1.803
lorClass[20,22]	0.13	-2.519	0.1223	2.789
lorClass[21,22]	0.2776	-2.071	0.2773	2.638

17.9.2.21 Outcome: discontinuation due to SE

Node	Mean	2.50%	Median	97.50%
lorClass[1,2]	1.585	0.7815	1.587	2.37
lorClass[1,3]	1.849	1.005	1.855	2.674
lorClass[1,4]	1.224	0.4808	1.219	1.994
lorClass[1,5]	-0.7329	-5.335	-0.5193	2.542
lorClass[1,6]	-0.6419	-6.175	-0.3006	3.064
lorClass[1,7]	2.127	-0.6058	2.132	4.889
lorClass[1,8]	-0.9613	-4.534	-0.8648	2.037
lorClass[2,3]	0.264	-0.8057	0.2667	1.323
lorClass[2,4]	-0.3617	-1.361	-0.3669	0.6624
lorClass[2,5]	-2.318	-6.944	-2.121	1.05
lorClass[2,6]	-2.227	-7.81	-1.902	1.566
lorClass[2,7]	0.5421	-2.238	0.5289	3.388
lorClass[2,8]	-2.547	-6.198	-2.453	0.5447
lorClass[3,4]	-0.6256	-1.691	-0.633	0.4652
lorClass[3,5]	-2.582	-7.143	-2.374	0.684
lorClass[3,6]	-2.491	-8.037	-2.161	1.263
lorClass[3,7]	0.2781	-2.559	0.2753	3.141
lorClass[3,8]	-2.811	-6.472	-2.728	0.3101
lorClass[4,5]	-1.956	-6.59	-1.751	1.411
lorClass[4,6]	-1.865	-7.429	-1.541	1.921
lorClass[4,7]	0.9037	-1.871	0.9004	3.69
lorClass[4,8]	-2.185	-5.81	-2.085	0.8497
lorClass[5,6]	0.09097	-6.113	0.1806	5.803
lorClass[5,7]	2.86	-1.387	2.702	7.987
lorClass[5,8]	-0.2285	-5.12	-0.2974	5.016
lorClass[6,7]	2.769	-1.954	2.532	8.859
lorClass[6,8]	-0.3194	-5.517	-0.5136	5.902
lorClass[7,8]	-3.089	-7.073	-2.993	0.3151

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

17.9.2.31 Outcome: remission in those randomised

	Mean	2.5%	Median	97.5%
lorClass[1,2]	-2.588	-6.837	-2.469	0.9781
lorClass[1,3]	-0.002	-1.73	-4.03E-04	1.728
lorClass[1,4]	0.2771	-0.8654	0.2763	1.427
lorClass[1,5]	0.1777	-0.6115	0.1794	0.9587
lorClass[1,6]	-1.796	-6.434	-1.688	2.243
lorClass[1,7]	0.477	-2.121	0.4775	3.051
lorClass[1,8]	0.4588	-1.625	0.4657	2.515
lorClass[1,9]	1.211	-0.6692	1.208	3.112
lorClass[1,10]	1.617	-0.8986	1.609	4.168
lorClass[1,11]	2.455	0.3822	2.454	4.524
lorClass[1,12]	2.037	0.004451	2.036	4.081
lorClass[2,3]	2.586	-1.337	2.49	7.061
lorClass[2,4]	2.865	-0.6124	2.752	7.032
lorClass[2,5]	2.766	-0.8429	2.648	7.014
lorClass[2,6]	0.7919	-1.136	0.7927	2.708
lorClass[2,7]	3.065	-0.6356	2.953	7.369
lorClass[2,8]	3.047	0.188	2.904	6.789
lorClass[2,9]	3.799	0.2909	3.679	8.015
lorClass[2,10]	4.205	0.3989	4.096	8.674
lorClass[2,11]	5.044	0.9268	4.947	9.672
lorClass[2,12]	4.625	0.505	4.53	9.221
lorClass[3,4]	0.2791	-1.636	0.2766	2.218
lorClass[3,5]	0.1797	-1.59	0.1794	1.949
lorClass[3,6]	-1.794	-6.654	-1.705	2.566
lorClass[3,7]	0.479	-2.533	0.4797	3.48
lorClass[3,8]	0.4608	-2.115	0.4662	3.036
lorClass[3,9]	1.213	-1.209	1.21	3.647
lorClass[3,10]	1.619	-1.325	1.615	4.576
lorClass[3,11]	2.457	-0.1018	2.465	5.005
lorClass[3,12]	2.039	-0.4751	2.042	4.571
lorClass[4,5]	-0.09947	-1.315	-0.0986	1.111
lorClass[4,6]	-2.073	-6.652	-1.969	1.905
lorClass[4,7]	0.1999	-2.281	0.2033	2.651
lorClass[4,8]	0.1817	-1.735	0.1862	2.07
lorClass[4,9]	0.9335	-0.7747	0.926	2.671
lorClass[4,10]	1.34	-0.9942	1.334	3.724
lorClass[4,11]	2.178	-0.0709	2.178	4.412
lorClass[4,12]	1.76	-0.4564	1.76	3.974
lorClass[5,6]	-1.974	-6.617	-1.88	2.108
lorClass[5,7]	0.2993	-2.333	0.2938	2.902
lorClass[5,8]	0.2811	-1.843	0.285	2.382
lorClass[5,9]	1.033	-0.8876	1.031	2.969
lorClass[5,10]	1.439	-1.113	1.434	4.025
lorClass[5,11]	2.278	0.1686	2.277	4.386

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.5%	Median	97.5%
lorClass[5,12]	1.86	-0.2139	1.858	3.936
lorClass[6,7]	2.273	-1.875	2.175	7
lorClass[6,8]	2.255	-1.192	2.139	6.428
lorClass[6,9]	3.007	-0.9743	2.9	7.644
lorClass[6,10]	3.413	-0.8708	3.318	8.273
lorClass[6,11]	4.252	-0.2538	4.173	9.249
lorClass[6,12]	3.834	-0.7243	3.759	8.841
lorClass[7,8]	-0.0182	-2.281	-0.01636	2.245
lorClass[7,9]	0.7337	-1.748	0.734	3.225
lorClass[7,10]	1.14	-1.781	1.132	4.089
lorClass[7,11]	1.978	-1.242	1.973	5.217
lorClass[7,12]	1.56	-1.633	1.554	4.768
lorClass[8,9]	0.7519	-1.204	0.7501	2.716
lorClass[8,10]	1.158	-1.307	1.146	3.689
lorClass[8,11]	1.996	-0.8342	1.988	4.827
lorClass[8,12]	1.578	-1.217	1.574	4.382
lorClass[9,10]	0.4062	-1.966	0.4013	2.803
lorClass[9,11]	1.245	-1.454	1.246	3.916
lorClass[9,12]	0.8265	-1.836	0.8246	3.493
lorClass[10,11]	0.8384	-2.319	0.8379	3.997
lorClass[10,12]	0.4203	-2.743	0.4187	3.552
lorClass[11,12]	-0.4181	-2.691	-0.4211	1.852

17.9.2.41 Outcome: response in completers

	Mean	2.50%	Median	97.50%
lorClass[1,2]	-0.4023	-2.795	-0.4179	2.057
lorClass[1,3]	0.8677	-1.151	0.8567	2.97
lorClass[1,4]	0.8752	-0.7839	0.8533	2.687
lorClass[1,5]	2.794	-0.00438	2.758	5.813
lorClass[1,6]	1.032	0.5029	1.03	1.574
lorClass[1,7]	1.352	0.6097	1.345	2.135
lorClass[1,8]	0.6657	0.07776	0.6672	1.251
lorClass[1,9]	1.651	-1.661	1.649	4.962
lorClass[1,10]	1.722	-0.3345	1.713	3.837
lorClass[1,11]	0.8023	-1.647	0.7855	3.345
lorClass[1,12]	1.586	-0.7111	1.573	3.932
lorClass[1,13]	1.087	-0.7625	1.075	3.035
lorClass[1,14]	3.336	0.5254	3.319	6.219
lorClass[1,15]	2.038	-0.08331	2.024	4.242
lorClass[1,16]	0.9971	-1.411	0.9911	3.458
lorClass[2,3]	1.27	-1.049	1.27	3.578
lorClass[2,4]	1.277	-0.6667	1.279	3.22
lorClass[2,5]	3.196	0.1854	3.182	6.306
lorClass[2,6]	1.435	-1.057	1.445	3.868
lorClass[2,7]	1.755	-0.5613	1.765	4.039

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[2,8]	1.068	-1.45	1.08	3.526
lorClass[2,9]	2.054	-1.423	2.056	5.543
lorClass[2,10]	2.124	0.05794	2.122	4.19
lorClass[2,11]	1.205	-1.478	1.204	3.884
lorClass[2,12]	1.988	-0.571	1.995	4.525
lorClass[2,13]	1.489	-0.7802	1.489	3.747
lorClass[2,14]	3.739	0.7596	3.74	6.756
lorClass[2,15]	2.44	0.01401	2.435	4.868
lorClass[2,16]	1.399	-1.381	1.4	4.178
lorClass[3,4]	0.00744	-1.291	0.008273	1.322
lorClass[3,5]	1.926	-0.7149	1.898	4.73
lorClass[3,6]	0.1645	-1.978	0.1737	2.236
lorClass[3,7]	0.4847	-1.441	0.4908	2.394
lorClass[3,8]	-0.202	-2.361	-0.1939	1.89
lorClass[3,9]	0.7836	-2.338	0.7857	3.891
lorClass[3,10]	0.8538	-1.095	0.8544	2.814
lorClass[3,11]	-0.06549	-2.305	-0.065	2.178
lorClass[3,12]	0.7184	-1.332	0.7151	2.767
lorClass[3,13]	0.2191	-1.456	0.2189	1.877
lorClass[3,14]	2.469	-0.1441	2.46	5.122
lorClass[3,15]	1.17	-0.8019	1.167	3.151
lorClass[3,16]	0.1294	-2.253	0.1277	2.521
lorClass[4,5]	1.919	-0.3555	1.879	4.406
lorClass[4,6]	0.1571	-1.698	0.1765	1.878
lorClass[4,7]	0.4773	-1.122	0.4896	2.002
lorClass[4,8]	-0.2094	-2.09	-0.1891	1.55
lorClass[4,9]	0.7761	-2.138	0.7771	3.667
lorClass[4,10]	0.8464	-0.6728	0.8475	2.356
lorClass[4,11]	-0.07293	-1.898	-0.07203	1.761
lorClass[4,12]	0.711	-0.9813	0.7125	2.401
lorClass[4,13]	0.2117	-1.115	0.2178	1.504
lorClass[4,14]	2.461	0.2108	2.446	4.784
lorClass[4,15]	1.163	-0.4076	1.161	2.731
lorClass[4,16]	0.1219	-2.009	0.127	2.211
lorClass[5,6]	-1.762	-4.807	-1.727	1.079
lorClass[5,7]	-1.442	-4.353	-1.411	1.288
lorClass[5,8]	-2.128	-5.184	-2.093	0.7188
lorClass[5,9]	-1.143	-4.897	-1.127	2.562
lorClass[5,10]	-1.072	-3.963	-1.048	1.658
lorClass[5,11]	-1.992	-5.084	-1.968	0.9688
lorClass[5,12]	-1.208	-4.183	-1.184	1.62
lorClass[5,13]	-1.707	-4.518	-1.682	0.9192
lorClass[5,14]	0.5424	-2.808	0.5561	3.794
lorClass[5,15]	-0.7563	-3.673	-0.7307	2.012
lorClass[5,16]	-1.797	-5.058	-1.778	1.3

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[6,7]	0.3202	-0.5431	0.3159	1.216
lorClass[6,8]	-0.3665	-1.129	-0.3654	0.3957
lorClass[6,9]	0.6191	-2.734	0.6218	3.96
lorClass[6,10]	0.6893	-1.409	0.6838	2.84
lorClass[6,11]	-0.23	-2.724	-0.2422	2.346
lorClass[6,12]	0.5539	-1.795	0.5451	2.938
lorClass[6,13]	0.0546	-1.851	0.04587	2.038
lorClass[6,14]	2.304	-0.5409	2.29	5.214
lorClass[6,15]	1.006	-1.174	0.9988	3.239
lorClass[6,16]	-0.03513	-2.483	-0.03953	2.464
lorClass[7,8]	-0.6867	-1.639	-0.6822	0.243
lorClass[7,9]	0.2989	-2.956	0.3029	3.528
lorClass[7,10]	0.3691	-1.575	0.3675	2.32
lorClass[7,11]	-0.5502	-2.902	-0.5587	1.858
lorClass[7,12]	0.2337	-1.965	0.2323	2.453
lorClass[7,13]	-0.2656	-1.991	-0.2689	1.497
lorClass[7,14]	1.984	-0.7382	1.972	4.765
lorClass[7,15]	0.6853	-1.32	0.6749	2.732
lorClass[7,16]	-0.3554	-2.665	-0.3593	1.982
lorClass[8,9]	0.9856	-2.382	0.9841	4.348
lorClass[8,10]	1.056	-1.077	1.05	3.236
lorClass[8,11]	0.1365	-2.379	0.1251	2.728
lorClass[8,12]	0.9204	-1.454	0.9085	3.328
lorClass[8,13]	0.4211	-1.523	0.4095	2.439
lorClass[8,14]	2.671	-0.1839	2.652	5.604
lorClass[8,15]	1.372	-0.8193	1.363	3.641
lorClass[8,16]	0.3314	-2.132	0.3249	2.843
lorClass[9,10]	0.07026	-3.172	0.06599	3.34
lorClass[9,11]	-0.8491	-4.26	-0.8493	2.582
lorClass[9,12]	-0.06517	-2.425	-0.06567	2.298
lorClass[9,13]	-0.5645	-3.633	-0.5712	2.529
lorClass[9,14]	1.685	-1.977	1.683	5.355
lorClass[9,15]	0.3864	-2.864	0.3811	3.66
lorClass[9,16]	-0.6542	-4.189	-0.6536	2.872
lorClass[10,11]	-0.9193	-3.291	-0.9208	1.456
lorClass[10,12]	-0.1354	-2.371	-0.1351	2.093
lorClass[10,13]	-0.6347	-2.521	-0.6352	1.249
lorClass[10,14]	1.615	-1.093	1.605	4.366
lorClass[10,15]	0.3162	-1.775	0.3106	2.434
lorClass[10,16]	-0.7245	-3.207	-0.7224	1.749
lorClass[11,12]	0.7839	-1.703	0.7886	3.271
lorClass[11,13]	0.2846	-1.968	0.2885	2.516
lorClass[11,14]	2.534	-0.3786	2.521	5.492
lorClass[11,15]	1.235	-1.153	1.235	3.625
lorClass[11,16]	0.1949	-2.602	0.1936	2.968

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[12,13]	-0.4993	-2.471	-0.4989	1.474
lorClass[12,14]	1.75	-1.041	1.745	4.599
lorClass[12,15]	0.4516	-1.786	0.4443	2.707
lorClass[12,16]	-0.589	-3.194	-0.5869	2.035
lorClass[13,14]	2.25	-0.3627	2.237	4.924
lorClass[13,15]	0.9509	-0.7951	0.9531	2.698
lorClass[13,16]	-0.08973	-2.087	-0.08366	1.884
lorClass[14,15]	-1.299	-4.086	-1.285	1.429
lorClass[14,16]	-2.339	-5.465	-2.335	0.7378
lorClass[15,16]	-1.041	-3.235	-1.039	1.14

17.9.2.51 Outcome: response in those randomised

	Mean	2.50%	Median	97.50%
lorClass[1,2]	-3.097	-5.001	-3.096	-1.201
lorClass[1,3]	-3.196	-5.116	-3.187	-1.312
lorClass[1,4]	-3.462	-5.057	-3.456	-1.888
lorClass[1,5]	-2.77	-5.078	-2.762	-0.4987
lorClass[1,6]	0.7552	0.202	0.7559	1.312
lorClass[1,7]	1.117	0.3707	1.115	1.868
lorClass[1,8]	0.5684	-0.03507	0.571	1.165
lorClass[1,9]	-2.303	-4.941	-2.298	0.3079
lorClass[1,10]	-3.083	-5.12	-3.081	-1.047
lorClass[1,11]	-1.222	-4.88	-1.213	2.387
lorClass[1,12]	-0.7716	-3.198	-0.7768	1.647
lorClass[1,13]	-2.477	-4.714	-2.467	-0.2955
lorClass[1,14]	-0.04474	-1.679	-0.04234	1.576
lorClass[1,15]	-1.564	-4.135	-1.556	0.9743
lorClass[1,16]	0.994	-0.6146	0.9937	2.605
lorClass[1,17]	3.4	1.368	3.399	5.424
lorClass[1,18]	0.421	-1.923	0.4209	2.769
lorClass[1,19]	-2.513	-4.96	-2.514	-0.05171
lorClass[2,3]	-0.09893	-1.878	-0.09985	1.673
lorClass[2,4]	-0.3652	-1.63	-0.3644	0.8916
lorClass[2,5]	0.327	-1.778	0.3248	2.429
lorClass[2,6]	3.852	1.909	3.856	5.82
lorClass[2,7]	4.214	2.274	4.217	6.152
lorClass[2,8]	3.665	1.732	3.665	5.627
lorClass[2,9]	0.794	-1.171	0.7946	2.749
lorClass[2,10]	0.01372	-1.676	0.01239	1.703
lorClass[2,11]	1.875	-1.695	1.887	5.377
lorClass[2,12]	2.325	-0.02374	2.328	4.65
lorClass[2,13]	0.6201	-1.506	0.6225	2.736
lorClass[2,14]	3.052	1.548	3.049	4.567
lorClass[2,15]	1.533	-0.9408	1.538	3.973
lorClass[2,16]	4.091	2.139	4.094	6.038

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[2,17]	6.497	3.744	6.491	9.285
lorClass[2,18]	3.518	1.04	3.518	6.003
lorClass[2,19]	0.5842	-1.675	0.5841	2.856
lorClass[3,4]	-0.2663	-1.563	-0.2649	1.018
lorClass[3,5]	0.4259	-1.449	0.4248	2.312
lorClass[3,6]	3.951	2.004	3.946	5.939
lorClass[3,7]	4.313	2.377	4.308	6.276
lorClass[3,8]	3.764	1.837	3.754	5.728
lorClass[3,9]	0.8929	-1.637	0.8965	3.412
lorClass[3,10]	0.1126	-1.718	0.1142	1.935
lorClass[3,11]	1.974	-1.588	1.987	5.495
lorClass[3,12]	2.424	-0.07558	2.427	4.906
lorClass[3,13]	0.7191	-1.36	0.7175	2.809
lorClass[3,14]	3.151	1.558	3.151	4.739
lorClass[3,15]	1.631	-0.8195	1.628	4.079
lorClass[3,16]	4.19	2.192	4.185	6.189
lorClass[3,17]	6.596	3.826	6.594	9.384
lorClass[3,18]	3.617	1.026	3.619	6.202
lorClass[3,19]	0.6831	-1.604	0.6799	2.995
lorClass[4,5]	0.6922	-1.013	0.6916	2.403
lorClass[4,6]	4.217	2.574	4.214	5.882
lorClass[4,7]	4.579	2.941	4.577	6.229
lorClass[4,8]	4.031	2.404	4.024	5.683
lorClass[4,9]	1.159	-1.035	1.162	3.357
lorClass[4,10]	0.3789	-0.926	0.38	1.678
lorClass[4,11]	2.24	-1.115	2.255	5.536
lorClass[4,12]	2.691	0.4723	2.692	4.875
lorClass[4,13]	0.9854	-0.7543	0.9876	2.711
lorClass[4,14]	3.417	2.316	3.415	4.522
lorClass[4,15]	1.898	-0.2208	1.9	3.997
lorClass[4,16]	4.456	2.761	4.46	6.132
lorClass[4,17]	6.862	4.321	6.858	9.426
lorClass[4,18]	3.883	1.552	3.879	6.22
lorClass[4,19]	0.9494	-0.9421	0.952	2.841
lorClass[5,6]	3.525	1.212	3.515	5.882
lorClass[5,7]	3.887	1.577	3.876	6.241
lorClass[5,8]	3.338	1.034	3.329	5.687
lorClass[5,9]	0.467	-2.305	0.4732	3.226
lorClass[5,10]	-0.3133	-2.443	-0.3126	1.825
lorClass[5,11]	1.548	-2.208	1.561	5.235
lorClass[5,12]	1.998	-0.7839	2.005	4.761
lorClass[5,13]	0.2932	-2.114	0.2925	2.685
lorClass[5,14]	2.725	0.7156	2.726	4.724
lorClass[5,15]	1.206	-1.504	1.209	3.893
lorClass[5,16]	3.764	1.414	3.762	6.117

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[5,17]	6.17	3.153	6.162	9.226
lorClass[5,18]	3.191	0.3234	3.197	6.049
lorClass[5,19]	0.2572	-2.298	0.2582	2.805
lorClass[6,7]	0.3615	-0.5112	0.3584	1.239
lorClass[6,8]	-0.1868	-0.965	-0.1845	0.5829
lorClass[6,9]	-3.058	-5.752	-3.055	-0.4052
lorClass[6,10]	-3.838	-5.929	-3.838	-1.742
lorClass[6,11]	-1.977	-5.67	-1.966	1.68
lorClass[6,12]	-1.527	-4.002	-1.531	0.9422
lorClass[6,13]	-3.232	-5.52	-3.22	-0.9954
lorClass[6,14]	-0.7999	-2.502	-0.7989	0.8893
lorClass[6,15]	-2.32	-4.937	-2.311	0.2761
lorClass[6,16]	0.2388	-1.438	0.2394	1.915
lorClass[6,17]	2.645	0.5496	2.644	4.733
lorClass[6,18]	-0.3342	-2.725	-0.3365	2.075
lorClass[6,19]	-3.268	-5.769	-3.27	-0.7604
lorClass[7,8]	-0.5483	-1.468	-0.5476	0.3679
lorClass[7,9]	-3.42	-6.09	-3.421	-0.759
lorClass[7,10]	-4.2	-6.275	-4.202	-2.112
lorClass[7,11]	-2.339	-6.018	-2.333	1.302
lorClass[7,12]	-1.888	-4.333	-1.89	0.5611
lorClass[7,13]	-3.593	-5.868	-3.585	-1.368
lorClass[7,14]	-1.161	-2.849	-1.162	0.5068
lorClass[7,15]	-2.681	-5.298	-2.677	-0.09245
lorClass[7,16]	-0.1227	-1.795	-0.1222	1.537
lorClass[7,17]	2.283	0.143	2.284	4.41
lorClass[7,18]	-0.6957	-3.042	-0.6984	1.66
lorClass[7,19]	-3.629	-6.117	-3.631	-1.137
lorClass[8,9]	-2.871	-5.554	-2.865	-0.2136
lorClass[8,10]	-3.652	-5.727	-3.652	-1.57
lorClass[8,11]	-1.79	-5.481	-1.779	1.846
lorClass[8,12]	-1.34	-3.806	-1.338	1.117
lorClass[8,13]	-3.045	-5.312	-3.039	-0.8205
lorClass[8,14]	-0.6131	-2.298	-0.6119	1.056
lorClass[8,15]	-2.133	-4.74	-2.127	0.4478
lorClass[8,16]	0.4256	-1.241	0.426	2.088
lorClass[8,17]	2.831	0.7563	2.83	4.915
lorClass[8,18]	-0.1473	-2.531	-0.1455	2.246
lorClass[8,19]	-3.081	-5.577	-3.086	-0.5808
lorClass[9,10]	-0.7803	-3.24	-0.7852	1.693
lorClass[9,11]	1.081	-2.92	1.092	5.045
lorClass[9,12]	1.531	-1.438	1.529	4.503
lorClass[9,13]	-0.1739	-2.957	-0.1675	2.601
lorClass[9,14]	2.258	-0.09724	2.256	4.635
lorClass[9,15]	0.7385	-2.311	0.7379	3.779

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[9,16]	3.297	0.6137	3.298	5.96
lorClass[9,17]	5.703	2.425	5.688	9.02
lorClass[9,18]	2.724	-0.353	2.724	5.842
lorClass[9,19]	-0.2098	-3.094	-0.2099	2.684
lorClass[10,11]	1.861	-1.729	1.876	5.394
lorClass[10,12]	2.312	-0.225	2.313	4.837
lorClass[10,13]	0.6064	-1.571	0.611	2.764
lorClass[10,14]	3.038	1.366	3.041	4.739
lorClass[10,15]	1.519	-0.9663	1.521	3.992
lorClass[10,16]	4.077	1.955	4.084	6.172
lorClass[10,17]	6.483	3.633	6.481	9.358
lorClass[10,18]	3.504	0.8692	3.503	6.143
lorClass[10,19]	0.5705	-1.731	0.5744	2.873
lorClass[11,12]	0.4503	-3.48	0.4373	4.439
lorClass[11,13]	-1.255	-4.79	-1.254	2.247
lorClass[11,14]	1.177	-2.269	1.157	4.678
lorClass[11,15]	-0.3425	-2.906	-0.344	2.229
lorClass[11,16]	2.216	-1.442	2.205	5.929
lorClass[11,17]	4.622	0.4982	4.621	8.789
lorClass[11,18]	1.643	-2.371	1.633	5.724
lorClass[11,19]	-1.291	-5.109	-1.304	2.605
lorClass[12,13]	-1.705	-4.455	-1.702	1.032
lorClass[12,14]	0.7268	-1.424	0.7215	2.9
lorClass[12,15]	-0.7928	-3.829	-0.7889	2.249
lorClass[12,16]	1.766	-0.6823	1.764	4.221
lorClass[12,17]	4.171	1.033	4.166	7.338
lorClass[12,18]	1.193	-1.663	1.196	4.042
lorClass[12,19]	-1.741	-4.645	-1.745	1.157
lorClass[13,14]	2.432	0.4682	2.43	4.396
lorClass[13,15]	0.9124	-1.48	0.9097	3.343
lorClass[13,16]	3.471	1.165	3.471	5.769
lorClass[13,17]	5.876	2.897	5.872	8.864
lorClass[13,18]	2.898	0.07493	2.895	5.715
lorClass[13,19]	-0.03595	-2.604	-0.03777	2.539
lorClass[14,15]	-1.52	-3.889	-1.516	0.8243
lorClass[14,16]	1.039	-0.6647	1.037	2.742
lorClass[14,17]	3.444	0.8726	3.439	6.044
lorClass[14,18]	0.4657	-1.851	0.466	2.77
lorClass[14,19]	-2.468	-4.655	-2.463	-0.2936
lorClass[15,16]	2.558	-0.09939	2.556	5.211
lorClass[15,17]	4.964	1.715	4.963	8.243
lorClass[15,18]	1.985	-1.112	1.983	5.125
lorClass[15,19]	-0.9484	-3.795	-0.9437	1.906
lorClass[16,17]	2.406	-0.1819	2.407	4.988
lorClass[16,18]	-0.573	-2.917	-0.5789	1.782

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
lorClass[16,19]	-3.507	-6.022	-3.514	-0.96
lorClass[17,18]	-2.979	-6.054	-2.984	0.1146
lorClass[17,19]	-5.912	-9.095	-5.914	-2.749
lorClass[18,19]	-2.934	-5.925	-2.936	0.07559

17.9.2.61 Outcome: SMD

	Mean	2.50%	Median	97.50%
diffClass[1,2]	1.407	0.2421	1.406	2.583
diffClass[1,3]	1.163	0.1123	1.159	2.23
diffClass[1,4]	1.219	0.3011	1.217	2.152
diffClass[1,5]	1.035	-0.5379	1.036	2.598
diffClass[1,6]	-0.2401	-0.7342	-0.2385	0.2429
diffClass[1,7]	-0.536	-1.181	-0.5357	0.1048
diffClass[1,8]	-0.2858	-0.8137	-0.2857	0.2366
diffClass[1,9]	0.5921	-1.505	0.5994	2.671
diffClass[1,10]	0.9586	-0.4885	0.9591	2.408
diffClass[1,11]	-0.05049	-1.9	-0.05194	1.8
diffClass[1,12]	0.6886	-0.9206	0.6795	2.339
diffClass[1,13]	-0.8629	-1.987	-0.8635	0.2554
diffClass[1,14]	0.2103	-1.696	0.211	2.107
diffClass[1,15]	-0.5171	-1.667	-0.5153	0.6219
diffClass[1,16]	-1.076	-2.545	-1.077	0.3933
diffClass[1,17]	-0.455	-2.273	-0.4567	1.353
diffClass[1,18]	0.8797	-0.9328	0.8814	2.681
diffClass[2,3]	-0.2436	-1.325	-0.2452	0.8489
diffClass[2,4]	-0.1879	-1.047	-0.1885	0.6925
diffClass[2,5]	-0.3716	-1.92	-0.3707	1.184
diffClass[2,6]	-1.647	-2.895	-1.646	-0.4174
diffClass[2,7]	-1.943	-3.172	-1.944	-0.7215
diffClass[2,8]	-1.692	-2.946	-1.69	-0.4611
diffClass[2,9]	-0.8146	-2.571	-0.8142	0.9379
diffClass[2,10]	-0.4481	-1.83	-0.4494	0.9389
diffClass[2,11]	-1.457	-3.274	-1.458	0.3585
diffClass[2,12]	-0.718	-2.365	-0.7227	0.9439
diffClass[2,13]	-2.27	-3.388	-2.269	-1.149
diffClass[2,14]	-1.196	-3.092	-1.194	0.6905
diffClass[2,15]	-1.924	-3.257	-1.922	-0.5995
diffClass[2,16]	-2.483	-4.352	-2.482	-0.6294
diffClass[2,17]	-1.862	-3.707	-1.861	-0.01517
diffClass[2,18]	-0.527	-2.306	-0.5305	1.25
diffClass[3,4]	0.05574	-0.631	0.0541	0.7469
diffClass[3,5]	-0.128	-1.525	-0.1298	1.259
diffClass[3,6]	-1.403	-2.548	-1.397	-0.2834
diffClass[3,7]	-1.699	-2.846	-1.698	-0.5565
diffClass[3,8]	-1.449	-2.602	-1.444	-0.3201

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
diffClass[3,9]	-0.571	-2.619	-0.5736	1.493
diffClass[3,10]	-0.2045	-1.534	-0.2024	1.112
diffClass[3,11]	-1.214	-3.076	-1.21	0.6528
diffClass[3,12]	-0.4744	-2.017	-0.4789	1.092
diffClass[3,13]	-2.026	-3.088	-2.024	-0.9774
diffClass[3,14]	-0.9527	-2.775	-0.9505	0.8456
diffClass[3,15]	-1.68	-2.978	-1.675	-0.4141
diffClass[3,16]	-2.239	-4.034	-2.237	-0.4488
diffClass[3,17]	-1.618	-3.483	-1.622	0.2464
diffClass[3,18]	-0.2834	-1.979	-0.2792	1.407
diffClass[4,5]	-0.1837	-1.483	-0.1829	1.112
diffClass[4,6]	-1.459	-2.491	-1.455	-0.4569
diffClass[4,7]	-1.755	-2.782	-1.753	-0.7404
diffClass[4,8]	-1.505	-2.543	-1.501	-0.4924
diffClass[4,9]	-0.6267	-2.569	-0.6295	1.326
diffClass[4,10]	-0.2602	-1.387	-0.2612	0.8736
diffClass[4,11]	-1.269	-3.02	-1.27	0.4915
diffClass[4,12]	-0.5302	-1.949	-0.536	0.9315
diffClass[4,13]	-2.082	-2.953	-2.08	-1.213
diffClass[4,14]	-1.008	-2.708	-1.007	0.6746
diffClass[4,15]	-1.736	-2.913	-1.733	-0.5778
diffClass[4,16]	-2.295	-4.029	-2.29	-0.5858
diffClass[4,17]	-1.674	-3.437	-1.677	0.1098
diffClass[4,18]	-0.3391	-1.894	-0.3383	1.204
diffClass[5,6]	-1.275	-2.898	-1.273	0.3476
diffClass[5,7]	-1.571	-3.191	-1.57	0.04882
diffClass[5,8]	-1.321	-2.947	-1.32	0.3004
diffClass[5,9]	-0.443	-2.77	-0.4425	1.88
diffClass[5,10]	-0.07647	-1.79	-0.07668	1.636
diffClass[5,11]	-1.086	-3.266	-1.086	1.088
diffClass[5,12]	-0.3464	-2.265	-0.3533	1.589
diffClass[5,13]	-1.898	-3.436	-1.898	-0.365
diffClass[5,14]	-0.8247	-2.94	-0.8228	1.291
diffClass[5,15]	-1.552	-3.275	-1.55	0.1608
diffClass[5,16]	-2.111	-4.246	-2.109	0.009197
diffClass[5,17]	-1.49	-3.664	-1.489	0.6769
diffClass[5,18]	-0.1554	-2.164	-0.1543	1.873
diffClass[6,7]	-0.2959	-1.043	-0.2964	0.45
diffClass[6,8]	-0.04568	-0.71	-0.04602	0.6173
diffClass[6,9]	0.8322	-1.297	0.8341	2.95
diffClass[6,10]	1.199	-0.309	1.2	2.708
diffClass[6,11]	0.1896	-1.706	0.1881	2.089
diffClass[6,12]	0.9288	-0.7266	0.9198	2.631
diffClass[6,13]	-0.6227	-1.81	-0.6224	0.5691
diffClass[6,14]	0.4505	-1.491	0.4467	2.388

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
diffClass[6,15]	-0.2769	-1.494	-0.274	0.938
diffClass[6,16]	-0.836	-2.367	-0.8359	0.6977
diffClass[6,17]	-0.2149	-2.07	-0.2159	1.634
diffClass[6,18]	1.12	-0.7237	1.119	2.965
diffClass[7,8]	0.2502	-0.5298	0.2503	1.041
diffClass[7,9]	1.128	-0.9973	1.132	3.24
diffClass[7,10]	1.495	-0.01134	1.495	2.995
diffClass[7,11]	0.4855	-1.379	0.4861	2.353
diffClass[7,12]	1.225	-0.4345	1.215	2.93
diffClass[7,13]	-0.3268	-1.516	-0.3273	0.8593
diffClass[7,14]	0.7464	-1.205	0.748	2.693
diffClass[7,15]	0.01895	-1.191	0.01996	1.219
diffClass[7,16]	-0.5401	-2.124	-0.5422	1.044
diffClass[7,17]	0.081	-1.736	0.07826	1.901
diffClass[7,18]	1.416	-0.4301	1.414	3.271
diffClass[8,9]	0.8779	-1.261	0.8828	3.001
diffClass[8,10]	1.244	-0.2629	1.243	2.761
diffClass[8,11]	0.2353	-1.665	0.2362	2.129
diffClass[8,12]	0.9744	-0.6914	0.9662	2.679
diffClass[8,13]	-0.5771	-1.781	-0.579	0.6237
diffClass[8,14]	0.4961	-1.454	0.4963	2.444
diffClass[8,15]	-0.2313	-1.46	-0.231	0.979
diffClass[8,16]	-0.7904	-2.325	-0.7911	0.7402
diffClass[8,17]	-0.1692	-2.039	-0.1715	1.69
diffClass[8,18]	1.165	-0.6936	1.169	3.015
diffClass[9,10]	0.3665	-1.867	0.3671	2.596
diffClass[9,11]	-0.6425	-3.166	-0.6444	1.886
diffClass[9,12]	0.09657	-2.3	0.094	2.507
diffClass[9,13]	-1.455	-3.551	-1.452	0.6192
diffClass[9,14]	-0.3817	-2.956	-0.3784	2.179
diffClass[9,15]	-1.109	-3.298	-1.108	1.079
diffClass[9,16]	-1.668	-4.204	-1.673	0.8656
diffClass[9,17]	-1.047	-3.58	-1.044	1.478
diffClass[9,18]	0.2876	-2.204	0.2912	2.775
diffClass[10,11]	-1.009	-3.08	-1.011	1.067
diffClass[10,12]	-0.2699	-2.075	-0.2732	1.552
diffClass[10,13]	-1.821	-3.242	-1.82	-0.4228
diffClass[10,14]	-0.7482	-2.781	-0.7452	1.288
diffClass[10,15]	-1.476	-3.079	-1.475	0.1331
diffClass[10,16]	-2.035	-4.094	-2.029	0.001502
diffClass[10,17]	-1.414	-3.5	-1.414	0.6798
diffClass[10,18]	-0.07889	-2.012	-0.0786	1.83
diffClass[11,12]	0.7391	-1.498	0.7366	2.969
diffClass[11,13]	-0.8124	-2.639	-0.8122	1.003
diffClass[11,14]	0.2608	-2.174	0.2625	2.681

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

	Mean	2.50%	Median	97.50%
diffClass[11,15]	-0.4666	-2.395	-0.4649	1.477
diffClass[11,16]	-1.026	-3.382	-1.02	1.317
diffClass[11,17]	-0.4045	-2.705	-0.4035	1.887
diffClass[11,18]	0.9302	-1.42	0.9297	3.256
diffClass[12,13]	-1.551	-3.201	-1.543	0.06442
diffClass[12,14]	-0.4783	-2.563	-0.4737	1.585
diffClass[12,15]	-1.206	-3.038	-1.197	0.557
diffClass[12,16]	-1.765	-3.955	-1.761	0.3852
diffClass[12,17]	-1.144	-3.407	-1.139	1.084
diffClass[12,18]	0.1911	-1.942	0.1989	2.289
diffClass[13,14]	1.073	-0.8118	1.074	2.949
diffClass[13,15]	0.3458	-0.9524	0.3473	1.642
diffClass[13,16]	-0.2133	-2.059	-0.2138	1.621
diffClass[13,17]	0.4078	-1.423	0.4022	2.254
diffClass[13,18]	1.743	-0.03913	1.74	3.518
diffClass[14,15]	-0.7274	-2.743	-0.7281	1.305
diffClass[14,16]	-1.287	-3.657	-1.285	1.113
diffClass[14,17]	-0.6654	-3.096	-0.6658	1.767
diffClass[14,18]	0.6693	-1.63	0.6718	2.972
diffClass[15,16]	-0.5591	-2.409	-0.5596	1.287
diffClass[15,17]	0.06205	-1.804	0.06106	1.93
diffClass[15,18]	1.397	-0.5368	1.4	3.333
diffClass[16,17]	0.6211	-1.696	0.6204	2.929
diffClass[16,18]	1.956	-0.3518	1.953	4.272
diffClass[17,18]	1.335	-1.019	1.334	3.687

Update 2017

17.10 Appendix 5: NMA posterior mean rank and 95% credible intervals by intervention

17.10.1 Population: less severe depression

Table 1: Discontinuation

Intervention	Posterior median rank	95% CrIs
Emotion-focused therapy (EFT)	5	(1, 46)
Relational client-centred therapy	5	(1, 46)
Yoga	6	(1, 42)
Non-directive counselling	7	(1, 34)
Mirtazapine	9	(1, 46)
Third-wave cognitive therapy individual	10	(2, 30)
Short-term psychodynamic psychotherapy individual + Any AD	10	(1, 40)
Exercise + CBT individual (under 15 sessions)	10	(1, 45)
Waitlist	13	(4, 28)
CBT group (under 15 sessions)	14	(3, 34)
Rational emotive behaviour therapy (REBT)	15	(2, 42)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior median rank	95% CrIs
Exercise	16	(6, 31)
Psychoeducational group programme	17	(3, 41)
CBT individual (under 15 sessions)	17	(5, 35)
CBT individual (over 15 sessions)	17	(7, 32)
Problem solving	19	(5, 41)
Short-term psychodynamic psychotherapy individual + any SSRI	19	(1, 49)
Aerobic exercise (supervised) + sertraline	19	(3, 43)
TAU	22	(11, 33)
Fluoxetine	23	(7, 39)
Interpersonal psychotherapy (IPT)	23	(7, 40)
Interpersonal psychotherapy (IPT) + imipramine	23	(1, 49)
Third-wave cognitive therapy group	24	(5, 46)
Attention placebo	25	(7, 42)
Behavioural activation	27	(7, 44)
CBT group (over 15 sessions)	28	(6, 48)
Interpersonal psychotherapy (IPT) + any AD	28	(2, 49)
Citalopram	29	(9, 44)
Escitalopram	29	(9, 44)
Cognitive bibliotherapy	29	(11, 43)
Self-examination therapy	29	(2, 48)
Amitriptyline	31	(13, 44)
Sertraline	31	(17, 43)
Short-term psychodynamic psychotherapy individual	31	(10, 45)
CBT individual (over 15 sessions) + amitriptyline	31	(3, 49)
Psychodynamic counselling	32	(4, 48)
Pill placebo	33	(20, 43)
Tailored computerised-CBT (CCBT) with support	36	(5, 48)
Computerised-CBT (CCBT) with support	37	(18, 46)
Lofepramine	39	(13, 49)
Online positive psychological intervention	39	(10, 49)
Short-term psychodynamic psychotherapy group	40	(7, 49)
Computerised-CBT (CCBT)	40	(26, 47)
Coping with Depression course (individual)	43	(7, 49)
Behavioural therapy (Lewinsohn 1976)	44	(11, 49)
Coping with Depression course (group)	44	(24, 49)
Cognitive bibliotherapy with support	45	(28, 49)
Computerised psychodynamic therapy with support	46	(13, 49)

Update 2017

1 **Table 2: Discontinuation due to SE**

Intervention	Posterior mean rank	95% CrIs
Exercise	2	(1 - 5)
Problem solving	3	(1 - 7)
CBT group (under 15 sessions)	4	(1 - 7)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior mean rank	95% CrIs
CBT individual (over 15 sessions)	4	(1 - 8)
Pill placebo	6	(3 - 9)
Short-term psychodynamic psychotherapy individual + any SSRI	7	(1 - 16)
Aerobic exercise (supervised) + sertraline	7	(2 - 15)
Escitalopram	9	(5 - 12)
Citalopram	9	(5 - 13)
Mirtazapine	11	(3 - 16)
Fluoxetine	11	(7 - 14)
Sertraline	11	(8 - 14)
CBT individual (over 15 sessions) + amitriptyline	13	(5 - 16)
Lofepramine	13	(7 - 16)
Short-term psychodynamic psychotherapy individual	14	(5 - 16)
Amitriptyline	15	(12 - 16)

Table 3. Remission in Responders

Intervention	Posterior mean rank	95% CrIs
Short-term psychodynamic psychotherapy individual + any SSRI	2	(1 - 10)
Short-term psychodynamic psychotherapy individual + Any AD	2	(1 - 10)
Behavioural activation	3	(1 - 5)
CBT individual (over 15 sessions)	6	(2 - 11)
CBT group (under 15 sessions)	6	(2 - 11)
Citalopram	6	(4 - 8)
Escitalopram	6	(4 - 8)
Fluoxetine	6	(4 - 8)
Sertraline	6	(4 - 8)
Interpersonal psychotherapy (IPT)	8	(1 - 12)
TAU	9	(2 - 12)
Pill placebo	10	(6 - 12)

Table 4. Remission in those randomised

Intervention	Posterior mean rank	95% CrIs
Directive counselling	5	(1 - 25)
Behavioural activation	5	(1 - 14)
Third-wave cognitive therapy individual	6	(1 - 17)
Interpersonal psychotherapy (IPT) + any AD	6	(1 - 29)
Relational client-centred therapy	7	(1 - 33)
Short-term psychodynamic psychotherapy individual + any SSRI	8	(1 - 32)
CBT individual (over 15 sessions)	9	(3 - 17)
Coping with Depression course (group)	10	(2 - 24)
Short-term psychodynamic psychotherapy individual + Any AD	10	(2 - 28)
CBT group (under 15 sessions)	12	(3 - 25)
Psychoeducational group programme	13	(1 - 32)

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior mean rank	95% CrIs
Interpersonal psychotherapy (IPT)	14	(5 - 24)
Rational emotive behaviour therapy (REBT)	15	(4 - 29)
Fluoxetine	16	(5 - 28)
Short-term psychodynamic psychotherapy individual	17	(5 - 31)
Tailored computerised-CBT (CCBT) with support	17	(2 - 32)
Escitalopram	18	(7 - 29)
Computerised psychodynamic therapy with support	18	(2 - 33)
Problem solving	18	(6 - 30)
CBT individual (under 15 sessions)	19	(9 - 29)
Amitriptyline	20	(7 - 32)
Citalopram	20	(5 - 32)
Sertraline	20	(8 - 30)
Psychodynamic counselling	22	(6 - 33)
CBT individual (over 15 sessions) + amitriptyline	23	(4 - 34)
Computerised-CBT (CCBT) with support	25	(13 - 32)
Computerised-CBT (CCBT)	27	(15 - 32)
Aerobic exercise (supervised) + sertraline	27	(9 - 34)
TAU	28	(22 - 33)
Pill placebo	29	(21 - 33)
Exercise	29	(17 - 33)
Cognitive bibliotherapy	32	(19 - 34)
Attention placebo	34	(31 - 35)
Waitlist	35	(33 - 35)

Update 2017

Table 5. Response (completers)

Intervention	Posterior median rank	95%CrI
Interpersonal psychotherapy (IPT) + any AD	2	(1, 23)
Interpersonal psychotherapy (IPT) + imipramine	6	(1, 38)
Cognitive bibliotherapy	8	(1, 30)
CBT individual (over 15 sessions)	10	(3, 20)
Behavioural therapy (Lewinsohn 1976)	10	(1, 34)
Coping with Depression course (individual)	10	(1, 33)
Behavioural activation	11	(3, 26)
Short-term psychodynamic psychotherapy individual + any SSRI	12	(1, 37)
Lofepramine	13	(2, 32)
Self-examination therapy	13	(1, 36)
Third-wave cognitive therapy individual	13	(1, 34)
Short-term psychodynamic psychotherapy individual + Any AD	13	(2, 36)
Amitriptyline	14	(4, 29)
Sertraline	14	(4, 27)
CBT individual (under 15 sessions)	14	(3, 31)
Mirtazapine	15	(1, 40)
Exercise	16	(4, 31)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior median rank	95%CrI
Computerised-CBT (CCBT) with support	18	(1, 38)
Emotion-focused therapy (EFT)	18	(2, 37)
CBT group (under 15 sessions)	19	(4, 35)
Short-term psychodynamic psychotherapy individual	22	(7, 35)
Psychodynamic counselling	23	(4, 38)
Interpersonal psychotherapy (IPT)	23	(8, 35)
Problem solving	23	(8, 35)
Citalopram	24	(9, 36)
Fluoxetine	24	(9, 36)
Aerobic exercise (supervised) + sertraline	26	(5, 39)
Coping with Depression course (group)	27	(7, 38)
CBT individual (over 15 sessions) + amitriptyline	27	(3, 40)
Escitalopram	28	(11, 38)
Non-directive counselling	28	(4, 40)
Cognitive bibliotherapy with support	29	(4, 40)
Computerised-CBT (CCBT)	31	(4, 40)
Psychoeducational group programme	32	(5, 40)
Exercise + CBT individual (under 15 sessions)	32	(6, 40)
TAU	33	(22, 39)
Relational client-centred therapy	33	(5, 41)
Attention placebo	34	(11, 40)
Online positive psychological intervention	36	(13, 40)
Pill placebo	37	(29, 40)
Waitlist	41	(39, 41)

Update 2017

Table 6. Response in those randomised

Intervention	Posterior Mean rank	95% CrIs
Interpersonal psychotherapy (IPT) + any AD	3	(1 - 14)
Short-term psychodynamic psychotherapy individual + Any AD	5	(1 - 16)
Interpersonal psychotherapy (IPT) + imipramine	5	(1 - 33)
Aerobic exercise (supervised) + sertraline	5	(1 - 20)
Long-term psychodynamic psychotherapy individual	10	(2 - 32)
Behavioural therapy (Lewinsohn 1976)	10	(2 - 30)
Behavioural activation	10	(4 - 21)
Short-term psychodynamic psychotherapy individual + any SSRI	11	(1 - 36)
CBT individual (over 15 sessions)	11	(6 - 19)
Third-wave cognitive therapy individual	12	(4 - 25)
CBT individual (over 15 sessions) + desipramine	12	(1 - 37)
Computerised-CBT (CCBT) with support	13	(4 - 28)
Mirtazapine	13	(1 - 39)
Rational emotive behaviour therapy (REBT)	15	(4 - 33)
CBT group (over 15 sessions)	18	(5 - 37)
CBT individual (under 15 sessions)	19	(9 - 31)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior Mean rank	95% CrIs
CBT group (under 15 sessions)	20	(8 - 34)
Exercise	20	(10 - 31)
Fluoxetine	22	(11 - 34)
Short-term psychodynamic psychotherapy individual	22	(11 - 35)
Computerised psychodynamic therapy with support	23	(6 - 38)
Cognitive bibliotherapy with support	23	(8 - 37)
Amitriptyline	23	(11 - 35)
Coping with Depression course (group)	24	(9 - 37)
Third-wave cognitive therapy group	24	(9 - 38)
Short-term psychodynamic psychotherapy group	25	(6 - 40)
Lofepramine	25	(7 - 39)
Citalopram	25	(10 - 37)
Sertraline	26	(15 - 35)
Psychoeducational group programme	27	(12 - 38)
Interpersonal psychotherapy (IPT)	27	(11 - 38)
Computerised-CBT (CCBT)	28	(16 - 37)
Non-directive counselling	29	(12 - 39)
Escitalopram	29	(12 - 39)
Directive counselling	30	(13 - 40)
Cognitive bibliotherapy	31	(20 - 38)
Online positive psychological intervention	34	(16 - 41)
Attention placebo	35	(25 - 39)
Pill placebo	37	(31 - 40)
TAU	40	(37 - 41)
Waitlist	41	(40 - 41)

Update 2017

Table 7. SMD

Intervention	Posterior Mean rank	95% CrIs
Interpersonal psychotherapy (IPT) + any AD	2	(1, 5)
Computerised psychodynamic therapy with support	3	(1, 10)
Short-term psychodynamic psychotherapy individual + Any AD	3	(1, 10)
Short-term psychodynamic psychotherapy individual + Any SSRI	3	(1, 38)
Long-term psychodynamic psychotherapy individual	6	(2, 24)
Third-wave cognitive therapy individual	6	(2, 17)
Computerised-CBT (CCBT) with support	7	(3, 19)
Aerobic exercise (supervised) + sertraline	9	(3, 30)
CBT individual (over 15 sessions) + desipramine	11	(3, 34)
Cognitive bibliotherapy with support	12	(5, 29)
CBT individual (over 15 sessions)	13	(7, 22)
Behavioural activation	13	(7, 24)
Rational emotive behaviour therapy (REBT)	14	(5, 32)
Computerised-CBT (CCBT)	15	(7, 27)
CBT individual (under 15 sessions)	15	(7, 27)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior Mean rank	95% CrIs
Coping with Depression course (group)	18	(7, 33)
CBT group (under 15 sessions)	19	(8, 32)
CBT group (over 15 sessions)	19	(5, 36)
Third-wave cognitive therapy group	19	(6, 35)
Exercise	20	(10, 29)
Psychoeducational group programme	20	(8, 32)
Amitriptyline	22	(10, 32)
Short-term psychodynamic psychotherapy individual	23	(12, 32)
Interpersonal psychotherapy (IPT)	23	(8, 35)
Lofepramine	24	(6, 36)
Citalopram	24	(8, 34)
Fluoxetine	25	(13, 33)
Sertraline	26	(16, 33)
Escitalopram	27	(11, 36)
Cognitive bibliotherapy	27	(16, 34)
Short-term psychodynamic psychotherapy group	28	(7, 37)
Directive counselling	28	(10, 37)
Non-directive counselling	31	(18, 36)
Pill placebo	33	(28, 37)
Attention placebo	34	(25, 37)
Online positive psychological intervention	35	(17, 38)
TAU	36	(34, 37)
Waitlist	38	(37, 38)

Update 2017

17.10.21 Population: more severe depression

2 **Table 8. Discontinuation**

Intervention	Posterior median rank	95% CrIs
Yoga	3	(1, 35)
Exercise	5	(1, 34)
CBT individual (under 15 sessions) + amineptine	5	(1, 25)
CBT individual (over 15 sessions) + any SSRI	7	(1, 24)
Computerised-CBT (CCBT) with support	10	(2, 28)
Emotion-focused therapy (EFT)	10	(1, 38)
Non-directive counselling	10	(2, 35)
Relational client-centred therapy	10	(1, 38)
Counselling (any type)	10	(1, 38)
Waitlist	11	(3, 25)
Long-term psychodynamic psychotherapy individual	11	(1, 35)
TAU	12	(5, 25)
Cognitive bibliotherapy with support	12	(2, 33)
CBT individual (over 15 sessions) + Pill placebo	12	(1, 35)
Short-term psychodynamic psychotherapy individual	14	(3, 34)

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior median rank	95% CrIs
CBT individual (under 15 sessions)	15	(5, 31)
CBT individual (over 15 sessions) + nortriptyline	15	(3, 36)
Third-wave cognitive therapy individual	16	(2, 36)
CBT individual (over 15 sessions) + imipramine	18	(4, 36)
CBT group (under 15 sessions)	19	(6, 36)
Attention placebo	20	(4, 38)
Third-wave cognitive therapy group	21	(5, 38)
Cognitive bibliotherapy	23	(6, 38)
Problem solving	23	(9, 38)
Computerised-CBT (CCBT)	24	(12, 37)
CBT individual (over 15 sessions)	25	(14, 37)
Interpersonal psychotherapy (IPT)	26	(9, 38)
Interpersonal psychotherapy (IPT) + any TCA	26	(6, 39)
Mirtazapine	28	(10, 37)
Lofepramine	28	(9, 38)
Long-term psychodynamic psychotherapy individual + fluoxetine	28	(4, 39)
Amitriptyline	30	(14, 37)
Fluoxetine	30	(14, 37)
Sertraline	32	(14, 39)
CBT individual (under 15 sessions) + Pill placebo	32	(8, 40)
Citalopram	33	(15, 39)
Escitalopram	33	(17, 39)
Pill placebo	35	(21, 39)
Behavioural activation (BA)	38	(8, 40)
Psychoeducational group programme	40	(37, 40)

Update 2017

Table 9: Discontinuation due to SE

Intervention	Posterior Mean rank	95% CrIs
Long-term psychodynamic psychotherapy individual + fluoxetine	2	(1, 11)
CBT individual (under 15 sessions)	3	(1, 12)
CBT individual (over 15 sessions)	3	(1, 12)
CBT individual (over 15 sessions) + imipramine	3	(1, 13)
Pill placebo	4	(1, 5)
Fluoxetine	6	(3, 9)
Escitalopram	8	(4, 12)
Sertraline	8	(4, 13)
Citalopram	9	(5, 13)
Mirtazapine	10	(5, 13)
Lofepramine	10	(5, 13)
Amitriptyline	11	(8, 13)
Long-term psychodynamic psychotherapy individual	12	(3, 13)

Table 10: Remission in those randomised

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior mean rank	95% CrIs
Long-term psychodynamic psychotherapy individual	1	(1, 6)
Long-term psychodynamic psychotherapy individual + fluoxetine	2	(1, 8)
CBT individual (over 15 sessions) + imipramine	4	(1, 12)
CBT individual (over 15 sessions) + nortriptyline	4	(1, 12)
Escitalopram	7	(3, 12)
Interpersonal psychotherapy (IPT)	7	(1, 15)
CBT individual (over 15 sessions)	7	(3, 14)
Problem solving	7	(1, 14)
Sertraline	9	(3, 14)
Amitriptyline	10	(4, 15)
Fluoxetine	10	(5, 14)
Pill placebo	11	(6, 15)
Mirtazapine	11	(3, 16)
Citalopram	13	(7, 16)
Computerised-CBT (CCBT) with support	15	(3, 16)
Waitlist	16	(8, 16)

Table 11: Response in completers

Intervention	Posterior median rank	95% CrIs
Exercise	2	(1, 18)
Behavioural activation (BA)	2	(1, 13)
Yoga	3	(1, 23)
CBT individual (over 15 sessions) + nortriptyline	5	(1, 20)
CBT individual (over 15 sessions) + any SSRI	6	(2, 21)
Short-term psychodynamic psychotherapy individual	8	(3, 19)
Non-directive counselling	9	(3, 22)
Counselling (any type)	9	(1, 25)
CBT individual (under 15 sessions)	9	(4, 18)
Lofepramine	10	(2, 21)
Amitriptyline	12	(3, 20)
Third-wave cognitive therapy individual	13	(3, 24)
CBT group (under 15 sessions)	14	(3, 25)
Mirtazapine	15	(4, 23)
Third-wave cognitive therapy group	15	(4, 25)
CBT individual (over 15 sessions) + Pill placebo	15	(4, 26)
Attention placebo	17	(5, 26)
TAU	17	(9, 24)
Escitalopram	17	(6, 23)
Fluoxetine	18	(7, 24)
Cognitive bibliotherapy	18	(4, 26)
Sertraline	20	(8, 25)
Citalopram	21	(10, 25)

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior median rank	95% CrIs
CBT individual (over 15 sessions)	21	(10, 26)
Pill placebo	25	(15, 26)
Waitlist	26	(10, 26)

Table 12: Response in those randomised

Intervention	Posterior mean rank	95% CrIs
Exercise + Fluoxetine	1	(1 - 3)
CBT group (under 15 sessions)	4	(1 - 12)
Lofepramine	4	(2 - 11)
Amitriptyline	6	(3 - 11)
CBT individual (over 15 sessions) + nortriptyline	6	(2 - 14)
CBT individual (under 15 sessions) + citalopram	7	(2 - 14)
Mirtazapine	8	(3 - 13)
Fluoxetine	8	(4 - 13)
Escitalopram	8	(4 - 13)
Third-wave cognitive therapy individual	9	(3 - 15)
Sertraline	10	(5 - 15)
Citalopram	11	(7 - 15)
Pill placebo	13	(10 - 18)
CBT individual (over 15 sessions)	15	(9 - 19)
Interpersonal psychotherapy (IPT)	15	(7 - 22)
Intensive clinical management	17	(3 - 30)
Behavioural activation (BA)	18	(12 - 25)
Social Rhythm Therapy (SRT)	18	(5 - 30)
CBT individual (under 15 sessions)	19	(16 - 24)
Emotion-focused therapy (EFT)	21	(14 - 29)
Computerised-CBT (CCBT) with support	22	(15 - 29)
Non-directive counselling	23	(17 - 28)
Short-term psychodynamic psychotherapy individual	23	(16 - 29)
Exercise	24	(17 - 30)
Relational client-centred therapy	24	(16 - 30)
Computerised-CBT (CCBT)	25	(20 - 29)
Waitlist	26	(19 - 30)
Attention placebo	26	(19 - 30)
Cognitive bibliotherapy	26	(19 - 30)
TAU	28	(25 - 30)

Table 13. SMD

Intervention	Posterior median rank	95% CrIs
CBT group (under 15 sessions)	1	(1, 2)
Third-wave cognitive therapy individual	3	(2, 12)

Update 2017

National Institute for Health and Care Excellence [2017]. All rights reserved.

Intervention	Posterior median rank	95% CrIs
Exercise + Fluoxetine	3	(1, 12)
CBT individual (over 15 sessions) + nortriptyline	5	(2, 16)
Lofepramine	6	(2, 17)
CBT individual (over 15 sessions) + Pill placebo	8	(3, 19)
Amitriptyline	9	(4, 17)
Sertraline	10	(4, 18)
CBT individual (under 15 sessions) + citalopram	10	(3, 19)
Escitalopram	11	(5, 18)
Fluoxetine	11	(5, 18)
Mirtazapine	12	(4, 20)
Citalopram	12	(6, 18)
CBT individual (over 15 sessions)	14	(5, 20)
Interpersonal psychotherapy (IPT)	15	(4, 23)
Pill placebo	16	(11, 23)
Behavioural activation (BA)	17	(4, 25)
Emotion-focused therapy (EFT)	19	(3, 29)
CBT individual (under 15 sessions)	19	(13, 24)
Computerised-CBT (CCBT) with support	20	(5, 29)
Non-directive counselling	21	(11, 28)
Computerised-CBT (CCBT)	22	(17, 26)
Relational client-centred therapy	23	(5, 29)
Short-term psychodynamic psychotherapy individual	23	(15, 28)
Exercise	24	(18, 29)
Cognitive bibliotherapy	25	(16, 29)
Attention placebo	26	(19, 29)
TAU	26	(23, 29)
Waitlist	28	(20, 29)